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Aims: To investigate alterations in flrbronectin (FN) and laminin (LN) levels, and the
expression of associated caseinolytic MMPs in tissues following skeletal muscle (SM)
ischemia and reperfusion (VR).
Materials and Methods: The rats were subjected to 4 h hindlimb ischemia, followed by
reperfusion for 0, 4, 24 or 72 h. Two further groups was administered doxycycline before
ischemia was induced. The rats were then sacrificed and samples were processed. ELISA,
Immunohistochemical techniques,Zymography and Westem blotting were employed.
Results: Plasma FN (pFN) decreased following hindlimb ischemia and subsequently
increased with reperfusion. FN accumulated in the basement membrane (BM) of SM, whereas
degradation occurred in the lungs and kidneys after SM I/R. FN decreased in the liver after
SM ischemia and then increased with reperfusion. However, LN was degraded in all BM.
Following doxycycline treaünent, levels of FN increased in lungs, kidneys, and liver.
Degradation of LN was inhibited in all tissues by doxycycline. In addition, a 20 l<Da
caseinolytic species was identified in lung tissues, which was inhibited by EDTA and 1,10-
phenanthroline, but not inhibited by PMSF. This species was down-regulated by anesthesia
only and then up-regulated immediately following bilateral hindlimb yR. An increased
production of this MMP was also found after treatment of the rats with doxycycline.
Conclusions: FN has a specific affinity to injured tissue, as was minored by rapid depletion
of pFN, which was secreted by the liver. Moreover, the degradation of FN in lungs and
kidneys and LN in all BM was suggested to be due to the effects of MMPs. In addition,
doxycycline reduced the degradation of FN in lungs and kidneys and LN in all tissues studied
by inhibiting the activity of MMPs. However, degradation of FN was not evident in SM,
because there was an over deposition of FN in SM following VR. Furthefinore, a caseinolytic
MMP, rather than a serine protease, was involved in lung injury following SM I/R
Doxycycline increased the production of this MMP. Although it has not been identified, this
MMP was suggested to be a lower molecular weight MMP, possibly MMP-7 or MMP-12.
Further study is needed for confirmation of its identity.
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Ischemia and reperfusion (I/R) is a common clinical event, which occurs in ischemic heart
disease, stroke, shock, following cardiopulmonary resuscitation, vascular surgery and organ
transplantation. Ischemic heart disease and stroke are two of three major causes of death in
western society. Reperfusion during vascular surgery includes by-pass of arterial occlusion,
thrombectomy of arteries and repair of abdominal aortic aneurysm (AAA), in which tissue
ischemia and reperfusion is unavoidable. AAA is a potentially fatal disease that occurs in 2-
9Yo of the over 65 year old population (1). Organ transplantation is an effective procedure for
improving quality and length of life of patients with organ failure, such as end stage chronic
renal failure and hepatic failure, cardiomyopathy, pulmonary insuficiency and short bowel
syndrome. More than 200,000 kidney transplants have been performed in the United States
since 1964 with best S-year graft survival rates of 90Yo (2). The number of liver transplant
performed annually in the United States more than doubled from I,713-4,689 between 1988-
1999 with one-year and 10- year patient survival rates 85% and 78 o% respectively (3).
Obviously, the allograft will suffer an inevitable ischemia and reperfusion insult during organ
retrival, preservation and implantation.
1.2 Mechanisms of Ischemia / Reperfusion (I/R) Injury
I/R injury is a very multi-factorial process involving complex biochemical reactions,
production of oxygen free radicals, release of cytokines, activation of neutrophils with
adhesion to the endothelium and migration, increase in microvascular permeability, cellular
apoptosis and necrosis.
1.2.1 Generation of Reactive oxygen species (ROS)
Under normal conditions, intracellular energy is stored in the form of adenosine 5'-
triphosphate (ATP) which is dephosphorylated to adenosine 5'-diphosphate (ADP) and
adenosine 5'-monophosphate (AMP), simultaneously accompanied by the release of energy
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during cellular metabolism. During ischemia, the blood supply to the tissue is interrupted and
oxygen is lacking, leading to anaerobic metabolism with an increase in local concentration of
lactic acid and changes to protease kinetics. Breakdown of ATP occurs resulting in the
formation of adenine nucleotides, hypoxanthine, xanthine, inosine and adenosine. Normally,
hypoxanthine is oxidized to uric acid by the enzyme xanthine dehydrogenase, even though it
can also be oxidized by xanthine oxidase, an isoform of xanthine dehydrogenase, and in the
process, transfers an electron to Oz forming Oz' Ø). It has been determined that ischemia
results in conversion of xanthine dehydrogenase to xanthine oxidase within endothelial cells'
The outcome of all these events will lead to endothelial cell damage and release of xanthine
oxidase into the plasma of the reperfused tissue (5). Increased xanthine oxidase uses
molecular oxygen introduced during reperfusion to convert hypoxanthine to xanthine,
releasing superoxide during this process (6). Hypoxanthine and xanthine serve as oxidizable
purine substrates for xanthine dehydrogenase or xanthine oxidase. Therefore, a burst of
superoxide radicals and hydrogen peroxide is produced following reperfusion. On the other
hand, the depletion of the cellular ATP results in increase in intracellular calcium
concentration due to the dysfunction of ATP-dependent membrane ion pumps. The elevation
of intracellular calcium may activate proteases, which are capable of converting the
dehydrogenase to the oxidase (7). The mechanisms of production of superoxide radicals and
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Fig 1.1. The mechanisms of ischemia/reperfusion-induced production of ROS (8).
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The activity of xanthine dehydrogenase is different in various tissues. Therefore, the duration
of ischemia required for conversion of xanthine dehydrogenase to oxidase is variable. For
example, in rat ileum, about 90%o of total activity is present as xanthine dehydrogenase. If
ileum is completely ischemic even for very short periods, there is a rapid conversion from
xanthine dehydrogenase to xanthine oxidase within 10 seconds, resulting in generation of
superoxide or hydrogen peroxide. The content of xanthine oxidase in the heart doubles after 8
minutes of ischemi a, and in the liver, spleen, lungs and kidney, the same increase requires
about 30 minutes (6). In contrast, skeletal muscle contains less xanthine dehydrogenase and
there is no conversion of xanthine dehydrogenase to xanthine oxidase during ischemia. This
observation is consistent with the clinical findings in which the skeletal muscle is capable of
resistance to longer periods of ischemia (up to 4 hours) (9).
The oxygen free radicals that are produced during ischemia-reperfusion of the tissues are
highly reactive, initiating peroxidation of cellular lipid membrane and resulting in structural
and functional cellular damage (10). In addition, lipid peroxidation of polyunsaturated fatty
acids produces lipid peroxyl radicals that may propagate a chain reaction in adjacent fatty acid
molecules. Moreover, hydroxyl radical ('OH) may cause direct oxidation of proteins and
DNA, ensuing errzyme inactivity and DNA strand breakage (11)' (12).
1.2.2 Lipid, p eroxid ation
Arachidonic acid is released during I/R following activation of phospholipase A2 due to
increased intracellular calcium and lipid peroxidation of cell membranes. The metabolites of
arachidonic acid are thromboxane A2 (Tx A2), leukotriene B4 (LTB4) and prostaglandins,
which have been demonstrated to have an important role in the pathogenesis of reperfusion
injury.
TxA2 is a powerful chemoattractant that induces neutrophil adhesion to endothelium during
ischemia-reperfusion. TxA2 will also stimulate platelet aggregation and induce
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vasoconsttiction (13), (14). In addition, TxA2 has been shown to have direct effects on
endothelium, increasing the permeability of the endothelial monolayer (15).
LTB4 is another potent chemotactic agent and plays an important role in endothelial
dysfunction. It binds to specific receptors on the surface of neutrophils and elicits a variety of
responses. LTB4 stimulates neutrophil degranulation and enhances the expression of cell
surface adhesion molecules, improving neutrophil binding to endothelial cells and migration,
increasing microvascular permeability (16). Moreover, LTB4 and TxA2 depend on each other
to exert their biological effects. The effects of LTB4 on vascular permeability require the
presence of TxA2 (15). It has been observed that administration of a LTB4 receptor
antagonist before reperfusion significantly reduced the interstitial edema and prevented
skeletal muscle necrosis (17).
The ischemia-induced oxidative burst of neutrophils is also thromboxane-dependent. The
initial neutrophil activation manifest by the oxidative burst is a graded response to stimulation
by thromboxane and is not an "all or none" event after ischemia. Thromboxane not only
increases the oxidative metabolism of the neutrophils but also primes the cell for enhanced
responses to other stimuli (18).
The prostaglandin endoperoxides (prostaglandin l/r2) are generated from arachidonic acid by
cyclo-oxygenase and converted to prostacyclin by the action of prostacyclin synthase (13).
Prostacyclin may result in relaxation of vascular smooth muscle and prevent platelet
aggregates binding to the endothelium. The analogue of prostacyclin, iloprost, was
determined to be useful in the treatment of peripheral vascular diseases, such as
thromboangiitis obliterans (19). Furthermore, some exogenous agents have been produced to
reduce I/R-induced injury. IJ74500, an inhibitor of lipid peroxidation, SC4 1930, a LTB4
receptor antagonist, and GR32191, aTxA2 receptor antagonist, have all been demonstrated to
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be able to increase muscle blood perfusion and preserve muscle viability after ischemia and
reperfusion (20), (21).
Platelet activating factor (PAF) is also produced by the endothelium through the action of
phospholipase A2 during lipid peroxidation of cellular membranes. It is a potent inflammatory
chemoattractant, promoting leukocyte adhesion to endothelial monolayers and increasing the
microvascular permeability and albumin extravasation. It has been demonstrated that
administration of PAF antagonists was able to attenuate leukocyte adhesion and emigration,
and therefore reducing microvascular permeabilíly (22), (23), (24).
Lipid peroxidation and the production of chemoattractants such as TxA2 and PAF are
considered to contribute to the activation of neutrophils and the release of cytokines (such as
TNF-g). The activated neutrophils that may subsequently be sequestered into the
inflammatory tissue have been implicated in playing a key role during the ischemia and
reperfusion injury.
1.2.3 Role of Neutrophils in ischemia/reperfusion injury
Considerable evidence supports an important role for neutrophils in the pathogenesis of
ischemia and reperfusion injury in various organs and tissues such as brain, heart, intestine,
liver, kidney, lung and skeletal muscle (25), (26), (27), (28), (29)' (30). Several studies in
animal models have shown that depletion of neutrophils by vinblastine or inhibition of
neutrophil infiltration by selectin antibodies reduced the severity of ischemia and reperfusion
injury (31), (32), (33).
A prerequisite for neutrophil-mediated injury is the adhesion of the neutrophils to
microvascular endothelium followed by transendothelial migration, which occurs by a
receptor-ligand mechanism. Many molecules and cytokines have been demonstrated to be
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involved in this process, including the neutrophil adhesion molecules, which are members of
CD1l/CD18 membrane glycoprotein complex. Related molecules on the endothelium are the
endothelial leukocyte adhesion molecules (ELAM-l) (34) and the intercellular adhesion
molecule (ICAM-l) (35). ICAM-I is a potent neutrophil adhesion receptor whose expression
is increased on the surface of endothelial cells following ischemia (36) and mediates firm
neutrophil attachment to activated endothelial cells by binding to ß2-integrins, heterodimeric
adhesion receptor glycoproteins which are expressed on the neutrophil surface. CD18, located
on the neutrophil surface is the common ß 2-subunit for both LFA-1 (CD11a/CD18) and Mac-
1 (CDllb/CDlS) and is responsible for ICAM-I-mediated leukocyte adhesion to endothelial
cells (37), (38). Antibody blockade of the CDl llCDIS complex will abolish leukocyte
adhesion to the endothelium, thus protecting against ischemia/reperfusion-induced injury and
also decreasing microvascular permeability (39), (40), (41). Similarly, other studies have
confirmed the importance of CD18 adhesion molecules in neutrophil influx into the heart
(29), Lung (42), and skeletal muscle (43) following I/R of these organs. In addition, the
binding of neutrophil CD18 to endothelium appears to be the signal required for the
neutrophil to release HzOz and proteases into the extracellular matrix (aa). The former
inversely promotes leukocyte adhesion to endothelium (22), while the latter may facilitate the
migration of leukocytes and increase of vascular permeability.
The selectin family, including L-selectin, P-selectin, and E-selectin have been found to play
an essential role in initiating neutrophil adhesion to endothelium, (45), (46). L-selectin is
constitutively expressed on leukocytes, while P-selectin is stored in preformed Weibel-Palade
bodies before constitutive or inducible translocation to the surface of activated platelets and
endothelial cells. However, the expression of E-selectin is slower than L-selectin on activated
endothelium (3a). Neutrophil rolling initiated by L-selectin seems to be the primary step
before the firm adhesion (47), (45). P-selectin and E-selectin contribute to the firm adhesion
of neutrophils to endothelium and emigration (49). Expression of P- and E-selectin is also
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upregulated in the vascular endothelium after ischemia and reperfusion, which contributes to
leukocyte recruitment and subsequent tissue injury (50), (51). Local production of IL-1ß and
/or TNF-a by these leukocytes induces P-and E-selectin expression on endothelium that
continues the cascade ofevents that increase cell adherence and infiltration ofneutrophils into
the injured tissues (52), (53). Blockade of selectins shows a beneficial effect in I/R injury,
which has been well documented in various organs, including the heart (54), lung (55), kidney
(56), Liver (57), and skeletal muscles (48).
Moreover, activation of the complement cascade, whether via the classical or alternative
pathway, finally leads to the cleaving of C3, which plays a role in the adhesion of neutrophils
and monocyte/macrophages to endothelium (58). Complement may also result in tissue
damage after I/R that is independent of neutrophil infrltration (59), (60). Inhibition or
blockade of complement could ameliorate l/R-induced inflammation and necrosis. These
protective effects could be attributed in part to reduced neutrophil infiltration, and decreased
C56-e deposition as well (61), (62); (63),6Ð.
Sequestration of activated neutrophils into the tissues during I/R may lead to local toxic
effects as well as remote organ injury (65), (66) by producing free oxygen radicals and
cytokines, releasing proteinases and peroxidases; increasing microvascular permeability and
albumin extravasation, and resulting in "no flow" phenomenon (67), (68), (69). Neutrophils
are known to produce Oz- andHzOz and to secrete myeloperoxidase, aî enzyme that catalyses
the formation of hypochlorous acid from HzOz and chloride ions (8). Activated neutrophils
are also able to produce nitric oxide (70). Of the 20 or more enzymes contained within the
polymorphonuclear cell (PMN) granules, which are released after PMN activation, elastase is
especially destructive. These enzymes are capable of degrading virtually all components of
the endothelial basment membrane as well as junctional proteins that maintain endothelial
barrier function (43), (71).
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Obstruction of capillaries may ensue, leading to "no flow" phenomenon. Plugging of
capillaries by neutrophils (72), microvascular constriction induced by prostaglandins and
endothelin-l (73), endothelial swelling (74), platelet aggregates (75), and compression of
extravasated albumin are considered to be factors in the development of "no reflow". Tissue
ischemia not only induces leukocyte activation and adhesion molecule expression, but also
renders remote organ such as lung, more vulnerable to vascular injury (71). Blockade of
leukocyte activation, adhesion, and infiltration (using monoclonal antibody to ICAM-I and
/or LFA-I, ICAM-I antisense oligonucleotides) have demonstrated protection of the organ
function against I/R injury (76), (77).
In conclusion, activation of neutrophils and consequently their sequestration into the tissues
plays a crucial role during the process of I/R injury. Adhesion molecules CD11/CD18 on
neutrophils, ICAM-I on endothelia and the selectin family are considered to contribute to
neutrophil adhesion and emigration. In addition, activated neutrophils can produce free
oxygen radicals and cytokines, release proteinases, leading to the increase in microvascular
permeability and albumin extravasation. Plugging of neutrophils and platelet aggregates in
capillaries; endothelial swelling and compression by extravasated albumin combine to result
in blood "no flow" phenomena and tissue injury.
1.2.4 Nitric oxide (NO)
Nitric oxide is an endothelium-derived vasodilator. It was initially named endothelium-
derived relaxing factor (EDRF) and later identified as nitric oxide G\fO) (78), (79). Under
normal conditions, NO is synthesized from the amino acid L-arginine by nitric oxide synthase
(NOS) which exists in the endothelium in four isoforms, NOS I, NOS II, NOS III and NOS
IV. NOS I and NOS III are constitutive enzymes which are calcium and calmodulin
dependent, whereas the others are inducible and depend on transcription (80), (81).
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NO stimulates soluble guanylate cyclase activity and increase intracellular guanosine 3'-
cyclic monophosphate (cGMP) production in vascular smooth muscle cells and platelets (70).
Elevated oGMP promotes relaxation of vascular smooth muscle and inhibits not only platelet
aggregation, but also platelet adhesion to the endothelium (82). Moreover, NO may protect
the vascular wall against the vasoconstrictive effects of endothelin (83). In addition, it was
suggested that NO is an important factor in the maintenance of normal diuresis and
natriuresis, as well as glomerular f,rltration rate (84).
During ischemia and reperfusion, the production of NO is dependent on the availability of the
substrates Oz and L-arginine. Depletion of L-arginine may lead to the disarrangement of the
domains of constitutive nitric oxide synthase, reduction of NO concentration, and an increase
in superoxide. NO relaxes the endothelial cells and thereby naffows the endothelial junctions.
Therefore, inhibition of NO production has been shown to increase microvascular
permeability and protein extravasation. Treatment with L-arginine can prevent the excessive
release of superoxide, preserve NO concentration, and thus inhibit microvascular constriction
in skeletal muscle subjected to ischemia and reperfusion, significantly reducing muscule
reperfusion edema (85). Furthermore, it was also observed that administration of NO donors
effectively attenuates ischemia/reperfusion-induced leukocyte adherence, emigration and
albumin leakage in postcapillary venules. This is consistent with in vivo studies indicating that
NO is also an antiadhesive molecule (86) The mechanism of the effects is probably due to NO
donors inactivating superoxide, preventing neutrophil activation and expression of adhesive
molecules, and increasing vascular shear rate. Moreover, the NO donors can effectively
prevent the platelet-leukocyte aggregation and degranulation of mast cells elicited by I/R.
Mast cells have already been shown to release a variety of substances that could induce the
leukocyte-endothelium adhesion, leukocyte-platelet aggregation and microvascular protein
extravasation (87).
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On the other hand, nitric oxide may react with superoxide to yield secondary cytotoxic
species via the peroxynitrite anion (ONOO). The production of peroxynitrite depends on the
product of superoxide and nitric oxide concentrations, relatively small increases of superoxide
and nitric oxide products lead to greatly increased peroxynitrite formation, up to potentially
cytotoxic levels (88). Peroxynitrite or its decomposition products can induce lipid
peroxidation without a requirment for iron (89). The protective effects of scavengers of
superoxide may be due to preventing the decomposition of nitric oxide by scavenging
superoxide, maintaining normal nitric oxide concentration and vasodilatation. Under normal
physiological conditions, the flux of NO exceeds the rate of superoxide production to allow
NO to scavenge the low levels of intracellular superoxide, reducing arteriolar tone,
maintaining vasodilation, preventing platelet aggregates and thrombosis, minimizing
leukocyte adhesion to the endothelium. However, during ischemia and reperfusion, the
balance between NO and superoxide is tipped in favour of superoxide production. This is
because of a great increase in the production of superoxide by endothelial cells and activated
leukocytes with concomitant decline in the synthesis of nitric oxide from endothelial cells.
The decreased NO levels are unable to maintain vasodilation. The accumulation of superoxide
elicits the production of platelet-activating factor (PAF), enhances the activation and
deposition of complement on the endothelial cell surface and promotes the leukocyte-
endothilial adhesion.
In summary, NO is an endothelium-derived vasodilator, capable of protecting the vascular
wall against vasoconstrictive effects of endothelin. The production of NO is dependent on the
availability of sgbstrates Oz and L-arginine. During ischemia and reperfusion, the balance
between NO and superoxide is tipped in favour of superoxide production. The decreased NO
is unable to maintain vasodilation, resulting in microvascular constriction and increase in
vascular permeability. Administration of L-arginine effectively ameliorates I/R injury by
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inactivating superoxide, preventing neutrophil activation and microvascular protein
extravasatron.
1.2.5 Endothelium and endothelin
Endothelium is enriched in xanthine oxidase, which is capable of generating superoxide (O2-)
and HzOz in response to an ischemia and reperfusion insult. It has been demonstrated that
plasma xanthine oxidase activity increased dramatically following aortic occlusion and
reperfusion, as well as during hepatic and intestinal I/R (90), (91), (92). Endothelial cells not
only release superoxide and hydrogen peroxide by the enzymic activity of xanthine oxidase,
but also gives rise to many chemoattractants and cytokines including intercellular adhesion
molecule-l (ICAM-l), endothelins, P-selectin and tumor necrosis factor alpha. In the
presence of these chemical substances, activated endothelium can promote leukocyte-
endothelial adhesion, leukocytes transendothelial migration, leukocyte-platelet aggregates and
finally enhance microvascular permeability and albumin extravasation (26), (93).
Endothelin-l (ET-l) is a 2l-amino acid p"ptide, which was discovered in 1988 and has been
determined to be the most potent known vasoconstrictor (94), (95). It is released from
endothelial cells under the stimulation of ischemia and reperfusion, thrombin, transforming
TGF- ß, noradrenaline, phorbol ester and the calcium ionophore A23187 (96), (94), (97), (98),
(99). Endothelin can initiate smooth muscle contraction by promoting an influx of calcium
ions and release of calcium from intracellular stores (100), (101). Furthermore, endothelin is a
potent mitogen and may stimulate DNA synthesis in vascular smooth muscle cells and
stimulate neutrophil adhesion to endothelial cells (102), (103).
Further studies have demonstrated that ischemia alone increases the expression of ET-l
6RNA, and that ET-l peptide was clearly elevated in the cortical peritubular capillary
network (PTCN) in the kidney following ischemia without any reperfusion. Reperfusion may
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continue to stimulate ET-l mRNA expression and therefore play a fundamental role in the
injury cascade (96)
Endothelin-l is a very important agent in the pathophysiology of acute renal failure (ARF)
due to its intense vasoconstrictive properties in the kidney. ET-l has been shown to result in
vasoconstriction in both the afferent and efferent arterioles of the glomerular tuft when added
exogeneously. This effect has been postulated to be the cause of ET-1-induced ARF that ET-1
initiates vasoconstriction in the glomerular tuft along with the arcuate and interlobular arteries
(104), (105). Similarly, the endogenous sites of ET-l peptide expression in the kidney after
ischemia are in the endothelium of the cortical PTCN, which represents a continuation of the
efferent arteriole of the glomerulus into a capillary bed that surrounds the convoluted tubules.
ET-1 would cause hypoxia to the adjacent cells lining the tubules by restricting blood flow in
the PTCN. The ongoing vasoconstriction in this area may prolong hypoxia and lead to cell
death and to the typical tubular epithelial sloughing which occuffs in acute tubular necrosis
(ATN). Therefore, the localization of ET-l to the PTCN further supports the hypothesis of
ET-l being a possible pathophysiological factor in ATN (96).
The evidence for ET-l action in the PTCN leading to ATN has been supported in other
studies by administration of a receptor antagonist. The administration of the ETa receptor
antagonist 8Q123 in isolated perfused kidney models as well as in vivo models of renal
ischemia improved the renal blood flow, promoted glomerular hltration rate (GFR) and
ameliorated the proximal tubular necrosis (106), (107). The ET-l peptide, once released, is
easily bound with high affinity to ET receptors that have also been up-regulated, or at least
increased in affinity for ET, following ischemia. Thus, the most optimal time to administer
ET receptor antagonists should be prior to the ischemic insult (108)'
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In liver, endothelin-l (ET-l) has been indicated to play a role in the development of hepatic
I/R injury by causing deterioration of the hepatic microcirculation. Endothelin is released
from vascular and sinusoidal endothelial cells, as well as macrophages. Hepatic stellate cells
are nonparenchymal liver cells which are abundant in ET receptors and induce
microcirculatory disturbance. ET-l has the strongest vasoconstrictive effects among the three
isotypes and with a high affinity for ET receptors. Release of ET-l and binding to the
receptors on the stellate cells may result in its contraction and sinusoidal constriction, thus
promoting microcirculatory disturbance and leading to hepatic ischemia reperfusion injury.
The administration of nonselective ET receptor antagonist, such as TAK-044, ameliorates
hepatic ischemia reperfusion injury through improvement of hepatic microcirculation and
oxygenation along with reduced hepatic neutrophil infiltration (109).
There is an interaction between oxygen radicals and ET-l by which the exogenous reactive
oxygen species increase ET-l release and expression of ET-1mRNA in cultured human
mesangial cells. There is evidence that oxygen radical scavengers reduce basal ET-l
production, indicating that endogenous oxygen radicals may also stimulate ET-1 production.
The mechanisms of this effect are probably due to reduction in NO levels, disruption of the
cell membrane with release of stored ET-l and through augmentation of thromboxane levels,
as well as of the transcription factor, NF-KB (110), (111), (ll2)'
Under normal conditions, there is a balance between the production of endothelin (ET) and
nitric oxide (NO) to maintain the well-established tissue microcirculation. After IiR, the
release of NO is damaged due to the action of the reactive oxygen species, in favour of the
production of endothelin, resulting in inhibition of vasodilation and an increase in
vasoconstriction. This has been suggested to be a major determinant in the regulation of
regional and systemic haemodynamic function and cellular proliferation (113).
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In summary, endothelin is a most potent vasoconstrictor, which is released from endothelium
under the stimulation of ischemia and reperfusion. Free oxygen radicals could furthur increase
the expression and production of ET-l. Endothelin is also able to stimulate neutrophil
adhesion to endothelium and restrict blood flow, prolonging hypoxia and leading to cell
death.
1.2.6 Cell death by apoptosis and necrosis
Apoptosis has been well known to play an important regulatory role in various disease
processes including cancer (114), (115), autoimmune disease (116); (l1l), ventricular
dysplasia (1 1S)) and renal cystic disease (1 19). Recently, apoptosis has been recognised to be
present in various tissues after ischemia/reperfusion injury, including brain, heart, lung,
kidney and liver (120), (l2l), (122), (123).Inhibition of apoptosis often leads to improved
function in many organ systems (I24), (125), (126). Fischer er al (127) have found that with
shorter periods of ischemia, the mode of cell death in lung tissues after reperfusion is
primarily apoptototic, while with longer periods of ischemia, cell death after reperfusion is
primarily necrotic. Increased necrosis was associated with a significant deterioration of
transplanted organ function. Therefore, it was suggested that the mild to moderate ATP
depletion triggers apoptosis, while severe depletion of ATP results in necrosis (128). It is
likely that many features of the cell signalling process leading to the apoptotic form of cell
death is shared with those associated with necrotic form of cell death. The pathway that is
followed by the cell is dependent on both the nature and severity of insults, evolving from
apoptotic to necrotic form ofcell death.
Apoptosis is a process of programmed cell death, morphologically characterized by overall
cellular condensation, shrinkage, and plasma membrane blebbing, with nuclear chromatin
margination and condensation followed by segmentation and DNA fragmentation.
Consequently, the apoptotic cell is broken up into smaller membrane-bound apoptotic bodies
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that are usually phagocytosed by macrophages without initiating an inflammatory response
(129), (130). The absence of inflammation is a crucial feature of apoptosis, thus it permits cell
death without destruction of adjacent cells, and therefore is advantageous for normal cellular
turnover, development and homeostasis of organs under physiological and pathological
conditions. In contrast, necrosis is a form of irreversible cell death accompanied by the loss of
cell membrane integrity and ion pump damage, leading to cell swelling, lysis, and release of
intracellular enzymes and lysozyme, followed by neutrophil migration, inflammatory
reactions and edema (131), (132). Moreover, the kinetics of apoptosis has been demonstrated
to include shrinkage and retraction of the cell, with an active phase of pseudopod formation
around the periphery of the cell, and a quiescent spherical phase with mitochondrial matrix
swelling, followed by a necrotic phase (133).
The apoptotic cascade is initiated either by death receptor ligation and activation of caspase-8
or by mitochondrial damage and activation of caspase-g (I34). Caspases ale a family of
intracellular cysteine proteases, which cleave their substrates at aspartic acid residues (135).
These proteases are present as inactive zymogens in essentially all animal cells, but can be
triggered to assume active states, generally involving their proteolytic processing at conserved
aspartic acid (Asp) residues (136). In humans and mice, approximately 14 caspases have
been identified, which are subgrouped according to either their amino acid sequence
similarities or their protease specificities. Functionally, it is useful to classify caspases into
upstream (initiator) caspases and downstream (effector) caspases (137). There are two
pathways for caspase activation, extrinsic and intrinsic. The extrinsic pathway can be induced
by members of the TNF family of cytokine receptors, such as TNFR1 and Fas (138). The
intrinsic pathway can be induced by release of cytochrome c into the cytosol, thereby
triggering apoptosis (139). In addition, it has been demonstrated that caspases participate in
hypoxic injury to renal tubular cells and I/R injury to the kidney (140), (141).
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Mitochondria become susceptible to damage during ischemia and reperfusion. Long periods
of ischemi a can alter the electron transport complexes in mitochondria. All of the complexes
show a reduction in their activity with structural damage to the subunits after 60 min of warm
ischemia (142). Damaged complexes of the electron transport chain may be more prone to
electron leakage and this may continue for an extended period after reperfusion (143). ATP
hydrolysis during ischemia causes a rise in free inorganic phosphate, which increases
membrane permeability Qa$. Extended warm ischemia causes progressive reduction of the
iron-sulfur proteins associated with complex I (NADH dehydrogenase) or complex II
(succinate dehydrogenase) of the electron transport chain and results in liberation of the
ferrous iron that can be critical in reperfusion by reducing H202 and forming ROS (145). In
addition, ischemia also results in the impairment of mitochondrial antioxidant defenses, and
renders cells more susceptible to oxidative stress (146), (l4l). After reperfusion, ROS
produced by mitochondria may play a significant role in reperfusion injury although xanthine
oxidase and polymorphonuclear leukocytes are a source of ROS. A burst of Oz- production
occurs from the mitochondria electron transport chain when oxygen is reintroduced to the
cell. 'With the introduction of 02 during reperfusion, the electron transport chain complexes
may be damaged, resulting in a leak of electrons that react with oxygen to generate Oz- which
leads to an oxidative burst (148), (149), (143). The change in the mitochondrial membrane,
which consists of disruption of the electrochemical gradient of the inner membrane,
development of permeability transition, production of ROS, and release of apoptotic factors
into the cytosol could trigger apoptosis (150), (151). Moreover, mitochondria contain the
members of the anti-apoptotic Bcl-2 family at the external membrane, which prevents
permeability transition in cells and the release of mitochondrial apoptogenic factors (152),
(153). Together with pro-apoptotic molecules, such as Bax and Bid, Bcl-2 plays an important
role in regulating apoptosis (153). Also, cytochrome c release into the cytosol has been
implicated as an intermediate event in the initiation of apoptosis after a variety of toxic and
other stimuli and injury in several cell types (154), (155), (156) Mitochondrial damage is
18
associated with the release of cytochrome c and apoptosis-inducing factor (AIF) from the
mitochondrial intermembrane space. Current evidence suggests that cytochrome c release
activates caspases, which result in typical apoptotic cell death (139).
On the other hand, oxidative stress and the production of reactive oxygen intermediates are
also considered as mediators for apoptosis (157), (158). Reactive oxygen species and
metabolites may induce apoptosis by direct DNA damage, oxidation of lipid membranes, or
npregulation of regulatory "apoptosis genes" (157). It is generally accepted that hydrogen
peroxide can gain access to the DNA, and in the presence of iron in the DNA, results in the
site-specihc generation of hydroxyl radicals that cause the DNA damage. Furthermore,
endonuclease activation occurs as an early event leading to DNA fragmentation and thus
inhibition of endonuclease prevents hydrogen peroxide-induced DNA strand breaks, DNA
fragmentation, and cell death (159), (160). Other studies also support the idea that reactive
oxygen metabolites may be important in endonuclease activation and subsequently apoptosis
(161). Feldenberg et al (162) have shown that apoptosis induced by partial ATP depletion is
accompanied by increased activity of caspase-8 and is ameliorated by pretreatment with
inhibitor of caspase-8. Intracellular ATP concentration, which has been shown to be required
for apoptosis signal transduction, both upstream and downstream of caspase activation, plays
a crucial role in the determination of cell death fate by apoptosis or necrosis (163), (164).
It has been suggested that excessive cell loss through apoptosis can cause acute and chronic
organ insufficiency. Jo et al (165) have demonstrated that apoptosis clearly contributes to
tubular cell loss in renal I/R injury and hence subsequent renal failure. Suzuki et al (166)
found that apoptosis of mycardium is related to infarct size after ischemia and reperfusion.
Similar studies have also provided evidence for apoptotic effects in organ function in liver,
intestine and lung graft(167), (168), (127). However, other studies (169), (170) have found
that apoptotic cell death makes a minor contribution to ischemia/reperfusion injury in skeletal
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muscles. These results suggest that although apoptosis occurs in a range of tissues under
ischemia and reperfusion insult, it is probably tissue specific.
In summary, apoptosis play an important role in a variety of tissues after ischemia and
reperfusion injury. The production of ROS, damage of mitochondria and depletion of ATP,
subsequent release of cytochrome c and apoptosis-inducing factors, and activation of caspase
family members all contribute to the process of apoptosis. The advantage of apoptosis is that
it permits cell death without destruction of adjacent cells. However, excessive cell loss due to
apoptosis can lead to the organ insufficiency, while inhibition of apoptosis improves organ
function. It seems that apoptosis plays a key role in a variety of tissues after IR injury, but
only a minor contribution in skeletal muscles.
1.2.7 Ãlterations of fibronectin (FN) after I
FN as a generally agreed name emerged in 1977 .It was previously known as cold-insoluble
globulin (CIg), antigelatin factor, cell attachment protein (o-CAP), cell spreading factor
(CSF), cell surface protein (CSP), or surface fibroblast antigen (SFA). The structure of
fibronectin is a large dimeric glycoprotein composed of a series of independently folding
modular domains known as fibronectin repeats I, II, III (171). These repeating units contain
regions of domains that interact with a number of other matrix molecules as well as different
cells, mediating cell migration, differentiation, proliferation and matrix assembly (172), (113).
Structural diversity in fibronectin arises by regulated alternative splicing of a single gene
transcript in three segments, termed EIIIA, EIIIB, and V in rats, and ED-A, ED-B, and IIICS
in humans (171). The EIIIA or ED-A and EIIIB or ED-B domains are either included or
excluded as intact type III homology repeats. The V or IIICS may be excluded, partially
included, or fully included. The latter form contains the connecting segment-l (CSl) region,
which is known to play a pivotal role in mediating leukocyte adhesion (174). FN variants
which include the EIIIA and EIIIB segments are prominent in FN produced during
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embryogenesis, and their expression in the adult tissues is minimal except when induced
under certain pathological conditions (175), (I76). Adult liver synthesizes the plasma form of
FN, which excludes the EIIIA and EIIIB domains, whereas these domains are markedly
increased during cutaneous wound healing (777), (178) and neointimal hyperplasia (179),
(1S0). Alternative splicing of the FN gene allows for the generation of multiple isoforms with
20 isoforms possible in humans (181). FN has a molecular weight of 440 kDa.
FN is considered as a multifunctional protein that is now studied by many different types of
biologists. It exists in two forms: plasma fibronectin and tissue (cellular) fibronectin. Plasma
fibronectin is a soluble form of FN in blood and lymph fluids, which is mainly produced by
hepatocytes and secreted into plasma. Macrophages, fibroblasts, endothelial cells, and smooth
muscle cells produce tissue fibronectin that is one of the major components of the basement
membrane of tissues. It plays an important role in cell to cell and cell to matrix interactions
such as lymphocyte adhesion, migration and activation (171), (182), (183), (184). Fibronectin
is also essential for embryonic development (185).
Plasma fibronectin (pFN) is an opsonic molecule that markedly enhances macrophage
phagocltic clearance ofblood-borne nonbacterial particulates (186), (187), (188). Clearance
of such debris from blood by macrophages of the liver and spleen minimizes their deposition
in extrahepatic beds such as the lungs and kidneys and is thought to ensure integrity of organ
function by preventing microembolization of these particulates in organ vascular beds with
subsequent organ failure (189). The depression in liver and spleen phagocytic function is
associated with a significant increase in the deposition of particles in the lung (188). Acute
depletion of pFN has been well documented after severe ttauma, burns, infections and
periphreal ischemia and reperfusion injury (190), (191), (192), (188). This acute depletion is
attributed to its rapid binding to sites of tissue injury and as well, its consumption as an
opsonic protein in the clearance of tissue debris circulating as a result of injury and wound
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infection (191), (193). Some studies have shown that the loss of lttl-1ub"ll"d f,rbronectin from
the plasma after injury is accompanied by its increased localization in the injured tissue as
well as in the liver, the latter reflecting Kupffer cell phagocytic clearance of fibronectin
opsonized blood-borne tissue debris (193), (188). The deposition pFN in tissue matrix
suggests that it may play a crucial role in early wound healing and tissue repair by improving
fibroblast, epithelial and endothelial cells adhesion and migration. In addition, rebound
hyperfibronectinemia has been observed following the initial decline of plasma FN after
thermal injury or skeletal muscle ischemic injury (193), (188). Whether the elevated pFN is a
beneficial response that contributes to host defense and wound repair or a reflection of tissue
injury without any protective role remains unclear. Elevated pFN may improve macrophage
phagocytosis and wound healing and promote restoration of lung endothelial integrity after
injury. The major source of rebound pFN elevation is from liver synthesis mediated by
cytokine IL-6 (188).
Alterations in FN have also been identified in the basement membrane during organ I/R. In a
small bowel transplant model, increased FN was observed in the basement membrane within
the villi cores and crypt areas after reperfusion as well as during rejection (I94). In heart
allografts, FN accumulation in the cytoplasm of cardiomyocytes was positively correlated
with the degree of cardiomyoclte coagulation necrosis. Labarrere et al (195) also found that
there was a correlation between the deposition of FN and later development of chronic
rejection or graft failure. Moreover, the increased FN deposition was observed in heart
allograft biopsies (1 96).
FN accumulation has been observed in experimental myocardial infarct. It was localized in a
patchy fashion in the cytoplasm and interstitial space of some myocytes in the infarct area.
Tlris accumulation continued to increase at 24 h, reached a maximum at 48 h and decreased
thereafter (197). pFN and platelet-derived FN were considered to contribute to the
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accumulation of FN observed in necrotic myocardium and interstitium (198), (199). It is
likely that this FN acts both as a chemotactic stimulus for inflammatory cells to migrate into
the areas of myocyte necrosis, and as a scaffold for endothelial cells and fibroblasts to grow
and collagen assembly. Furthermore, the accumulation of FN may function as a template for
the deposition of collagen during healing of the infarct. In addition, FN may improve platelet
aggregation (200) and induce the release of platelet products such as TGF-ßr and platelet-
derived endothelial cell growth factor (201), (202). Local synthesis of fibronectin by
sprouting endothelial cells and connective tissue cells at the border zone of the infarct area
appears to play a role in the angiogenesis that characterizes infarct healing (197). FN has been
found to accumulate more rapidly in animal models of cardiac I/R than in hearts of animals
with permanent ligation of a coronary artery (179), (203).
Similar phenomena were observed in the kidney following ischemia and reperfusion injury.
The concentration of hbronectin rapidly increased in all areas of the kidney as early as 3 h
after ischemia, reached a maximum at day 5, and declined thereafter (204), (205). In
particular, there was a marked accumulation of FN in the distal tubular lumen (205). It is
unclear whether the source of fibronectin is from plasma, the tubular epithelial cells or a
combination of both. It is possible that the pFN escapes into the peritubular space and tubular
basement membrane during the congestion and hyperemia associated with early ischemia and
reperfusion injury and with increased capillary permeability. At later stages, FN may be
synthesized locally by tubular epithelium. Likewise, local synthesis of FN by injured
epithelial cells has been observed in the restitution of skin wound, intestinal epithelium and
cornea (1 78), (206), (207).
Furthermore, accumulation of FN has also been found in lung injury. In the lung, FN existed
in the interstitial matrix as well as under both the alveolar epithelial and endothelial cell layers
(208), (209). These cells can also synthesize FN and incorporate FN into the extra cellular
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matrix via a cell-depencent polymeization process (210), (2Il). Thus, FN was considered to
support attachment and survival of normal human bronchial epithelial cells and induce
integrin clustering and focal adhesion, implicating FN plays a role in lung injury and repair
(2I2), (213).It has been demonstrated that plasma FN escapes and incorporates into the lung
extracellular matrix during lung acute injury in postsurgical bacteremia, and then attenuates
the increase in lung endothelial protein permeability and stabilize the integrity of the lung
vascular barrier (208), (214), (215), (216). Curtis and colleagues (217) have also found that
purified human plasma FN was able to incorporate into subendothelial matrix and co-
localized with endogenous bovine FN in the inflammation-induced lung injury and reduce the
protein permeability. The mechanism of increased FN in the injured lung is possibly due to
the interstitial and alveolar spaces being flooded with plasma and local synthesis by activated
macrophages, fibroblasts, endothelial cells and type II alveolar epithelial cells in damaged
pulmonary parenchyma(216).It could be postulated that fibronectin may function to organise
the subsequent deposition of other matrices such as collagen in the extracellular matrix and
improve repair of injury.
The effects of increased expression of fibronectin following ischemia and reperfusion are not
well elucidated. Fibronectin as a multifunctional protein, contains multiple functional sites
including cellular binding, spreading, proliferation and differentiation domains, all of which
are of potential importance in cellular regeneration and recovery from injury after ischemia
and reperfusion (171), (2I5).In one recent study, Sakai eI al (218) found that deposition of
plasma fibronectin in the infarcted area of the brain in control mice was related to the
upregulation of the anti-apoptotic protein Bcl-2, thereby preventing caspase-3-mediated
apoptosis" However, deposition of plasma fibronectin was not detected in the infarcted brains
of plasma hbronectin-deficient (gene knockout) mice, which was accompanied by an
increased number of caspase-3-positive apoptotic cells and greater infarction volumes. These
24
results suggest that plasma fibronectin incoporated into the tissue matrix may protect cells
against ischemic injury by inhibiting cellular apoptosis.
Moreover, others found that synthetic hbronectin peptides could inhibit polymorphonuclear
leukocyte (PMN) recruitment in ischemic tissue concomitant with reduced infarct volume and
improve neurological outcome in rat cerebral ischemia / reperfusion (219), (220). The role of
the synthetic FN peptides (FN-C/H-V) in mediating the adhesion of leukocl'tes to the
endothelium is complex and poorly understood. Possibly, this may be attributed to its
interaction with integrins on the cell surface and modification of leukocyte adhesion (220).
Not only is FN a target of I/R- induced injury, but it is also an active participant in the
immune cascade leading to graft rejection (221), (194) In more recent studies, FN has been
found to play a crucial role in allograft rejection. EIII A 
* FN expression by macrophages is a
critical feature of graft rejection versus tolerance. The lack of EIII A* f'N expression by
infiltrating macrophages in the tolerant state was associated with marked depression of IL-2
and IFN-r at both mRNA and protein levels. The expression of EIIIA* FN may amplify the
rejection cascade through upregulation of type 1 cytokines,IL-2 and IFN-r in allografts (222).
The interaction between o4-integrin and FN may be important to leukocyte homing to the
graft site (223). Pathologically, the most prominent feature of chronic rejection is expansion
of extracellular matrix and widening of the basement membrane. Clinically, in patients with
acute or chronic kidney allograft rejection, urinary FN levels are found to be significantly
higher than those of patients with stable graft function. This enhanced urinary FN is likely to
be derived from glomerular protein leakage and tubular cell secretion (224). The integrin
family of cell surface receptors has long been known to play an essential role in the physical
aspects of cellular adhesion. These molecules represent the principal receptors for
extracellular matrix proteins such as FN but also participate in transduction of outside/inside
signals and contribute to trigger a multitude of cellular events including activation and
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differentiation (225). The adhesion of T cells to FN via c¿4-integrin and a5-integrin could up-
regulate the levels of NF-KB (226) and promotes the activation of fhe pl25 F^K lzap-7T
complex in human T cells (226).
FN exerts synergistic effects on T-cell activation by acting as a costimulator for both CD4*
and CD8* T cells through the T cell receptor (227), (1S3) and cytokine release (228).The
production of IL-2 and TNF-a is also stimulated by interactions between CD4* T cells and FN
(228), (229). It was found that there were a molecular heterogeneity in FNs observed in
cardiac allografts and that the incorporation of the EIIIA, EIIIB, and V domains in the FN had
distinct temporal and spatial distribution patterns during rejection (230).In addition, FN was
increased in cardiac allografts as early as 3 hours post transplant, and its preferential
expression by day 4-6 before the actual rejection was accompanied by a concomitant rise of
VLA-4* cells (231). Administration of fibronectin connective segment-l (CS1) peptide could
block CS1-g4ß1 interactions and decrease intragraft infiltration by CD25* cells, then interrupt
the host immune cascade. CSI peptide therapy is capable of abrogating acute rejection and
prolongs cardiac allograft survival in rats. This effect was accompanied by decreased
intragraft expression of total FN and cellular adhesion molecules, cr4 ß1, VCAM-I and
ICAM-1, and reduced infiltration of CD4*, CD8, and CD25* cells with diminished expression
of mRNA coding for Thl (lL-2, IFN-r) and Th2 (IL-4, IL-6) cytokines. This
immunosuppressive effect could be reversed and acute rejection recreated by adjunctive
treatment with recombinarrt IL-2 in rats (232). Furthermore, the use of CSl peptides
effectively prevented progressive allograft failure associated with chronic rejection (233). The
lack of FN in tolerant rats associated with infiltrating leukocytes plays an important role in the
maintenance of tolerance by depressing local expression of Thl cytokines that otherwise
facilitate acute graft rejection in transplant recipients (234).It was also found that FN could
augment T cell adhesion, proliferation and secretion of the cytokines IL-2 and IFN-r triggered
by peptide-MHc complexes (235). Therefore, administration of CSl peptide to attenuate
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lymphocyte sequestration and cytokine dependent immune cascade in the allografts could be a
novel therapeutic approach to modulate graft rejection. Others have found that CSl peptides
inhibite leukocyte recruitment and attenuate the acute inflammatory response with an almost
complete blockade of chronic inflammation in an erosive model of polyarthritis (236).
Moreover, in a murine contact hypersensitivity model, it was found that CSl peptides could
partially inhibit T-cell migration to skin inflammatory areas (237).
On the other hand, T-lymphocyte migration into tissues during allogragt rejection requires
local degradation of the basement membrane. Transient adherence to fibronectin induces the
production of activated forms of matrix metalloproteinase-2 (MMP-2) and MMP-9, as well as
down regulation of tissue inhibitor of metalloproteinase-2 (TIMP-2) by T cell lines,
facilitating the T cell migration into the extracellular matrix (238).
Fur-thermore, FN plays a key role in several stages of wound healing including platelet
aggregation, epidermal cell migration and differentiation, collagen matrix assembly and
wound contraction (239), (240). Macrophages are the first cells in healing wounds to express
increased amounts of FN mRNA locally as early as 2 days after injury. Some of these FNs
contain the EIIIA and EIIIB domains. At a later stage, granulation tissue fibroblasts assume
the role of expressing FNs in both adult and embryonic forms (171).In some forms of wound
healing, fibronectin splicing patterns resemble embryonic patterns, suggesting that specific
types of fibronectin are important in wound healing (178).
A complex interaction between FN and members of the integrin family occurs on cell surface,
by which the cellular function could be changed. The fibronectin fragments that bind to cells
may help to regulate monocyte interactions with tissue matrix by acting upon the monocyte
FN receptor VLA-5 (241). The interactions between VLA-5 and FN significantly enhance
both spontaneous and monocyte chemoattractant protein-l (MCP-l) driven monocyte
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migration into a tissue matrix. It was also observed that VLA-5 - mediated adhesion of
monocytes to native FN may induce cellular apoptosis (242). The adhesion of fibronectin to
macrophages could augment macrophage phagocytosis of apoptotic neutrophils at
inflammatory sites during the resolution of inflammatory responses. This observation suggest
that the extracellular matrix enviroment may provide regulatory signals that act indirectly to
alter the potential for removal of apoptotic cells and influence the process of resolution of
inflammation (243).In addition, it has been shown that soluble fibronectin peptides trigger
apoptosis of nontransformed fibroblasts in culture and in fibrin gels through disruption of an
integrin-mediated survival-signalling pathway (244). Synthetic FN peptides (Trp-9-tyr) have
been found to alter the progression of leukocyte-mediated tissue destruction after thermal
injury (245). Moreover, FN-bound TNF-o has been observed to stimulate significantly the
secretion of MMP-9 by monocytes. This interaction was suggested to limit the availability
and bioactivity of TNF-oc to target areas of inflammation (246).
The production of FN has considered to be influenced by cytokines due to their combined
elevation during many pathological conditions. TNF-cr was demonstrated to stimulate the
expression of fibronectin in fibroblasts isolated from the heart (247). TGF-p is abundant in
injured lungs and has profound effects on FN production by alveolar type II cells (248). TGF-
beta and IL-l were also known to promote FN synthesis in glomerular basement membrane in
autoimmune glomerulonephritis (249).
In conclusion, FN is a multifunctional protein that exists as plasma and cellular FN. Plasma
FN is an opsonic molecule that markedly enhances macrophage phagocltic clearance of
blood-borne nonbacterial particulates. cFN is one of the major components of the basement
membrane. Alterations of both pFN and cFN were observed during the process of ischemia
and reperfusion. The rapid deposition of FN in the basement membrane during I/R was
considered to attenuate tissue injury and, as well, to facilitate tissue repair. Moreover, there
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are complex interactions between FN and members of integrin family on cell surface or
cytokines by which cellular functions could be changed. FN was also found to be an active
participant during the immunoreactive cascade in an allograft that undergoes I/R insult.
1.2.8 Alteration of laminins after IlR.
Laminins (LNs), discovered in 1979, are multifunctional glycoproteins and major components
of extracellular matrix that contribute to the architecture of the basement membrane and play
significant roles in adhesion, growth, migration, and differentiation of several cell types (250),
(251). LN is composed of three subunit molecular chains: cr, ß, and y. Five a, 4 ß, and 3y
chains have been identified to date that combine to form 12 different isoforms which have
tissue-specific and developmentally regulated expression patterns. The differential expression
of LN isoforms under differential endothelial cell activation suggests a role for LN in
inflammatory events (252), (253), (254).It has been demonstrated that the amount of LN in
glomerular basement membrane (GBM) is significantly less than that in the tubular basement
membrane (TBM), implying that the GBM is vulnerable to the damage in a multitude of renal
diseases (254). The change in expression of LN chains in glomeruli may aggravate
progressive immune injury in a mice model of lupus nephritis (255). Moreover, it was found
that LN could protect mesangial cells from apoptosis induced by serum starvation and DNA
damage in a in vitro rat model. This effect is not associated with changes in cellular levels of
apoptosis regulatory proteins of the BcI-2 family, suggesting that the glomerular mesangial
cell survival is dependant on interactions with certain components of ECM (256).
Furthermore, the occurrence of some diseases, such as epidermolysis bullosa and congenital
muscular dystrophies are related to certain LN chain gene defects (257), (258). It has also
been found that lack of the a3 ß1 chain causes defective kidneys and lungs (259).
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Laminin-5, an isoform of LN, has been demonstrated to promote adhesion, migration, and
scattering of several types of cultured cells more efficiently than all other ECM proteins. The
extracellular deposition of laminin-5 is mediated by the short arm of the y2-chain that steers
intermolecular interactions with basement membrane components and promotes cellular
adhesion (260).In addition, another LN isoform, laminin-8 is synthesized and secreted by
blood lymphoid cells, and this LN isoform could promote chemokine-induced migration and
proliferation of the cells (261). The laminin-8 and laminin-lO are able to improve T cell
migration into the sites of inflammation (262).
Moreover, it has been found that anti-LN treatment significantly reduced the migration of
peripheral lymphocy.tes into the allograft. This observation implies that LN may play a crucial
role in lymphocyte traff,rc, involved in immunoreactivity of the allograft (263) and allograft
rejection (264). In another study, LNs have been determined to be able to influence
immgnocompetent cells and possibly play an important role in overcoming the allograft acute
rejection (265).Indeed, LNs have been observed to play a key role in T cell migration (263),
(266) and T cell differentiation (267).
Recently, ECM including LNs, has been suggested to play an important role in I/R injury and
organ allograft rejection. The level of LN in plasma was significantly increased after
reperfusion and the anti-LN staining enhanced as well in the basement membrane of small
bowel in a rat transplant model. This enhanced staining was also observed during the
occuffence of graft rejection (194) In addition, it was found that elevated LN was correlated
significantly with the extent of preservation and reperfusion injury in human liver transplants.
These ongoing changes in basement membrane may increase the risk of subsequent early
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allograft rejection (268). Thus, investigation of levels of LN may be of value for predicting
the development of allograft rejection.
However, the change in patterns of LN in brain and kidney are different from those observed
after ischemia and reperfusion in the gut or liver. The LN fluorescence intensity was found to
decreased in the basal lamina components following cerebral I/R. The loss of LN and other
components in basement membrane were considered to be responsible for the disruption of
microvascular integrity and increased vascular permeability (269).In kidney I/R injury, LN in
tubular basement membrane showed a dramatic decrease after 18 h of reperfusion, which
persisted for 48 h. This was followed by a marked increase up until day 5 (204). These results
imply that the alterations of LN is tissue specific and time dependent after I/R. Alterations of
LN are also temperature dependent during ischemia. The changes in LN were more prominent
during cold ischemia than those during warm ischemia in small bowel (270). LN in the
basement membrane of skeletal muscle found to be degraded after moderate ischemia without
reperfusion. This degradation is closely associated with the up-regulation of matrix
metalloproteinases, MMP-2 and MMP-} (27I). Thereby, modulation of the expression of
MMPs could provide a new therapeutic target for critical skeletal muscle ischemia injury.
Furthermore, it has been determined that there are some interactions between LN and
cytokines. For example, TNF-a may function together with LN to strengthen cellular binding
to the ECM and promote immune cell recruitment to inflammatory site (272).
In summary, LN is another multifunctional glycoprotein and major component of
extraoellular matrix. Different isoforms of LN were found to play a role in the development of
certain disease. Alterations of LN were also observed during ischemia and reperfusion injury.
The administration of LN peptide was demonstrated to ameliorate ischemia-induced tissue
3l
injury. In addition, LN was found to participate in allograft immunoreactivity and graft
rejection.
1.2.9 Remote organ lung injury after lower torso IlR.
Remote organ injury following lower torso I/R is associated with high rates of morbidity and
mortality. This injury manifests as adult respiratory distress syndrome (ARDS), renal failure
and liver dysfunction (273), (274), (275). Lung is the distant target organ most frequently
affected. Lung injury is characterised by progressive hypoxemia, pulmonary hypertension,
increased pulmonary vascular permeability, pulmonary edema and neutrophil sequestration
(273), (216), (65).
Lower torso I/R is a common clinical event, which frequently occurs in vascular surgery, such
as in elective and ruptured abdominal aortic aneurysm repair. A number of studies have been
conducted to investigate the mechanisms of the remote lung injury associated with lower
torso I/R, implicating humoral mediators during I/R in playing a pivotal role in pathogenesis
of lung injury. The injury is neutrophil-mediated with the destruction of the endothelial
basement membrane. lmmuno-depletion of neutrophils before the ischemic insult was shown
to moderate both the local and remote organ injury in animal models (277), (278). The
basement membrane of the capillary endothelium and the alveolar epithelium is a complex of
type IV collagen and other proteins. MMPs and serine proteases are the primary neutrophil
products that may degrade the basement membrane. Oxygen free radicals are generated and
released from the ischemic tissue and lead to peroxidation of lipid cellular membrane and
production of Tx A2,LTB4 (279), (30), (66). Interleukins such as IL-10, TNF-o are also
produced and released and complement activation also occurrs during ischemia and
reperfusion (280). These chemoattractants and cytokines can activate the circulating
neutrophils and facilitate the neutrophil-endothelial cell interaction via the selectin family of
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adhesion molecules (281), (34), (282)) and result in the adherence, migration and
sequestration of neutrophils into interstitium (283), therefore leading to an increase in
microvascular permeability and extravasation of albumin (284).
Complement inhibition by using soluble recombinant form of complement receptor type 1
(sCRl) has been successfully shown to ameliorate local and remote organ injury after skeletal
muscle and gut I/R (285), (286). Remote lung injury after hind limb VR was also reported to
be selectin dependent. Blockade of selectin using selectin antibodies or recombinant soluble
selectin glycoprotein ligand 1, was demonstrated to reduce remote lung injury (287), (283). In
addition, Harkin et al (288) have found that rBPI zr, which is a recombinant amino-terminal
fragment of the bactericidal/permeability-increasing protein (BPI), can reduce endotoxemia
and cytokine production, therefore attenuating circulating neutrophil priming, and
ameliorating the remote acute pulmonary dysfunction after lower limb ischemia-reperfusion'
Furthermore, activated neutrophils can release oxygen free radicals and proteolytic enzymes,
thereby degrading and remodelling the extracellular matrix, resulting in the destruction of
broncho-alveolar basement membrane (283), (289), (290).
In recent studies, upregulation of MMPs was identified to contribute to acute lung injury in
several pathological processes. Increased expression of MMP-1, MMP-2, and MMP-9 was
detected in the lungs of patients with idiopathic pulmonary fibrosis and histocytosis X (29I),
(292). Increased MMP-9 activity and mRNA expression were observed in lung tissue
following ischemia and reperfusion. This increased MMP-9 was contributed by leukocytes
recruited into the pulmonary interstitum (293). In patients with adult respiratory distress
syndrome and asthma, over-expression of MMP-9 and TIMP-I were demonstrated in the
bronchoalveolar lavage fluids (294), (295).In a model of airway injury, MMP-7 (matrilysin)
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expression was up regulated in migrating epithelial cells and the activity of this proteinase is
required for repair of airway wounds (296). The level of MMPs correlates directly with an
increase in the concentration of degradation products of type IV collagen within the basement
membrane (297). The effect of inhibition of matrix metalloproteinase by chemically modified
tetracyclines in lung injury following cardiopulmonary bypass was investigated in a pig
model (298). It was found following administration of tetracycline 3 (COL-3) that levels of
both elastase and MMP-9 and MMP-2 activity were reduced, associated with decreased
neutrophil infiltration into the pulmonary interstitium and decreased extracapillary
extravasation of protein. This prevention of lung injury is due not only to inhibition of MMPs,
but also to the reduction of neutrophil infiltration. Likewise, Tobias et al (299) demonstrated
up-regulation of MMP-9 in lung tissue in acute pancreatitis and this increased expression was
colocalized with transmigrated neutrophils. MMP inhibition by administration of batimastat
(BB-94), was recognised to reduce neutrophil transmigration and alveolar capillary
permeability in pancreatitis-associated lung injury. In abdominal sepsis induced lung injury,
increased serine protease activity was demonstrated in circulating leukocytes and a substantial
increase in the spontaneous release of oxygen radicals by circulating granulocytes was also
observed, suggesting that systemic priming of granulocytes and increased production of toxic
neutrophil products may be critical for the development of organ injury (300). The pro-
inflammatory mediators IL-lß and TNF-cr were speculated to be potent stimulants for MMP-9
release from neutrophils (301). These results suggest that up-regulation of MMPs may play a
central role in acute distant lung injury. This elevated activity of MMPs is induced by pro-
inflammatory cltokines. Thus, inhibition of MMP activity may be a new therapeutic target to
reduce the lung injury. Previous work in our laboratory has identified that the levels of
MMP-2 and MMP-9 were elevated after 4 bilateral hind limb ischemia with shorter times
reperfusion and returned to lower levels following T2hreperfusion (302). This result implies
that over production of MMPs may play a role in distant lung injury after lower torso I/R.
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It is clear that lower torso I/R can initiate a systemic inflammatory response, which is
characterised by the production of proinflammatory cytokines, release of free oxygen radicals
and adhesion molecules, and activation of circulating neutrophils. These activated neutrophils
can be sequestered into the lung tissue via activation of selectins and adhesion molecules.
Following stimulation by cytokines, activated neutrophils produce matrix metalloproteinases
and serine proteinase, which degrade the basement membrane. The progression of this
damage will inevitably result in the increase of vascular permeability, the extravasation of
albumin into the bronchi-alveoli and finally, causing pulmonary insufficiency.
1.2.10 Defence strategies for IiR injury
Based on the studies of the mechanisms of I/R injury, a number of therapeutic strategies have
been introdued to ameliorate this unavoidable injury. Antioxidation and scavenging of ROS is
one of the major targets for ameliorating I/R injury. Glycine infusion has been shown to have
a cytoprotective effects on skeletal muscle I/R injury, leading to less muscular edema and
necrosis (303). The mechanism of protective effect is that glycine can promote the formation
of phosphocreatine (Pcr), which is an energy source for cells, and therefore preserve
mitochondria integrity and maintain the oxidative-phosphorylation pathway, resulting in
resistance against the effects of oxygen radicals, tumor necrosis factor and metabolic acidosis.
These protective effects of glycine have also been observed in kidney undergoing I/R injury
(304), (305). Protective effects were also observed in skeletal muscle I/R injury following
administration of adenosine, resulting in overproduction of nitric oxide and down regulation
of TNF-u (306). M40401, a highly active SOD mimetic, has a protective effects in splanchnic
ischemia and reperfusion injury by reducing lipid peroxidaton and inhibiting of peroxynitrite
production (307). The bioflavonoid quercetin was demonstrated to be useful in protecting
skeletal muscle against I/R injury. It can prevent excessive accumulation of superoxide,
preserve the concentration of nitric oxide at a sufficient level to maintain vasorelaxation in the
surrounding smooth muscles and inhibit platelet aggregation and adhesion within the lumen.
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Moreover, it may increase the total nitric oxide concentration by scavenging superoxide in the
endothelial cells (308)
Vitamin E is a powerful antioxidant, which is able to reduce the extent of peroxidation-related
I/R injury. Most studies have shown that vitamin E can enhance cardiac function and recovery
after aperiod of experimental l/R or after coronary artery bypass (309), (310). It has also been
found that there was a marked consumption of vitamin E in abdominal aortic surgery
including cross clamping of the aorta. Supplementary administration of vitamin E to patients
undergoing abdominal aortic repair was determined to have a protective effect against I/R.
The mechanism of this effect is not only due to direct effects of the antioxidant, but also due
to limiting neutrophil infiltration into the tissues during the period of ischemia and
reperfusion (3 1 1), (312).
Furthermore, Allopurinol has been shown to protect skeletal muscle against I/R injury. This is
related to the inhibition of free oxygen radical generation rather than interference with purine
salvage (313). Pyruvate, is a 3-carbon compound physiologically present in tissues and used
by the cells as energy substrate during anaerobic glycolysis. Pyruvate has been shown to act
as an ROI scavenger by reacting with hydrogen peroxide to form water and carbon dioxide,
thereby preventing the formation of the toxic hydroxyl ion and inhibiting superoxide
formation (314). The protective role of Pyruvate after I/R injury has been shown in small
bowel, kidney and liver (315), (316), (3Il). Propionyl-L-carnitine, an acyl derivative of
carnitine involved in fatty acid oxidation pathway and adenosine 5'-triphosphate (ATP)
generation of mitochondria, has been shown to lower lipid peroxidation and free radical
generation and to be able to preserve tubular cell structure after renal I/R (318)' Guanosine
was observed to protect against renal ischemic injury by replenishing GIP stores and
preventing tubular apoptosis (319). In addition, L-arginine and glutathione have both been
shown to be protective against oxygen radical-induced I/R injury (320), (321). Insulin has
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been determined to reduce postischemic myocardial apoptotic death through phosphorylation
of eNOS and the concurrent increase of NO production (321). Similarly, a protective effect of
insulin was observed in kidney after I/R injury (322).
Iinhibition of the production and binding of proinflammatory cytokines should be another
mechanism for reducing I/R injury. IL-l receptor antagonist (Il-lra) has been shown to
inhibit the effects of IL-lo and IL-IB, leading to attenuated inflammatory injury during I/R,
and to protect cells against ll-l-induced apoptosis. It has been observed that ll-lra gene
transfection protect myocardium from I/R injury shown as reduced inflammatory response
and decreased apoptosis (166). Administration of C5a receptor antagonist or blockade of
selectin has also been observed to significantly reduce ischemia and reperfusion injury (323),
(324).IL-10, an anti-inflammatory cytokine has been found to ameliorate I/R injury to the
I,,ng (325), hind limb (326), kidney (327), and heart (328). This cytokine acts by inhibition of
TNF-cr, ICAM-I and leukocyte activation.
Inhibition of caspase-3 has been observed to upregulate bcl-2 expression and down-regulate
TNF-cr, reducing cardiac allograft damage from I/R injury. This result may indicate a greater
role for the direct antioxidant effects of bcl-2 (329). More interestingly, pretreatment with
low-dose cyclosporine A (CsA) or tacrolimus (FK 506) was shown to prevent subsequent I/R
injury in the liver, brain,heart, small bowel, lung and kidney (330), (331). The mechanism of
these protective effects may involve the inhibition of NF-KB, a central transcription factor
mediating inflammatory injury and also induction of hsp 70 expression (331), (330).
Having demonstrated the importance of MMPs in tissue ischemia and reperfusion injury, it is
likely that inhibition of MMP activity may result in protective effects during ischemia and
reperfusion. A few studies have emerged to show that inhibition of MMPs either by MMP
antibody or doxycycline significantly decreased ischemic/reperfused organ injury and
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improved organ function (332), (333)). A previous study in our laboratory has also shown that
doxycycline could partially inhibit the activity of MMP-9 and MMP-2 and subsequently
reduce the degradation of collagen IV in the basement membrane of skeletal muscle (302).
Further studies are still needed to investigate the effects of inhibition of MMPs on ischemia
and reperfusion injury.
In conclusion, ischemia and reperfusion injury is a very complicated pathological event.
Although many agents have been shown to offer protective effects against I/R injury in
experiment models, few have been observed to be clinically effective. Further investigations
are still required to explore the mechanisms of I/R injury and identify effective strategies to
modify or avoid this injury.
1.3. Matrix metalloproteinases (MMPs)
Matrix metalloproteinases (MMPs) are a. family of zinc-dependent enzymes that have a
crucial role in regulation of extracellular matrix. Previous studies have identified that these
enzymes, together with tissue inhibitors of metalloproteinases (TIMPs), have been involved in
many pathophysiological processes including embryonic development, cancer invasion and
metastasis, vascular diseases, arthritis, wound healing, and I/R injury (334), (335), (333).
MMPs have many characters in common as follows; they are secreted in a latent form and
activated by removal of the amino-terminal propeptide-sequence; they contain a zinc ion at
the active site and thus are inhibited by the zinc chealtor, ethylenediamenetetraacetic acid
(EDTA); they have proteolytic activity against components of the extracellular matrix, and
their activity can be inhibited by tissue inhibitors of metalloproteinase (TIMPs) (336)' In
addition, it has been reported that some MMPs are involved in the processing of cytokines
such as TNF-a (337). MMPs have been divided into four subfamilies according to their
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substrates and structures, namely collagenases, gelatinases, stromelysins and membrane-type
MMPs.
1.3.1 Role of Matrix Metalloproteinases (MMPs) in I/R injury
Among the consequences resulting from the exposure of tissue to ischemia and reperfusion is
increased vascular permeability and edema, involving degradation of vascular basement
membrane and extracellular matrix. MMPs have been suggested as participants in this
process. It has been observed that the expression and production of MMP-2 by vascular
endothelial cells is upregulated after prolonged hypoxia and reoxygenation further increases
its expression (338). The up-regulation of MMP-2 gene expression and its protein activity
indicate that MMP-2 is of prime importance in the reponse of endothelial cells to
hypoxia/ischemia.
The expression of MMPs after ischemia and reperfusion has also been studied in vivo.
Enhanced activity of MMPs, primarily MMP-2 and MMP-9 coupled with a reduction in
TIMP expression, has been demonstrated in a variety of models of brain and heart ischemia.
Some investigations have found that both pro-MMP-9 and pro-MMP-2 are markedly
increased after focal cerebral ischemia and reperfusion and the peak of elevation is at different
times (339), (340). The early appearance of activated MMP-2 and MMP-9 is associated with
an increase in blood-brain barier permeability and hemorrhagic transformation (341). The
disruption of the blood-brain barrier during focal cerebral ischemia is also considered to be
due to activation of metalloproteinases (342). The increased activity of MMPs contribute to
degradation of vascular basement membrane and extracellular matrix, thus enhancing
microvascular permeability and albumin extravasation, even subsequent hemorrhage (343),
(269). Differential expression of MMPs during cerebral ischemia was observed by Rosenberg
et aI (344) in which MMP-9 and MMP-3 were produced, and MMP-3 may activate pro-
MMP-9. Elevation of MMP-2 was detected early by Heo et al (341) in focal cerebral ischemia
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and this elevation was highly correlated with the extent of neuronal injury. Furthermore, the
role of MMP-9 in ischemic cerebral injury was demonstrated in a mouse model by Gursoy-
Ozdemir and his colleagues (345). Mice treated with N-nitro-1-arginine (L-NA), an inhibitor
of nonselective nitric oxide synthase (NOS) showed significantly reduced levels of vascular
damage, correlating with decreased MMP-9 expression. Decreased expression of MMP-9 was
consistent with better-preserved vascular integrity and reduced infarct volume. Moreover, up-
regulation of MMPs was suggested to facilitate cell migration and angiogenesis after I/R
injury (346).
In ischemic myocardium, it has been observed that increased activity of MMPs was
accompanied by decreased levels of myocardial collagen (347), (348). Robert and colleagues
(349) have found that endogenous procollagenase could be activated by the ischemic insult,
leading to degradation of extracellular matrix and thus resulting in a decrease in cardiac
collagen and enlargement of the heart. Accordingly, Etoh et al (350) demonstrated that
myocardial MMP activation could occur within the myocardial infarction region during the
early post ischemia period in the absence of reperfusion. The role of MMPs in myocardial
dysfunction after I/R was further studied by Cheung et al (333). They found that the release of
MMPs from the heart into the coronary effluent was immediately increased as a consequence
of ischemia and reperfusion. The production of pro-MMP-2 and active MMP-2 peaked during
the first and fifth minutes of reperfusion and the degree of elevation of MMP-2 correlatd with
the duration of ischemia. The over-expression of MMP-2 was associated with impaired
mechanical function of the heart. In contrast, inhibition of MMP-2 by MMP antibody or
doxycycline was able to promote recovery of heart function following I/R
It has been found that reactive oxygen species can activate pro-MMP-2 in human smooth
muscle cells and inactivate TIMP-1 invitro (351), (352). Therefore, the increased biosynthsis
of peroxynitrite and decreased TIMP-I gene expression may contribute to the up-regulation of
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MMP activity observed during heart ischemia and reperfusion (353), (354). Moreover, an
elevation of MMP-9 was observed by Lindsey et al (355) both in lymph and reperfused
myocardium, with MMP-9 localized to the perineutrophil area, suggesting activation might be
initiated by neutrophils adhering to the extracellular matrix during the first hour of
reperfusion. Potential beneficial effects of early MMP-9 activation include the removal of
matrix and necrotic myocytes, releasing growth factors and cell surface receptors, remodeling
of the extracellular matrix for scar formation, processing inflammatory mediators such as IL-1
and influencing angiogenesis (356), (357), (358), (346)). The more focused secretion and
activation of MMP-9 might obviate the danger of inappropriate proteolytic degradation (355).
During the healing phase, damaged collagen must first be degraded and removed before
necrotic myocytes can be resorbed and new collagen generated to form a scar. Expression of
MMP-9 could clearly play a role in monitoring the timing, localization, and levels of matrix
degradation to optimize events of remodeling after I/R injury (359).
The alterations of MMPs in lung tissue after I/R were investigated by Soccal et al (289) and
Yano et al (293). MMP-9 activity and gene expression were low during ischemia and then
increased upon reperfusion, while no changes or only smaller increase for MMP-2 werc
observed during I/R. TIMP-I gene expression was low during ischemia and during the early
phase of reperfusion, then was dramaticlly increased at the late phase of reperfusion.
Expression of MMPs contributes to the degradation of extracellular matrix, resulting in the
increase in alveolar-capillary permeability and lung damage. The production of MMP-9 is
most widely found in inflammatory cells especially neutrophils, monocytes/macrophages and
T lymphocytes, while MMP-2 is constitutively expressed by fibroblasts, endothelial cells and
vascular smooth muscle cells (360), (361). Bronchial and type II alveolar epithelial cells
produce both gelatinases (362).Increased MMP-9 activity may be induced by the elevation of
pro-inflammatory cytokines such as tumor necrosis factor TNF-cr and IL-lß (363). In recent
studies, MMPs have been shown to facilitate shedding of molecules such as ICAM-I and L-
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selectin, from the cell surface, Their release might decrease the attachment of neutrophils to
the endothelium and ameliorate I/R-induced injury (364), (365). The increase in TIMP-I
expression observed during the late phase of reperfusion may compensate for the MMP-9
activity and reduce the extent of lung injury (293).
MMP-2 has also been determined to play an important role in renal damage following I/R. It
was found that gene expression of MMP-2 was significantly increased at an early stage of
ischemia/reperfusion and then was decreased progressively, associated with increasing
expression of TIMP-I, as well as an increase in gene expression of TGF-B. These changes
may shift the balance of extracellular matrix towards accumulation, leading to fibrosis and
development of proteinuria (366).
Apart from MMP-2, Meprin A has been determined to be another major matrix degrading
eîzyme in renal tubules, and is localized in the corticomedullary part of the proximal
convoluted tubules in kidney (367). After I/R, meprin A undergoes translocation to reach and
adhere to the tubular basement membrane, degrading the laminin-nidogen complex and
destroying the tubular basement membrane. The increase in meprin A and destruction of
tubular basement membrane may lead to acute renal failure following ischemia-reperfusion
injury (367). Moreover, it has been demonstrated that mice with low levels of renal tubular
meprin A have less ischemia induced renal damage than those with normal levels of meprin A
(363). Therefore, it is suggested that meprin A play a crucial role in renal l/R injury.
The role of MMPs in the skeletal muscle I/R injury has been studied in our laboratory. Initial
experiments have shown that ischemia and reperfusion of rat skeletal muscle resulted in
upregulation of MMF -2 and MMP-9, both in local skeletal muscle and remote organs such as
lung, correlating with degradation of interstitial collagen IV (302). The production of MMP-9
was attributed to infiltrating leukocytes, while the site of production of MMP-2 was not clear,
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possibly from skeletal muscle satellite cells (369), (370). Doxycycline, an inhibitor of MMPs
was able to reduce the activity of MMP-2 and MMP-9 and protect against collagen IV
breakdown (302).
In general, it has been observed that MMPs together with TIMPs play a pivotal role during
ischemia and reperfusion injury. Elevated expression of MMPs contributes to the disruption
of basement membrane, increasing vascular permeability and tissue edema. In addition,
upregulation of MMPs combined with adhesive molecules facilitates neutrophil adhesion to
and transmigration through endothelial cells into the target site, improving tissue remodeling.
It seems clear that production of MMP-9 can be attributed to infiltrating leukocytes.
Alterations of MMPs and TIMPs result in the imbalance of degradation and synthesis of
extracellular matrix, in favour of accumulation of extracellular matrix at the later stage of
reperfusion, leading to tissue fibrosis. Inhibition of the activity of MMPs is able to diminish
tissue injury after I/R. Therefore, modulation of the activity of MMPs following I/R could be
a new therapeutic strategy for ameliorating tissue injury.
1.3.2 The role of MMPs in vascular diseases
The blood vessel wall is an integrated functional component of the circulatory system that is
continually remodeling in response to hemodynamic changes and diseases. The endothelium
releases active mediators, such as endothelin, cytokines and nitric oxide which have
immediate vasoactive properties and longer-term trophic effects on the medial smooth muscle
cells (SMCs) that actively control vessel wall tension and synthesize the major structural
components: collagens type I, III, IV and V, elastin, proteoglycans and glycoproteins. These
components interact to form a complex network, which gives the blood vessels elastic
pþsical characteristics. The matrix therefore is a dynamic structure rather than being merely
scaffolding for the surrounding cells. Matrix integrity involves the synthesis and degradation
of these components under certain conditions.
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The most striking histological feature of abdominal aortic aneurysms is the fragmentation
and relative decrease in medial elastin and cellular inflammatory response (377), (372)"
suggesting those MMPs and their inhibitors, the TIMPs may play a key role during this
process. A number of studies have determined that MMPs play an important role in the
formation and expansion of abdominal aortic aneurysms (AAA). MMP-I, MMP-2 and MMP-
t have each been identified in aortic aneurysmal tissues proposed as etiologic agents for this
disease (373), (374), (375). Natalia et al (376) have found that increased mRNA expression of
MMP-I, MMP-9 and MMP/TIMP ratios in aneurysmal tissues as compared with normal
aortas may shift the balance towards matrix degradation, leading to the formation of aortic
aneurysms. In addition, MMP-9 was identified to be the predominant metalloproteinase
expressed in aneurysms. MMP-9 mRNA levels have been shown to be 20 times and 2 times
higher respectively than those of MMP-1 and MMP-2. These elevations in MMP and TIMP-1
mRNA are corresponded to the increases in protein levels and activity. Both mRNA and
protein levels of MMP-2 and MMP-9 were also found to be elevated within aneurysmal
tissues in other studies (377), (378), (319). Davis et al (335) found that the precursor of
MMP-2 in AAA is largely activated locally and binds to the tissue matrix tightly, facilitating
matrix degradation. Such activation may be mediated by recently characterised plasma
membrane-anchored MT-MMPs (380), other proteases MMP-I and MMP-7 (381) or reactive
oxygen species (351).
In recent studies, it was identified that MTI-MMP and TIMP-2 arc both present in the
aneurysm and normal arterial wall in the same distribution as MMP-2, suggesting an effect of
MTI-MMP complexing with TIMP-2 on the activation of MMP-2 in the media layer (382),
(383). Nollendorfs et al (384) also demonstrated that both mRNA and protein of MT-1-MMP
are increased in AAA tissue and suggested the importance of MT-I-MMP in AAA
pathogenesis was through its ability to activate pro-MMP-2. lt/'i|y'rP-2 was produced by
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mesenchymal cells and production was most prominent when mesenchymal cells were
surrounded by inflammatory cells, whereas MMP-9 was produced by macrophages
infiltrating into the vessel wall (385), (386). Patel et al (387) found that aneurysm-derived
SMCs had greater elastolytic activity than cells from age-matched normal aortic tissue.
Many cytokines that are identif,red within AAA tissue secreted from macrophages, have been
shown to enhance MMP production by vascular smooth muscle cells (SMCs) (388), (389).
Both MMP-9 and MMP-2 have potent elastolytic ability, implicating a major role in the
remodeling that occurs with AAA. MMP-2 is a more active elastase than is MMP-9 and has
the ability to degrade interstitial collagen (390). These observations support a role for MMP-2
in the medial elastolysis that accompanies aneurysm formation, causing fragmentation of
elastin and the initiation of a proteolytic inflammatory reaction, leading to aneurysm
degeneration. Moreover, Arurabi et al (391) have demonstrated that chronic aortic wall
inflammation was also mediated by macrophage infiltration and production of active MMP-I
and MMP-I2. The altered MTI-MMP proteolytic turnover and differential regulation of
TIMP-I was also observed by Annabi et al (391), suggesting that tight regulatory mechanisms
are involved in the molecular regulation of MMP activation in the pathogenesis of AAAs.
Carrell et al (392) have detected mRNA expression of 14 MMPs and 4 TIMPs in samples of
aortic wall from the patients with AAA and aortic occlusive disease (AOD). They found that
MMP-3 and TIMP-3 were significantly over-expressed in the AAA samples compared to
AOD, while a wide range of other MMPs and MT-MMPs were found at similar levels in both
AAA and AOD. This study suggests that MMP-3 (Stromelysin-1) may also be involved in
aneurysm patho genesis.
Based on the proteolytic effects of over-expressed MMPs, particularly MMP-2, MMP-9 and
MMP-3 on formation of AAA, studies have been conducted to determine if MMP inhibition
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could control the development and progression of AAA. Marimastat, an inhibitor of a range
of MMPs, especially MMP-2 and MMP-9 (393), has been shown to inhibit elastin
degradation and reduce levels of active MMP-2 within aortic tissue cultures (394). Batimastat,
an anticancer agent and MMP inhibitor, has been demonstrated to restrict the expansion of
AAA in arat model (395). Clinically, doxycycline, an inhibitor of matrix metalloproteinases,
reduced the growth rates of small abdominal aortic aneurysms. The aneurysm expansion rate
in the doxycycline group was significantly lower than that in the placebo group during 18
months follow-up in a pilot study (396).
Moreover, matrix metalloproteinases are known to be expressed in human atherosclerotic
plaques by both SMCs and foam cells (397), (388). Advanced human atherosclerotic plaques
contain chronic inflammatory infiltrates of macrophages and T lymphocytes with a lipid core
covered by a fibrous cap. These macrophages are certainly potent producers of MMP-1,-3 and
-9 (398), (399). Plaque instability, such as ulceration of the fibrous cap, intraplaque
hemorrhage or plaque rupture is responsible for the complications of atherosclerosis, resulting
in the onset of heart ischemia or stroke (400). Recent studies have shown that plaque
instability is related to the release of proteolytic enzymes, in particular matrix
metalloproteinases (40 1), (402).
MMP-1 was found to be over-expressed by several cell types in human carotid atherosclerosis
and this was correlated to the histopathological evidence of plaque instability. MMP-I
degrades the major structural collagens of the plaque, leading to plaque expansion, rupture,
and hemorrhage (403). Henney ef al (397) demonstrated the presence of mRNA for MMP-3
in coronary plaques. Loftus et al (404) found that the concentration, production and
expression of MMP-9 was significantly higher in unstable carotid plaques compared with
plaques from less symptomatic patients, while there were no differences in the levels of
MMP-I, MMP-2 and MMP-3. In addition, a sharp but transient increase in plasma levels of
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MMP-9 was detected in patients with acute coronary syndromes (405). These results suggest
that MMP-9 may play an important role in acute plaque disruption, leading to the onset of
symptoms. Furthermore, the expression of MMP-8 mRNA and protein were detected in
human atheroma in situ. This MMP-8 colocalized with cleaved, but not intact, type 1 collagen
within the shoulder region of the plaque, a frequent site of rupture (406). This evidence
suggests that MMP-8 may also exert an effect in rupture of atherosclerotic plaques. Fu et al
(407) also identified that hypochlorous acid (HOCI) generated by myeloperoxidase may
activate MMP-7, which, with myeloperoxidase, was colocalized to lipid-laden macrophages
in human atherosclerotic lesions in the artery wall, contributing to plaque rupture.
Vein graft stenosis appears to be associated with increased expression of MMP-9 and
increased MMP-2 activation (40S). In one study (409) MMPs were found to be critical for
smooth muscle cells migration and proliferation, which serve as the cellular basis for
neointimal proliferation in vivo. Recently, the TIMPs have also been implicated in the
pathogenesis of vein graft disease. The expression of TIMP-I , -2, -3 was identified during
neointima formation in organ cultures of human saphenous veins (410). This observation
suggests that TIMPs may have a potential role in graft vein neointimal proliferation. Vein
grafts transfected with the gene for TIMP-3 showed an 84o/o reduction in neointim a at 14 days
and a 58oá reduction at 28 days (411). Transfer of the TIMP-1 gene inhibited smooth muscle
cell migration and neointima formation in human saphenous vein (4I2). Gene therapy will
possibly be a new approach to the vein graft restenosis.
The role of MMPs in iatrogenic vascular pathogenesis has also been investigated. An
induction of collagenase and stromelysin gene expression was observed in response to
mechanical injury in vascular SMCs (413). MMP-9 was induced at day 3 and MMP-2 at day
7 and both enzymes persisted at elevated levels for up to 21 days after angioplasty in a pig
model (414). Other studies have also shown a transient increase in MMPs activity after injury
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during balloon angioplasty injury (415), (416). These investigations suggest that MMPs play
an important role in vascular tissue remodeling and neointima formation after balloon
angioplasty. Therefore, MMP inhibition may prevent the vascular restenosis after angioplasty.
Batimastat, an inhibitor of MMP activity, has been shown to reduce signif,rcantly late lumen
loss signihcantly after balloon angioplasty (417).
1.3.3 Matrilysin (MMP-7)
Matrilysin (MMP-7) is a member of the matrix metalloproteinase (MMP) family, which is
believed to play an important role in both physiologic and pathologic conditions. It was f,rrst
discovered in the involuting rat uterus and has a molecular weight pro-form 28 kDa and
active-form 19 kDa (418). It is the smallest known MMP and can degrade a wide range of
gelatins, proteoglycans, and glycoproteins of the matrix (418), including fibronectin, collagen
type IV, laminin and entactin (419), (420). MMP-7 unlike other MMPs that are expressed or
released only in tesponse to injury, disease, or inflammation, is expressed by non-injured,
non-inflamed exocrine and mucosal epithelium in most adult tissues. The production of
MMP-7 appears to be limited only to a few normal human cell types including glandular
epithelium of the pancreas, liver, breast, intestine and urogenital tissues (421), (422)
mononuclear phagocytes, and renal mesangial cells (423). Moreover, MMP-7 expression has
only been demonstrated in vivo in glandular epithelium (424), (425) and in human
endometrium (426).Its expression in exocrine epithelial cells suggested that it may participate
in the normal function of exocrine glands by preventing glandular obstruction (42I).It has
also been demonstrated that MMP-7 can activate several other MMPs, such as collagenase
and MMP-2 (418), (427).
Numerous studies have found that up-regulation of MMP-7 is related to tumour invasion and
metastasis. Overexpression of MMP-7 mRNA was observed in 6lo/o of gastric cancer
specimens. Immunohistochemical studies revealed that MMP-7 was mainly expressed in
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cancer cells but not expressed on other normal cells. In addition, expression of MMP-7 was
shown significantly higher in the gastric cancers of subserosa or beyond than in those within
the submucosal layer. These investigations suggested that MMP-7 may directly and strongly
contribute to the invasion step of human gastric cancer. Furthermore, expression of MMP-7,
which was increased in gastric cancer cells by DNA transfection, rendered the gastric cancer
cell more invasive in vitro (428), (429). Honda and colleagues (430) also found that the
enhanced production of MMP-7 and its activation in gastric cancinoma cells are implicated in
invasion and metastasis of human carcinomas. Therefore, MMP-7 may be a useful marker for
determining the biolo gical aggressiveness of gastric carcinoma
Enhanced secretion and activation of MMP-7 have also been observed during colorectal
carcinogenesis. The levels of MMP-7 correlated positively with invasiveness in an in vitro
assay (43 1 ). Down-regulation of MMP-7 by the introduction of anti-sense MMP-7 in BM 3 1 4
colon cancer cells caused these cells to become less invasive (432). This observation implies
that MMP -7 may contribute to invasiveness of colon cancer cells. MMP-7 mRNA has also
been detected in tumor-positive lymph nodes. Ichikawa et al (433) found that all 10
histologicaþositive lymph nodes were positive using sensitive RT-PCR techniques for
MMP-7, whereas only eight of 60 histological-negative lymph nodes were positive for MMP-
7. Tlrus an RT-PCR assay for MMP-7 may be a sensitive method for screening occult
metastases in patients with colon cancer and may complement histologic examination.
Moreover, the expression of MMP-7 mRNA and protein was also detected in endothelial cells
of arterioles and venules adjacent to MMP-7 positive tumors, while endothelial cell adjacent
to MMP-7-negtive tumors and those in normal tissues were negative for MMP-7. This
endothelial cell-derived MMP-7 may contribute to tumor angiogenesis and tumor metastasis
(434).In addition, Mori et al (435) demonstrated that MMP-7 mRNA levels were greater in
the colorectal carcinoma than in paired adjacent normal colonic or rectal mucosa. The
expression of MMP-7 mRNA in tumor tissues was also increased with increasing Duke's
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stage and was greatest in the metastatic liver lesions. These findings imply that the over-
expression of MMP-7 in human colorectal carcinomas is a useful marker for biologic
aggressiveness.
Furthermore, expression of MMP-7 has been found in other tumor cells including lung,
prostate, leukaemia, and multiple myeloma. Expression of MMP-7 in tumor cells has been
considered to be related to tumor progression and metastasis (436), (437), (438), (427).
MMP-7 has also been suggested to play an important role in the differentiation of organ
development. 'Wilson (422) found that MMP-7 was expressed in the juvenile small intestine
and reproductive organs during postnatal development. The accumulation of signifrcant levels
of MMP-7 appeared to correlate with organ maturation. It was shown that upregulation of
MMP-7 altered the integrity of the extracellular matrix and thereby induced cellular
differentiation and destruction in a tissue-specific manner (439).
The prodution of MMP-7 in normal epithelium implies that this eîzyme serves a common
homeostatic function among various types of epithelia. Some observations suggest a role of
MMP-7 in innate immunity of epithelium. Tissues in which MMP-7 is expressed are open to
the environment and therefore are vulnerable to bacterial exposure. It has been demonstrated
that acute infection of human colon, bladder, and lung carcinoma cells, primary human
tracheal epithelial cells and human tracheal explants with typel-piliated Eschericha coli
mediated a marked and sustained induction of MMP-7 expression. Based on mRNA levels,
MMP-7 expression increased as early as 2 hours after infection, continuing to rise 10 hours
after bacteria were removed and remaining elevated at 48 hours after infection. Bacterial-
mediated stimulation of MMP-7 is confined to mucosal epithelial cells. Bacterial exposure
does not affect the expression of other MMPs and does not influence MMP-7 expression in
other cell types such as macrophages, fibroblasts, and keratinocytes (296). In addition,
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bacterial infection can cause activation of the zymogeî form of MMP-7 that is selectively
released at the apical surface (440). It was recently found that cryptdins are processed to their
active forms by MMP-7 and a deficiency in this enzyme resulted in impaired bactericidal
activity in vitro and in vivo. lt was observed that MMP-7-null mice cannot effectively kill
pathogenic E. coli due to the lack of defensin activation by MMP-7 (441).It was therefore
speculated that the expression of MMP-7 in epithelial cells, along with increasing display of
epithelial defense molecules (defensins and cathelicidins) (442) may play a direct role in the
first line of defense against infection.
Interestingly, MMP-7 was also expressed in the epithelium of peribronchial glands and
conducting airways in normal lungs. It has been determined that MMP-7 was increased in
migrating airway epithelial cells in wounded human and mouse trachea. The production of
MMP-7 in conducting airways, its upregulation following injury, its induction by alveolar
epithelium, and its secretion either apically or basally suggest that MMP-7 serves multiple
functions in intact and injured lungs (443). Although MMP-7 is regulated by bacterial
exposure, it is also likely that the production of MMP-7 is induced in response to injury.
Infection can lead to injury that in turn provides an opportunity for infection. Dunsmore and
co-worlçers (443) demonstrated that MMP-7 was expressed in injured trachea. In their study,
they found epithelial cells migrated over the edge of the cut surface in an attempt to heal the
wounded tissue. Low levels of MMP-7 protein were detected in airway epithelial cells and
stronger staining was evident in ductal epithelial cells in fresh trachea. From days 1-5 of
culture, airway epithelial cells at the margin of the tissue samples moved off the basement
membrane and migrated progressively along the surface of the adjacent interstitial matrix.
High levels of expression of MMP-7 were seen in all epithelial cells that had migrated away
from the wound edge. A stronger signal for MMP-7 protein was seen in migrating cells in
contact with the underlying interstitial matrix than in cells in the migratory front without
obvious contact to the matrix. Moreover, MMP-7 was observed being released towards the
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matrix from some of these strongly positive cells, suggesting MMP-7 may be acting on an
extracellular protein to facilitate cell migration. The same pattern of MMP-7 expression was
also identifred in mouse tracheas following injury. These investigations support the idea that
MMP-7 functions in repair of the airway epithelium and reepithelialization.
It has also been observed that both the gene expression and active form of MMP-7 protein
were induced in animals exposed to combustion and ambient air particles. The alveolar
rnacrophages and monocytes were the primary source of air pollution particle-induced MMP-
7 expression (444). In addition, expression of MMP-7 was found to be involved the
pathogenesis of idiopathic fibrosis and cystic fibrosis of the lungs (445).
Furthermore, the expression of MMP-7 has been observed in cerebral ischemic insult, with
variable patterns of expression. MMP-7 expression was low up to 1 week after infarct, and
then increased remarkably in conjunction with macrophages infiltration from 1 week up to 5
years. This finding suggested a role for MMP-7 as a mediator of blood-brain barrier
breakdown and tissue destruction in cerebral ischaemic injury (446).
The biosynthesis of MMP-7 is modulated by a number of cytokines. It was found that lL-4,
IL-10, and IFN-y all inhibited the expression of MMP-7, while other cytokines such as IL-l,
TNF-a, and IL-6 do not influence the production of MMP-7. Moreover, glucocorticoids and
retinoids suppress MMP-7 biosynthesis (423), (447).
1.3.4 MMP-12
Human macrophage metalloelastase (HME, MMP-12) is another member of the stromelysin
subgroup that was initially found in alveolar macrophages of cigarette smokers (448). Its
molecule weight of pro-enzyme form is 54 kDa, while the active form of the enzyme is 22
kDa, with broad substrate specificity, being capable of degrading elastin, FN, vitronectin and
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heparan, and chondroitin sulfates (449). It has been demonstrated that alveolar macrophages
from rats produce a spectrum of MMPs, including MMP-12 that is similar to the spectrum of
enzymes produced by human alveolar macrophages (450). However, the catalytic properties
and natural substrate specificity of rat MMP-I2 catalytic domain differ from those of human
MMP-12. The purified rat MMP-I2 catalylic domain was highly active in digesting substrates
such as collagen-V, vitronectin and fibronectin, but not luaminin and albumin (451). The
cafalytic domain of human recombinant MMP-12 has been crystallised in complex with the
broad-specificity inhibitor batimastat, revealing an overall fold similar to that of other MMPs.
The active-site cleft of MMP-12 is well equipped to bind and efficiently cleave the
AlaMetPheleuGluAla sequence in the reactive-site loop of o1-proteinase inhibitor (cr1-PI)
(452). MMP-12 shares many substrates with matrilysin (MMP-7) due to similarities in
contouring and in particular, a common surface hydrophobicity both inside and distant from
the active site cleft (452). Ectopic or excessive MMP-12 proteolysis has been associated with
several pathological conditions including vascular disease, cancer growth and metastasis, host
defense against infection, chronic obstructive pulmonary disease, and gastrointestinal
ulcerations.
Extensive remodeling of the extracellular matrix plays a critical role in the development,
progression, and rupture in aneurysmal disease, which is characterised by chronic aortic wall
inflammation and destruction of medial elastin. It has long been suspected that aneurysmal
degeneration is mediated by one or more proteinases specif,rcally capable of degrading
insolubie elastin. It has been demonstrated that substantially greater amounts of MMP-12 are
present in AAA tissue than in normal aorta, with high affinity to elastin fibers observed both
in vitro and in vivo (453) (1). MMP-12 expression was localised to aneurysm- infiltrating
macrophages within the degenerative media of the AAA. In contrast, it was not observed
within the elastic media of either normal aorta or AOD tissues. These findings support the
view that localised expression of elastolytic MMPs at the site of aortic tissue damage plays an
53
important role in the pathogenesis of aortic aneurysm disease. Inhibition of the activity of
MMPs was observed to retard progression and limit expansion of experimental abdominal
aortic aneurysms (453) (395). Similarly, it was observed that the expression and activity of
MMP-12 was increased in AAA lesions from patients, which in turn, can also activate other
MMPs such as pro-MMP-2. Therefore, the formation of fuA.A lesions could be considered to
be due to a cascade of actions of MMPs including MMP-2, MMP-9 and MTI-MMP (391).
MMPs have also been identihed in vulnerable areas of atherosclerotic lesions and may
contribute to plaque instability through extracellular matrix degradation (454). Among MMPs
identified in atherosclerotic lesions, human macrophage metalloelastase (MMP-12) is a major
elastase, a macrophage-specific MMP with broad substrate specificity, which is able to
degrade many components of extracellular matrix in atheromas. Increased expression of
MMP-12 in atherosclerotic lesions is likely to be a critical step in the initiation and
progression of the atherosclerotic cascade (455). In addition, it was observed that rupture
frequently occurs over macrophage-rich areas near the shoulder of the plaque (456).
Moreover, it has been found that MMP-12 was up regulated by several cytokines such as IL-
1ß, TNF-o and GM-CSF and growth factors such as Platelet-derived growth factor-BB
(PDGF-BB) and vascular endothelial growth factor (VEGF) (456), (457). On the other hand,
the expression of MMP-12 mRNA has been observed to be inhibited by TGF-ßI and this
inhibition also occurs at the level of transcription (456).
It has been demonstrated that MMP- 12 was an efficient angiostatin-producing enzyme that
inhibits the proliferation of human microvascular endothelial cells and metastatic tumor cell
growth. That is, MMP-12 is required for the production of angiostatin and the subsequent
inhibition of endothelial cell proliferation and neovascularisation (458). Generally, tumor-
derived MMPs have been well recognised as promoters of tumor growth both by degrading
matrix barriers and by enhancing angiogenesis (459). The contribution of macrophages to
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angiogenesis must then depend on the fine regulation and balance of pro-and anti-angiogenic
factors. Moreover, Dong et al showed that MMP-12 was involved in the generation of the
angiogenesis inhibitor, angiostatin from plasminogen (460). Tumor cell lines transfected with
MMP-12 showed a reduced ability in growth and metastasis (461).
MMP-12 also appears to play a role in host defenses during a period of neutropenia. In the
absence of MMP-12, mice subjected to radiation therapy followed by allogeneic mismatched
bone marrow transplant (BMT) are prone to pulmonary hemorrhage, tissue necrosis, and
bacterial infection. It has been determined that MMP-12 is also involved in macrophage-
mediated killing of Gram-positive bacteria (462).
The proteolytic activity of MMP-12 is likelyto contribute to the pathogenesis of pulmonary
emphysema @63) (464).It has been found that mice without macrophage elastase failed to
recruit macrophages to the lung tissues and did not develop lung destruction in response to
cigarette smoke, while wild-type mice exposed to cigarette smoke developed inflammatory
cell recruitment and dilatation and destruction of alveolar walls and alveolar ducts. These
observations mirror the pathology of smoker's lungs, although human lungs also have
destruction and dilatation of respiratory bronchioles. These findings suggest a primary role for
macrophages and macrophage elastase in the development of emphysema induced by
cigarette smoke (464).In addition, MMP-12 has been found to be an important mediator in
immune complex-induced acute lung injury. It was observed that metalloelastase is necessary
for the full development of acute alveolitis in this model of lung injury, whereas reduced
injury was found in metalloelastase-deficient mice model (465). Moreover, the synthesis and
secretion of MMP-12 by alveolar macrophages was stimulated by surfactant protein D (SP-D)
(466).
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The repair process after acute lung injury depends on the balance between deposition and
breakdown of matrix molecules. MMP-12 has been found to be involved in this process. It
has been shown that MMP-12 increased significantly during the acute phase of bleomycin-
induced pulmonary fibrosis in animal experiment. MMP-12 is produced by activated
macrophages and is capable of degrading elastin and collagen type IV, the components of the
basement membrane. This activation appears to be associated with areas of hemorrhage (467)
(468). In contrast, it has been observed that macrophages from MMP-12-deficient mice have
a reduced capacity to degrade extracellular matrix protein, rendering them unable to penetrate
basement membrane (468). Clinically, it was found that the secretion of MMP-12 by
macrophages was associated with damaged areas in the lung (463).
The expression of MMPs has been demonstrated to be associated with gastrointestinal
ulcerations, involving epithelial cell migration and remodeling of intestinal stroma (469).
Macrophages are the major cell types known to express MMP-12 in adult tissues and these
cells are crucial in the immune and inflammatory events ongoing in the intestinal mucosa.
Abundant expression of MMP-12 was detected in macrophages of the inflamed lamina
propria and the ulcer base just beneath the shedding epithelium of the intestinal wall
particularly in samples of colitis ulcerosa. This result suggested that MMP-12 produced by
macrophages might mainly cleave fibronectin or laminin, leading to epithelial cell shedding,
because continuity of the basement membrane under the shedding epithelium was not
disturbed based on type IV collagen staining (470).
In summary, MMP-12, also known as macrophage metalloelastase, is mainly produced by
macrophages, facilitating the migration of macrophages during cerlain pathological
conditions. Some studies have demonstrated that MMP-12 was involved in the pathogenesis
of pulmonary emphysema, abdominal aortic aneurysms, and gastrointestinal ulcerations,
through its ability to degrade basement membrane partieularly elastin, f,rbronectin and
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laminin. In addition, MMP-12 was determined to play a role in host defense systems,
participating in the removal of Gram-positive bacteria. MMP-12 was also capable of
inhibiting angiogenesis through the production of angiostatin and abolishing the tumor growth
and metastasis.
1.4. Aims of the current studies
An animal model for ischemia and reperfusion has been established in our labarotory
imitating the surgical procedure of abdominal aortic aneurysm repair. Previous work has
demonstrated the degradation of collagen type IV in the basement membrane both in ischemic
skeletal muscle and remote organs, associated with increased expression of MMP-9 and
MMP-2 (511). To explore the further mechanisms of ischemia and reperfusion injury, the
aims of present study are to investigate the alterations in fibronectin and laminin in the tissues








ISCHEMIA AND REPERFUSION INJURY
58
2.1 Establishment of Rat model of bilateral hind limb ischemia and
reperfusion.
Male Sprague-Dawley rats weighing 250-280 gram were used for the experiment.
Anaesthesia was induced wíth 3.5Yo halothane (Zeneca Ltd. Cheshire, U.K.), lllmin of
nitrous oxide (Linde gas PTY. Ltd, Yennora, N.S.W. Australia) and 1Llmin of oxygen (Linde
gas PTY, Ltd) until the animal was asleep. Anaesthesia was maintained for 4hr using a
Midget-3 anaesthetic apparatus, administering 1-l .5Yo halothane via a Fluotec-3 vapoizer
(Cyprane Ltd, Keighley, U.K.), 0.6Llminof nitrous oxide and lllmin of oxygen.
A rat model of skeletal muscle ischemia/reperfusion has been established in the surgical
laboratory at The Queen ElizabethHospital (169), (302) and was employed in this study with
minor modihcations. Briefly, the lower limbs were shaved, taped to the table and bilateral
pneumatic digital cuffs (size 3) applied to the proximal thighs. Ischemia was produced by
inflation of the cuffs to the pressure between 220 mm Hg-240 mm Hg and monitored by
means of bilateral photo-plethysmography probes attached to the skin, distal to the cuffs and
over the femoral artery. A Doppler ultrasound machine (Parks Medical Electronics; Aloha,
Oregon, U.S.A.) was used to conhrm distal ischemia every 15 minutes by the presence of a
flat trace. Animals were monitored with a rectal thermometer probe and the core temperature
maintained at 37 "C with a heating lamp. In addition, the respiratory rate of rats was
monitored clinically.
Ischemia was maintained for 4 h before the digital cuffs were released and the return of blood
flow to the limb monitored by the return of the Doppler trace. The anaesthetic agents were
ceased firstly and inhaled oxygen was continued until the rat was completely awake. The rat
was then allowed to recover from anesthesia and returned to the holding facility.
To control for the effects of anesthesia, sham-operated rats were treated identically, except the
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digital cuffs were left deflated. The Animal Ethics Committees of The Queen Elizabeth
Hospital and The Adelaide University approved all experimental procedures used in this
study. Animals were obtained from Central Animal House, University of Adelaide and
housed at The Queen Elizabeth Hospital Animal House. All animals were fed on standard rat
chow and water ad libitum.
Reperfusion was allowed to proceed for 0, 4,24 or 72 h prior to the rats being sacrif,rced with
an intraperitoneal injection of 0.8 ml pentobarbitone sodium (l{embutal 160 mglkg, 60
mg/ml) and tissues harvested. A midline laparotomy was followed by a left nephrectomy and
middle lobe hepatectomy. Continuation of the incision to a midline sternotomy allowed for
the aspiration of 2 ml of blood by direct cardiocentesis and abllateral pneumonectomy to be
performed. Finally both medial gastrocnemii were excised below the site of the cuff. The left
lung, the middle segment of middle liver lobe and middle third of kidney and both
gastrocnemii were homogenized for later zymographic analysis. The upper lobe of the right
lung, the lower segment of middle liver lobe, inferior pole of kidney and distal third of both
gastrocnemii were frozenin liquid nitrogen for immunohistochemistry. The lower lobes of the
right lung, upper part of middle liver lobe, superior pole of kidney and distal third of the
gastrocnemii were fixed in paraffin and embedded.
2.2 Processing of tissue Samples
Blood was placed into an eppendorf tube containing 0.08 ml of sodium citrate (3.2%) añ
centrifuged at 300 x g for 5 minutes af 4C. The plasma was collected, snap-frozen in liquid
nitrogen and stored at - 80"C for later analysis. The histopathology samples were fixed in l)Yo
buffered formalin prior to setting in paraffin blocks and the immunohistochemistry samples
were snap-frozen directly in liquid nitrogen and stored at - 80"C until required.
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Tissues for zymographic analysis were weighed, 10mls of homogenising buffer (2.3.2
Homoginising Buffer) added per gram of tissue and the tissue was then homogenised at 1500
rpm for ten min (B.Braun Melsungen AG). Homogenized tissue was then centrifuged for 60
minutes (4"C) at 8131 x g. The supernatant was aspirated, placed in previously boiled Visking
dialysis tubing (14 kDa cut off) and dialysed for 18 hours at 4oC in dialysis buffer (2.3.3
Dialysis Buffer) on a magnetic stirrer to remove the urea used in the homogenising buffer.
The dialysed supernatant was snap-frozen in liquid nitrogen and stored at - 80 oC for later
analysis.
A total of 75 rats were used throughout the entire experiments. Thirty-five, which had been
previously used in other projects in the laboratory (302), were employed for subsequent
investigation of alterations in f,rbronectin and laminin in the basement membrane. The groups
of rats are summarised in Table 2.7. At the initial stage of experiment, it was realised that
fibronectin was rapidly accumulated in the basement membrane of skeletal muscle and as
well, the alterations in fibronectin in the liver is significant at the hrst glance. The changes of
plasma fibronectin were postulated to be significant after skeletal muscle ischemia and
reperfusion. Therefor, another 40 rats were used in the experiment according to the protocol
mainly for plasma fibronectin analysis and zymography investigation. These experimental
groups of rats are sunìmarised in Table2.2.
6T
Table 2.1: Rats Employed from DM.Roach
I/R : Ischemia/reperfusion.
Low dose doxycycline was defined as 50 mg/kg twice daily for 7 days.
High dose doxycycline was defined as 200 mg/kg twice daily for 7 days
52444Bilateral hindlimb IiR +
high dose doxycycline
























2.3 Buffers and Solutions Used in This Study
2.3.l.0.17oBovine Serum Albumin solutionÆhosphate Buffer Solution (BSA/PBS)
NaCl 7.2 g lL 7.2 g
NazHPO+ L48 glL 1.48 g
KHzPO¿ 0.43 glL 0.43 g
Made up to 1000 ml with Mili Q water, pH 7 .2 and then 1 g of bovine serum albumin added
to the solution.
2.3.2. Homo genising buffer:
Urea 2M 6oe
Tris (Hydroxymethyl aminomethane) HCI 50mM 3.94 g
NaCl lglL 0.5 g
EDTA (Ethylene diamine tetra acetic acid) lglL 0.5 g
Made up to 500 ml solution, pIF'7.6. This solution was then divided and hltered with 0.2 ¡rm
f,rlter into 5 aliquots of 100 ml each. 330 ul of Brij 35 solution (0.1%) and 100 ul of
phenylmethanesulfonyl fluoride (0.1 mM) were added into the solution immediately prior to
homogenising. (0.8719 PMSF in 50ml of ethanol stored under - 80 "C).
2.3.3. Dialysis buffer:
Tris (Hydroxymethyl aminomethane) Base 25 mM 19.7 g
CaClz 10 mM 7.35 g
Made up to 5 litres, pH 8.5. This solution was then divided into 5 individual of lL and
sterilised in the autoclave for 20 minutes.
0.1% Brij 35 3.3mls and 0.1mM PMSF lml were added to each lL immediately before
dialysis.
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2.3.4 Resolving gel for zymogra;phy (constituents for one gel )
MQ H2O 2.0 ml
30o/o Acrylamide mix 1.7 ml
1.5M Tris (pH 8.8) 1.3 ml
10% SDS 50 pl
10% APS 50 pl
TEMED 2 pl
Gelatin (for gelatinolytic zymography) 0.005 g
Casein (for caseinolytic zymography) 0.0075 g
2.3.5 Stacking gel for rymography (constituents for one gel )
MQ H2O 1.4 ml
30o/o AcrylamideiBis 0.33 ml
0.5 M Tris HCI (pH 6.8) 0.25 ml
10% SDS 20 p'l
10% APS 20 p'I
TEMED 2 prl
2.3.6 Solutions for zymogra;phy gel
1.5 M Tris-HCl pH 8.8
Made tp 23 .6 g of Tris-HCl in I 00ml HzO (236.4 g in lL) (Autoclave)
10% SDS (Lauryl sulfate)
0.1g in 1000 ul of Mili Q HzO.
10% APS (Ammonium persulfate)
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0.1g in 1000ul Mili Q H2O.
0.5M Tris-HCl pH 6.8
7.9g of Tris-HCl in 100 ml Mili Q HzO (Autoclave)
1 M CaClz
54 gCaCl2was dissolved in 200 ml Mili Q HzO (Autoclave)
5M NaCl
146.1 gNaCl was dissolved in 500 ml Mili Q HzO (Autoclave).
2.3.7 2 xSDS gel loading buffer
100mM Tris-HCl pH6.8
4% SDS
0.2%ó Br omophenol blue
20Yo glycerol
Plus HzO to 10 ml
2ml 0.5M Tris-HCl pH 6.8
4 ml 10% SDS
0.4 ml 5olo Bromophenol blue solution
2.5 ml 80% glycerol
2.3.8 10 xlaemmli Running Buffer
Tris Base 25 mM 15.15 g
Glycine 200 mM 72.1 g
SDS 3.5 mM 5 g
Made up to 500m1with HzO. Dilute 10 ml in 100ml Mili Q HzO when using
2.3.9 2.5"/o Triton X-100
25 mI of Triton X-100 in975 ml Mili Q HzO and stir with magnetic stirrer
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2.3.11 Coomassie Blue Staining solution
Acetic acid l0 % 50 ml
Methanol 50 % 250 mI
Coomassie Blue 0.25 % 25 ml
Plus 175 ml Mili Q HzO to 500 ml.
2.3.12 D estain solution
Acetic acid t0%
Methanol 50%
Plus 200m1 Mili Q HzO to 500 ml.












33.3 ml 1.5M Tris-HCl pH 8.8
40ml 5MNaCl











Made upto 2 liters with Milli Q FIzO and stored at 4C.







Prepared fresh before use.
2.3.15 Tris Buffered Saline for Western Blots
Tris HCI 2 42 o
NaCl 29.22 g
Made up in 1 L of Milli Q HzO, pH adjustedT.5 and autoclaved.
2.3.16 'Western Antibody Buffer
Phosphate buffered saline 45 ml
Foetal calf serum 5 ml
Tween-20 25 ¡Ã
2.3.17'Western Loading Buffer
Tris HCI 62.5 mM
SDS I.4 M
Glycerol 45 %
Bromophenol Blue 0.025 Yo
B-mercaptoethanol 2%
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3.1 Introduction
Gelatinolytic matrix metalloproteinases (MMPs) have been investigated in
ischemia/reperfusion injury, but the activity of caseinolytic MMPs has not yet been reported
in the literature. The aims of this chapter were to investigate the changes in caseinol¡ic
MMPs both in skeletal muscle following ischemia/reperfusion and in remote organs including
lung, kidney, and liver. Zymography and western blotting were employed to conduct the
investigation.
3.1.1 Matrix metalloproteinases (MMPs)
Matrix metalloproteinases (MMPs) are a family of Zinc-dependent endopeptidases targeting
extracellular matrix (ECM) compounds as well as a number of other proteins. Their
proteolytic activity acts as an effector mechanism of tissue remodeling in physiological and
pathological conditions and as modulators of inflammation. MMPs are regulated at different
levels. At the transcriptional level, MMP expression is precisely controlled by various
cytokines acting through positive or negative regulatory elements in the MMP gene promotor
sequences. In addition, MMP activity is regulated at the post-transcriptional level by
proteolytic activation of the latent proenzymes and by interaction with specific tissue
inhibitors of matrix metalloproteinases (TIMPs). Expression and secretion of both MMPs and
TIMPs are also influenced by cytokines (471). There are more than20 known MMPs, which
have been defined having the following characteristics as: (1) they are proteinases that
degrade at least one component of the extracellular matrices, (2) they contain a zinc ion and
are inhibited by chelating agents, such as phenanthrolin, (3) they are secreted in a latent form,
being activated for proteolytic activity, (4) they are inhibited by tissue inhibitors of
metalloproteinases (TIMPs), and share conìmon amino acid sequences (472), (473). The
known members of the MMP family are listed in Table 3.1, together with their preferred
substrates (473).
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Laminin, fibronectin, non-fibrillar collagenStromelysin 2MMP-10
Type IV and V collagensGelatinase B (92 kDa)MMP-9
Fibrillar collagensPMN collagenaseMMP-8
Laminin, fibronectin, non-fibrillar collagenMatrilysinMMP-7
Laminin, fibronectin, non-fibrillar collagenStromelysin 1MMP-3






MMP: matrix metalloproteinase. PMN: polymorphonuclear neutrophil. MT (1-6)-MMP
membrane-type ( I -6) matrix metalloproteinase.
3.1.2 Inhibitors of MMPs-Doxycycline
With an understanding of the effects of MMPs during pathological conditions such as tumor
invasion and progression and ischemic injury, attention has been drawn to the study of the
effects of inhibitors of MMPs on inhibition of the pathological process. Doxycycline, one of
tetracycline derivatives, has been investigated extensively for its properties of inhibition of
MMPs. Clinical trials have commenced in patients with periodontal disease and abdominal
aortic aneurysm (AAA). With good results (474), (475). The effects of doxycycline on the
severity of ischemia /reperfusion injury has also been investigated by Roach and co-workers
(302).It was shown that degradation of collagen IV in skeletal muscle after ischemia was
attenuated after administration of doxycycline by inhibition of the activity of MMP-9 and
MMP-2. Doxycycline, (6-deoxy-5-hydroxy tetracycline) interacts with the ZrJ* cation by
binding to the active Zn site in the most of MMP enzyme to mediate its inhibitory effect
(476). The dosage used in these in yivo studies was 50 mg/kg to rats twice daily or 200 mglkg
to rats twice daily by gavage. There was no evidence of toxicity of doxycycline in the rats in
this experiment.
3.1.3 Methods for detection of MMPs-Zymography
MMPs can be detected by a variety of techniques, each with its own advantages and
disadvantages. These methods include immunohistochemistry, enzyme-linked immunosorbent
assay (ELISA), mRNA analysis and zymography. Zymography has the advantages of
measuring enzymatic activity quantitatively and of distinguishing the active form from the
inactive pro-enzyme. Immunohistochemistry and in situ RNA analysis are able to localise the
MMPs and their TIMPs, thus determining the site of production (473). In studies of
mechanisms of ischemia and reperfusion injury, zymography has been extensively employed
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to investigate the activity of MMPs during the ischemic insult and following reperfusion
(47 7), (47 8), (340), (293), (302).
Zymography is an electrophoretic technique used to identify proteolytic activity for enzymes
separated in polyacrylamide gels embedded with target substrate under ceftain condition.
Basically, the substrate gelatin has been used to investigate the activity of MMP-2 and MMP-
9, whereas casein used to investigate the activity of stromelysin and matrilysin. In this
experiment, the specific substrate gelatin or casein was embedded in the polyacrylamide gels.
MMPs migrate through the gel according to their size, and then degrade the substrate at this
point on the gel. To identify the proteolytic action, the gel is stained with Coomassie Brilliant
Blue for a certain period and then washed in destain solution until the proteolytic band is
clearly observed (479). The results of MMP activity were shown as white bands on a blue
background.
3.1.4 Western blotting
Western blotting is also known as protein immuno-blotting, in which the protein of MMP's
can be examined further using a specific antibody. Combined with zymography, 
'Western
blotting was used in this experiment for confirmation of MMPs detected on the caseinolytic
zymography gels.
3.2 Materials and Methods
3 .2.1 Bradford Protein Assay
The Bradford Protein Assay is a dye-binding assay, in which a differential colour change of a
dye occurs in response to the concentrations of protein. The manufacturer's instructions for
the microassay pïocedure were conducted to determine the level of protein in the tissue
dialysate for each rat sample.
13
Using bovine serum albumin (BSA) standard concentration, The Bio-Rad Protein Assay Dye
Reagent was mixed with various concentration of BSA. Five dilutions of BSA from 1-10
¡"rg/ml were produced. Two hundred ¡rl of Dye reagent was mixed with BSA at appropriate
dilution and mili-Q water to make up to 1 ml. The solution was incubated at room
temperature for at least five minutes and the absorbance measured at 595 nm. Each sample
was duplicated in the same run and the average of absorbance was recorded. A graph was
drawn from the result of these known standard protein concentrations, indicating the protein
level versus absorbance at 595 nm (An example graph in Figure 3.f ).
The tissue samples were diluted with Dye reagent and milli-Q water in the same run as above.
Protein concentration of tissue samples was calculated according to the standard equation,
which was displayed in the graph by Excel software.
Figure 3.1 The standard graph for protein concentration assay (Bradford assay'
example)
X: Protein concentration in the samples. Y: Average absorbance measured at 595 nm
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3.2.2 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE)
Substrate-Embedded Zymography
The protein concentration of tissue samples was determined using a Bradford Assay method
(BioRad, Hercules, CA, U.S.A). SDS-PAGE was performed using a modification of the
procedure as described by Frisdal et al (27I). Briefly, aI0 %o polyacrylamide resolving gel
(2.3.4) embedded with either 0.1 o/o gelatin or 0.15 Yo þ-casein (Sigma Aldrich). A 5%
stacking gel (2.3.5) was layered on top and allowed to set for 45 min. Wells were loaded with
equal amounts of protein (80 ¡rgllane) diluted 1:1 in laemmli loading buffer (2.3.I8). In order
to identify the molecular weight of the proteolytic bands a standard protein molecular weight
rainbow marker (Amersham) was loaded onto the gel. A standard MMP positive control
(Sigma-Aldrich) was also loaded to allow for comparisons between gels. Gels were run for 40
min at 60 volts, followed by 90 min at 100 volts or until the dye front ran off the bottom of
the gel. The gels were then washed 3 times in2.5 o/oTritonx-l00 solution 3 times for 15min,
followed by 5 minutes wash in development buffer before incubation at 37 
oC in development
buffer for 18 h. Having allowed for the gelatinolytic or caseinolytic digestion to occur during
the incubation period, the gels were stained with Coomassie Brilliant Blue Staining Solution
(Sigma Aldrich, 2.3.1I) for 30 min. De-staining was carried out with 40 % methanol and 10
%o acetic acid (2.3.12) until the white bands of enz5nnic activity appeared clearly against the
blue background. To conhrm the identity of the proteolytic bands as MMPs, gels containing
tissue samples were incubated either with 10 mM EDTA or 10 mM (1,10)-Phenanthroline
added to the development buffer respectively, or with lmM PMSF added to the samples for
18 h at 37 oC. Gels were photographed by digital camera and saved as Tagged Image File
Format (TIFF files) using Kodak lD image analysis software. Zymograms \¡/ere assessed
descriptively without any quantification of the bands.
3.2.3 Western blotting
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Immuno-blotting was performed under reducing conditions. Briefly, stacking and resolving
gels were assembled as described above without gelatin or casein. Protein samples (80
p.gllane) were loaded into each well with 2 Yo ß-mercaptoethanol in final volume of samples
and Western loading buffer (2.3.I7) and incubated at 100oC for 10 minutes. An MMP positive
control (Sigma Aldrich) was included on all gels to verify the identity of the immunoreactive
bands. The gels were electrophoresed as above, removed and allowed to equilibrate in transfer
buffer (2.3.I3) for 30 min at room temperature. Gels were then placed against a nitrocellulose
membrane (Hybond ECL Amersham Biosciences, Little Chalfont, Buckinghamshire, U.K.)
and transfer of proteins was performed at 400 mA for 60 min in transfer buffer (2.3.13). Non-
specific binding to membrane was blocked with 5 o/o skimmed milk powder in phosphate-
buffered saline (2.3.I4) for 2 h prior to overnight incubation with polyclonal goat MMP-7 or
MMP-13 antibody (Santa Cruz) in a 1/100 Western Antibody Dilution Buffer (2.3.16).
Secondary detection was carried out for t h at room temperature with perioxdase-labelled
rabbit anti-goat IgG antibody (Santa Cruz) in 1:1000 Western Antibody Dilution Buffer. The
membrane was washed twice for 10 minutes with TBS solution (2.3.15) and placed on clean
glass plate and the excess solution removed with tissue paper. ECL reagents (Amersham
Biosciences) were prepared according to the manufacture's instructions and poured onto the
membrane. A top glass plate was placed over the membrane and incubated for 1 minute
before unbound reagents were removed by blotting with filter paper. The membrane was then
exposed to a film (Amersham ECL) for 30 - 60 seconds before being developed in the
radiology department at The Queen Elizabeth Hospital.
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3.3 Results
3.3.1 Screening zymographic detection of caseinolytic activity in the tissues of rats
following skeletal muscle I/R.
Referring to substrate gel zymography, MMP-3 (Stromelysin), MMP-7 (Matrilysin) and
MMP-12 would be detectable more sensitively on casein gels.
Skeletal muscle
There were no proteolytically active bands detected on caseinolytic zymography in skeletal
muscle tissue which was either subjected to 4 h ischemia with varying times of reperfusion or
in sham-operated group (Figure 3.1 lane 2 and 6 in panel A, B, C and D).
Kidney
Two proteolytically active bands were observed on caseinol¡ic zymography in renal tissue
both in all experimental groups and in sham-operated animals. No alterations of activity
occurred in rats that underwent 4 h bilateral hindlimb ischemia and reperfusion, when
compared with corresponding sham-operated group. The molecular weight of these active
enzymes was between 80-90 kDa. The identity of these bands is unknown, but the
investigationwill be conducted in later on study. (Figure 3.1 lane 3 and 7 inpanel A, B, C,
and D).
Lung
An active caseinolytic band was detected on bottom of caseinolytic zymography gel in lung
tissue of rats either in experimental group or sham-operated group. Compared to sham-
operated group, the caseinolytic activity in the lung was increased immediately after skeletal
muscle ischemia and during early reperfusion within 4 h, then decreased with reperfusion, to a
lowest level (absent) at 24 hours of reperfusion, then recovered thereafter to baseline levels
t8
Figure 3.1: Screening zymographic detection of caseinolytic activity in tissues
following skeletal muscle ischemia and reperfusion
Rats were subjected to 4 h bilateral hindlimb ischemia or no ischemia followed by 0,
4, 24, or 72 h reperfusion before tissues were harvested. Lane 1: molecular weight
marker and Lane l0: MMPs positive control. All experimental lanes (2-9) contain 80
pg of total protein. Bands corresponding to MMP-9, proMMP-2, active MMP-2 and a
new caseinolytic MMP are shown (arrows)
Panel A: Rats were subjected to 4 h ischemia and no reperfusion (4/0) or no

















Panel B: Rats were subjected to 4 h ischemia and 4 h reperfusion (4/4) or no
ischemia and 4 h reperfusion (0/4).






































Panel C: Rats were subjected to 4 h ischemia and 24 h reperfiision (4124) or no
ischemia and 24 h reperfi.rsi on (0 124).
Lane 2z Skeletal muscle, 4/24.
Lane 3: Kidney,4/24.
Lane 4: Lung, 4124.
Lane 5: Live , 4124.




Panel D: Rats were subjected to 4 h ischemia and 72 h reperfusion (4172) or no
ischemia and 72 h reperfusion (0172).
Lane 2: Skeletal mvscle,4172.
Lane 3: Kidney,4172.
Lane 4:Lung,4172.
Lane 5: Live4 4172.




































gradually. The molecular weight of this active species was approximately 20 kDa when
compared with molecular weight standard. This species therefore needs to be investigated
fuither (Figure 3.1 lane 4 and 8 in panel A, B, C, and D).
Liver
There was no active caseinolytic band detected in liver tissue of rats either in experimental or
sham-operated groups (Figure 3.1 lane 5 and 9 in panel A, B, C, and D).
3.3.2 Zymographic detection of gelatinolytic MMP-2 and MMP-9 activity in skeletal
muscle, kindey, lung and liver of the rats following bilateral hindlimb I/R for
determining that the samples \ryere harvested and processed properly and the present of
activity of MMPs.
Figure 3.2 illustrates the zymographic analysis of gelatinolytic activity in skeletal muscle,
kidney, lung and liver.
Skeletal muscle
PToMMP-2 was detected both in ischemic skeletal muscle with varying reperfusion time and
sham-operated skeletal muscle, but there was no MMP-9 activity in skeletal muscle that
underwent 4 h ischemia before reperfusion and in sham-operated group. However, MMP-9
activity was detected in the skeletal muscle that underwent 4 h ischemia followed by 4,24 h,
and72 h reperfusion respectively. The production of proMMP-2was also increased following
skeletal muscle ischemia and reperfusion (Figure3.2lane2 and 6 in panel A, B, C and D).
Kidney
PToMMP-2 was detected at baseline level in kidney of rats, both in experimental groups and
in the sham-operated groups. There was no increase in proMMP-2 levels in kidney following
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X'igure 3.22 Zymographic detection of gelatinoþtic activity in tissues following
skeletal muscle ischemia and reperfusion
Rats were subjected to 4 h bilateral hindlimb ischemia or no ischemia followed by 0,
4, 24, or 72 h reperfusion before tissues were harvested. Lane 1: molecular weight
marker and Lane 10: MMPs positive control. All experimental lanes (2-9) contain
80 trg of total protein. Bands corresponding to MMP-9, proMMP-2, active MMP-2
and are shown (arrows).
Panel A: rats were subjected to 4 h ischemia and no reperfusion (4/0) or no
ischemia and no reperfusion (0/0).
Lane 2: Skeletal muscle, 4/0.
Lane 3: Kidney,4/0.
Lane 4: Lung,4/0.
Lane 5: Liver, 410.




Panel B: Rats were subjected to 4 h ischemia and 4 h reperfusion (4/4) or no
ischemia and 4 h reperfusion (0/4).
Lane 2: Skeletal muscle, 4/4.
Lane 3: Kidney ,414,
Lane 4:Lung,4/4.
Lane 5: Liver,4l4.




Panel C: Rats were subjected to 4 h ischemia and 24 h rcperfusion (4124) or no
ischemia and 24 h reperftrsi on (0/24).
Lane 2: Skeletal muscle, 4124.
Lane 3: Kidney ,4/24.
Lane 4z Lung, 4124.
Lane 5: Liver,4l24.




Panel D : Rats were subjected to 4 h ischemia and 72 h reperfusion (4/72) or no
ischemia and 72 h reperfusion (017 2).
Lane 2: Skeletal mttscle, 4 17 2.
Lane 3: Kidney ,4172.
Lane 4: Ltng,4172.
Lane 5: Live44l72.
Lane 6: Skeletal mtrscle,0172.
LaneT:Kidney,0172.
Lane 8: Ltng,0172.














































ischemia and reperfusion. There was no MMP-9 activity detected in renal tissue (Figure 3.2
lane 3 andT in panel A, B, C and D).
Lung
MMP-Ç, proMMP-2 and active MMP-2 were all detected in lung tissues both in all
experimental groups and sham-operated groups. MMP-9 and active MMP-2 were increased in
lung tissue of rats that underwent 4 h bilateral hindlimb ischemia and by 4 h reperfusion,
compared with corresponding sham-operated group. Levels of MMP-9 and active MMP-2
then decreased with 24 h reperfusion, maintaining at lower level below the baseline upto 72 h
(Figure 3.2lane 4 and 8 in panel A, B, C, and D).
Liver
PToMMP-2, but not MMP-9 and active MMP-2, was detected in liver at a low level both in all
experimental rats and sham-operated rats. There was no alterations observed after bilateral
hindlimb ischemia and reperfusion (Figure 3.2lane 5 and 9 in panel A, B, C, and D).
3.3.3 Further investigation if there is a caseinolytic MMP activity present in skeletal
muscle following IlR.
Four individual skeletal muscle tissues of rats from each group that underwent 4 h ischemia
followed by 24 h of reperfusion or in corresponding sham-operated group were used for
detection. Skeletal muscle tissues following ischemia with different times of reperfusion were
also used for detection of the change patterns of caseinolytic MMP if any.
There was no caseinolytic activity detected in skeletal muscle either in experimental groups
where rats underwenl 4 h bilateral hindlimb ischemia followed by reperfusion at varying
times or in sham-operated rats that under 4 h anesthesia, no ischemia, no reperfusion (Figure
3.3 lane 2-9 inpanel A and B).
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Figure3.3: Further zymogrâphic detection of caseinolytic activify in skeletal
muscle following ischemia and reperfusion
Rats were subjected to 4 h bilateral hindlimb ischemia or no ischemia followed by 0,
4, 24, or 72 h reperfusion before skeletal muscle were harvested. Lane l: molecular
weight marker and Lane 10: MMPs positive control. All experimental lanes (2-9)
contain 80 pg of total protein. Bands corresponding to MMP-9, proMMP-2 and
active MMP-2 are shown (arrows).
Panel A: Skelet¿l muscle of rats that were subjected to 4 h ischemia and 24 h
reperfusion (4124) or no ischemia and 24 h reperfusion (0/24).
Lane 2-5: Individual skelet¿l muscle,4124.
Lane 6-9: Individual skeletal muscle, 0/24.
Panel B: Skeletal muscle of rats that were subjected to 4 h ischemia followed by 0,
4, 24, or 72 h reperfusion (410, 414, 4124, 4172 ) or no ischemia with 0, 4, 24, 72 h
reperfusion ( 0 10, 0l 4, 0124, 017 2).
Lane 2: Skeletal muscle, 4/0.
Lane 3: Skeletal muscle, 4/4.
Lane 4: Skeletal muscle,4124.
Lane 5: Skeletal mttscle,4172.
Lane 6: Skeletal muscle, 0/0.
Lane 7: Skeletal muscle, 0/4.
Lane 8: Skeletal muscle,0124.























3.3.4 Zymographic detection of gelatinolytic activity in the same skeletal muscle tissues
as above determining thnt the samples were harvested and processed properly with
detectable MMP-2 and MMP-9 activity.
PToMMP-2 was detected both in ischemic skeletal muscle with varying reperfusion time and
sham-operated skeletal muscle (Figure 3.4lane 2-9 in panel A&B), but there was no MMP-9
activity detectable in skeletal muscle that underwent 4 h ischemia with early reperfusion and
in sham-operated group (Figure 3.4 lane 2,3 in panel B). However, MMP-9 activity was
detected in the skeletal muscle after 24 h or 72 h of reperfusion following ischemia (Figure
3.4 lane 4,5 in panel A&B). In addition, the production of proMMP-2 increased in the
skeletal muscle following 4h ischemia and 24 h or T2hreperfusion respectively (Figure 3.4
lane 2-5 in panel A and lane 4-5 in panel B). There was no active MMP-2 detected in the
skeletal muscle either in experimental group or in sham-operated group (Figure 3.4 panel A
and B).
3.3.5 Effects of anesthesia on the production of caseinolytic activity in the lung tissues of
rats (Sham-operated rats versus normal control rats).
There was a new caseinolytic active band detected in the normal lung tissues (Figure3.5 lane
6-9 in panel A, B, C, and D). The molecular weight of this proteolytically active species was
approximately 20 kDa according to standard protein molecular weight in lane 1. This active
band was absent in the lung tissues of rats that underwent 4 h anesthesia (Figure 3.5 lane 2-5
in panel A). This active species then increased gradually with time of recovery (Figure 3.5
lane 2-5 in panel b and c), reaching to the level observed in normal rats after 72 h of recovery
from anesthesia (Figure 3.5 lane 2-5 inpanel D). These results suggest that the activity of this
new species is suppressed by anesthesia.
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Figure3.4: Zymographic detection of gelatinolytic activity in skeletal muscle
using the same samples as those in Figure 3.3 for determining the presence of
emzymic activity of MMPs
Rats were subjected to 4 h bilateral hindlimb ischemia or no ischemia followed by 0,
4,24, or 72 h reperfusion before skeletal muscle were harvested. Lane l: molecular
weight marker and Lane 10: MMPs positive control. All experimental lanes (2-9)
contain 80 pg of total protein. Bands corresponding to MMP-9, proMMP-2 and
active MMP-2 are shown (arrows).
Panel A: Skeletal muscle of rats that were subjected to 4 h ischemia and 24 h
reperfusion (4124) or no ischemia and 24 h reperfusion (0/24).
Lane 2-5 : Individual skeletal mluscle, 4/24.
Lane 6-9: Individual skeletal muscle, 0/24.
Panel B: Skeletal muscle of rats that were subjected to 4 h ischemia followed by
0, 4,24, or 72 h reperfusion (410, 414, 4124, 4172 ) or no ischemia with 0, 4, 24, 72
h reperfusion ( 0/0, 014,0124,0172).
Lane 2: Skeletal muscle, 4/0.
Lane 3: Skeletal mtscle,4l4.
Lane 4: Skeletal muscle,4124.
Lane 5: Skeletal mvscle,4172.
Lane 6: Skeletal muscle, 0/0.
Lane'l: Skeletal muscle, 0/4.
Lane 8: Skeletal muscle, 0/24.
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Figure 3.52 Zymographic detection of caseinolytic activity in the lung
Rats were subjected to 4 h anesthesia, no ischemia followed by 0, 4, 24, or 72 h
recovery compared to normal control rats, no anesthesia, no ischemia. Lane l:
molecular weight marker and Lane 10: MMPs positive control. All experimental
lanes (2-9) contain 80 pg of total protein. Bands corresponding to MMP-9, pro-MMP-
2, active MMP-2 and new caseinolytic bands are shown (arrows).
Panel A: Lung tissue samples from 4 individual rats following 4 h anesthesia, no
ischemia (0/0) compared to 4 individual rats in normal control group (Normal, no
anesthesia, no ischemia, no reperfusion).
Lane2-5: Lungs,0/0.
Lane 6-9: Lungs, Normal.
Panel B: Lung tissue samples from 4 individual rats following 4 h anesthesia, no
ischemia with 4 h recovery (0/4) compared to 4 individual rats in normal control
group (Normal, no anesthesia, no ischemia, no reperfusion).
Lane2-5: Lungs,0/4.
Lane 6-9: Lungs, Normal.
A
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t 2 3 4 5 6 7 8 910
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Panel C: Lung tissue samples from 4 individual rats following 4 h anesthesia, no
ischemia with 24 h recovery (0/24) compared to 4 individual rats in normal control
group (Normal, no anesthesia, no ischemia, no reperfusion).
Lane 2-5:Ltngs,0124.
Lane 6-9: Lungs, Normal.
Panel D: Lung tissue samples from 4 individual rats following 4 h anesthesia, no
ischemia with 72 h recovery Ql72) compared to 4 individual rats in normal control
group (Normal, no anesthesia, no ischemia, no reperfusioÐ.
Lane 2-5:Llrrgs,0/72.
























3.3.6 Effects of anesthesia on production of gelatinolytic MMP-2 and MMP-9 in the lung
tissues of rats using the same samples as above for determining that samples were
harvested and processed properly and for the presence of activity of MMPs (Sham-
operated rats versus normal control rats).
The gelatinolytic activity of MMP-9, proMMP-2 and active MMP-2 were detected in all lung
tissues from sham-operated group or normal control group (Normal tats, no anesthesia, no
ischemia, no reperfusion). There was an increased production of MMP-9 in the lung tissue of
rats that underwent 4 h anesthesia and during early period of recovery (Figure 3.6 lane 2-5 in
panel A&B). The elevated MMP-9 levels returned to baseline level after 24 h or 72 h of
recovery (Figure 3.6 lane 2-5 in panel C&D). There were no alterations of proMMP-2
observed following 4 h anesthesia with varying times of recovery. The levels of active MMP-
2 werc increased immediately after 4 h anesthesia, and then returned to baseline level (Figure
3.6 lane 2-5 inpanel A, B, C, and D).
3.3.7 Alterations of caseinolytic activity in the lung tissues following skeletal muscle I/R
(Ischemic rats versus sham-operated rats).
The activity of the newly identified 20 kDa caseinolytic species was increased in the lung
tissues of rats that underwent 4 h bilateral hindlimb ischemia only (I/R: 4/0, Figure 3.7 lane 2-
5 in panel A). It then decreased with reperfusion (IIR: 414, Figure 3.8 lane 2-5 panel B),
becoming undetectable (Figure 3.7 Iane 2-5 in panel C) after 24 hours of reperfusion (I/R:
4124), then a weak band was detected following 72h of reperfusion (UF.: 4172, Figure 3.7 lane
2-5 in panel D). In the sham-operated rats, this band was down-regulated in the lung tissues,
presumably due to effects of anesthesia (Figure 3.7 lane 6-9 in panel A). It then increased
gradually with recovery (Figure 3.7 lane 6-9 in panel B & C), reaching to the baseline level
after 72 h (Figure 3.7 lane 6-9 inpanel D).
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Figure3.6: Zymographic detection of gelatinolytic activity in the lung using the
same samples as those in X'igure 3.5 for detemining the presence of enzymic
activity of MMPs
Rats were subjected to 4 h anesthesia, no ischemia followed by 0, 4, 24, or 72 h
recovery compared to normal control rats, no anesthesia, no ischemia. Lane 1:
molecular weight marker and Lane l0: MMPs positive control. All experimental
lanes (2-9) contain 80 pg of total protein. Bands corresponding to MMP'9, pro-
MMP-2 and active MMP-2 are shown (arrows).
Panel A: Lung tissue samples from 4 individual rats following 4 h anesthesia, no
ischemia (0/0) compared to 4 individual rats in normal control group (Normal, no
anesthesia, no ischemia, no reperfusion).
Lane2-5: Lungs,0/0.
Lane 6-9: Lungs, Normal.
Panel B: Ltrng tissue samples from 4 individual rats following 4 h anesthesia, no
ischemia with 4 h recovery (0/4) compared to 4 individual rats in normal control
group (Normal, no anesthesia, no ischemia, no reperfusioÐ.
Lane2-5: Lungs,0/4.
Lane 6-9: Lungs, Normal.
Panel C: Lung tissue samples from 4 individual rats following 4 h anesthesia, no
ischemia with24 h recovery (0124) compared to 4 individual rats in normal control
group (Normal, no anesthesia, no ischemia, no reperfusion).
Lane 2-5:Lwgs,0124.
Lane 6-9: Lungs, Normal.
Panel D: Lung tissue samples from 4 individual rats following 4 h anesthesia, no
ischemia wiIh7z h recovery (0172) compared to 4 individual rats in normal control
goup (Normal, no anesthesia, no ischemia, no reperfusion).
Lane 2-5:Lungs,0172.
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Figure 3.72 Zymographic detection of caseinolytic activity in the lung
Rats were subjected to 4 h bilateral hindlimb ischemia followed by 0, 4,24, or 72 h
reperfusion before tissues were harvested compared to sham-operated rats with 4 h
anesthesia, no ischemia followed by 0, 4,24, or 72 h recovery. Lane 1: molecular
weight marker and Lane 10: MMPs positive control. All experimental lanes (2-9)
contain 80 pg of total protein. Bands corresponding to MMP-9, pro-MMP-Z, active
MMP-2 and new caseinolytic bands are shown (arrows).
Panel A: Lung tissue samples from 4 individual rats following 4 h ischemia and no




Panel B: Lung tissue samples from 4 individual rats following 4 h ischemia and 4h
reperfusion (4/4) compared to those from 4 individual rats following 4 h anesthesia
with 4 h recovery, no ischemia (01Ð.
Lane2-5:Lungs,4l4.
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Panel C: Lung tissue samples from 4 individual rats following 4 h ischemia and 24 h
reperfusion (4124) compared to those from 4 individual rats followng 4 h anesthesia
with24 h recovery, no ischemla(012$.
Lane 2-5:Lrxrgs,4124.
Lane 6-9: Lttngs,0124.
Panel D: Lung tissue samples from 4 individual rats following 4 h ischemia and 72 h
reperfusion (4172) compared to those from 4 individual rats following 4 h anesthesia
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3.3.8 Alterations of gelatinolytic MMP-2 and MMP-9 in the lung tissues following
skeletal muscle I/R using the same samples as above for determining that the samples
were harvested and processed properly and the presence of activity of MMPs (Ischemic
rats versus sham-operated rats).
The activity of proMMP-9, active MMP-9, proMMP-2, and active MMP-2 were detected in
the lung tissues of rats. The proMMP-9 and active MMP-9 were elevated in the lung tissues
of rats that underwent 4 h bilateral hindlimb ischemia either with no reperfusion or 4 h,24 h,
and 72 h reperfusion respectively (Figure 3.8 lane 2-5 in panel A, B, C, and D), compared
with those in correspondent sham-operated group (Figure 3.8 lane 6-9 in panel A, B, C, and
D). There was no difference of MMP-2 activity between ischemic rats and sham-operated rats
(Figure 3.8 panel A, B, C, and D).
3.3.9 Zymographic identification of the newly-detected active caseinolytic species in the
lung tissues.
To identify if this newly-detected active caseinolyic species is an MMP or another protease,
samples were incubated with EDTA, an inhibitor of MMPs, phenanthroline, a zinc chelator,
and PMSF, an inhibitor of serine proteinase respectively. This new active caseinolytic species
was completely inhibited by EDTA and phenanthroline (bands absent, Figure 3.9 panel B and
panel C), but it was not inhibited by PMSF (bands present, Figure 3.9 panel D). This implies
that the newly-identified active caseinolyic species in the lung was considered as one of
MMPs rather than serine proteinase.
3.3.10 Confirmation of this newly-detected active caseinolytic MMP by Western Blot in
the lung tissues.
This new active caseinolytic MMP in the lung tissues was considered to be a low molecular
weight MMP according to the standard protein molecular weight. Therefore, MMP-7, whose
molecular weight is 28119 kDa (latent/active), was considered as a candidate. However, there
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Figure 3.8: Zymographic detection of gelatinolytic activity in the lung using the
same samples as those in Figure 3.7 for determining the presence of enrymic
activity of MMPs
Rats were subjected to 4 h bilateral hindlimb ischemia followed by 0, 4, 24, or 72 h
reperfusion before tissues were harvested compared to sham-operated rats with 4 h
anesthesia, no ischemia followed by 0, 4, 24, or 72 h recovery. Lane 1: molecular
weight marker and Lane l0: MMPs positive control. All experimental lanes (2-9)
contain 80 pg of total protein. Bands corresponding to MMP-9, pro-MMP-2 and
active MMP-2 are shown (arrows).
Panel A: Lung tissue samples from 4 individual rats following 4 h ischemia and no
reperfrrsion (4/0) compared to those from 4 individual rats following 4 h anesthesia,
no ischemia (0/0).
Lane2-5: Lungs,4/0.
Lane 6-9: Lungs, 0/0.
Panel B: Lung tissue samples from 4 individual rats following 4 h ischemia and 4 h
reperfusion (414) compared to those from 4 individual rats following 4 h anesthesia
with 4 h recovery, no ischemia(01\.
Lane 2-5:Lwgs, 414.
Lane 6-9: Lungs, 0/4.
Panel C: Lung tissue samples from 4 individual rats following 4 h ischemia and24h
reperfüsion (4124) compared to those from 4 individual rats following 4 h anesthesia
with24 h recovery, no ischemia(012\.
Lane2-5:Lungs,4124.
Lane 6'9:Lungs,0124.
Panel D: Lung tissue samples from 4 individual rats following 4 h ischemia and72h
reperfusion (4172) compared to those from 4 individual rats following 4 h anesthesia
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Figure3.9: Caseinolytic zymography to identiff nature of the new matrix
metalloproteinase bands observed in lung tissue samples
For each panel: Lane l: molecular weight marker and Lane 10: MMPs positive
control. All experimental lanes (2-9) contain 80 pg of total protein. Bands
corresponding to MMP-9, pro-MMP-2, active MMP-2, MMP-13 and new
caseinolytic MMP are shown (arrows).
Panel A: Casein zymography showing the new caseinol¡ic bands in lung tissue as
positive control panel.
Lane 2-5 arc 4 individual lung tissue samples from rats following 4 h bilateral
hindlimb ischemia without reperftrsion (410).
Lane 6,'1 are 2 individual lung tissue samples of rats in correspondent sham-operated
group that underwent 4 h anesthesia, no ischemia (0/0).
Lane 8.9 are 2 individual wounded skin samples which have been demonstrated to
produce MMP-13 as positive control (V/ound Healing Laboratory at The Queen
Elizabeth Hospital) (Skin).
Panel B: Casein zymographic identification of the nature of new caseinol¡c bands
in lung tissue.
The lane structure is the same as panel A. The samples were incubated with l0 mM of
EDTA in the development buffer.
A 410 0/0 Skin
























Panel C: Casein rymognphic identification of the nature of new caseinoþic
bands in lung tissue.
The lane struoture is the s¿rme as panel A. The samples were incubated with 10 mM
ofphenanthroline in the development buffer.
Panel D: Casein zymographic identification of the natr¡re of new caseinol¡ic
bands in lung tissue.
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X'igure 3.10: \ilestern blotting analysis for confirmation of the new active
caseinolytic MMP bands detected in the lung
For each panel: Lane l: molecular weight marker and Lane l0: MMPs positive
control. All experimental lanes (2-9) contain 80 pg of total protein. Bands
corresponding to MMP-9, pro-MMP-2, active MMP-2, MMp-13 and new
caseinol¡ic MMP are shown (arrows).
Panel A: Confirmation of the active caseinolytic MMP bands in the lung using the
anti-MMP-7 affinity-purified goat polyclonal antibody (Santa Cruz).
Lane 2'5 are 4 individual lung tissue samples from rats following 4 h bilateral
hindlimb ischemia without reperfusion (410).
Lane 6,7 are 2 individual lung tissue samples of rats in correspondent sham-operated
group that underwent 4 h anesthesia, no ischemia (0/0).
Lane 8.9 are 2 individual wounded skin samples which have been demonstrated to
produce MMP-13 as positive control (Wound healing laboratory at The Queen
Elizabeth Hospital) (Skin).
Panel B: Confirmation of the active caseinol¡ic MMP bands in lung tissue using
anti-MMP- I 3 affinity-purified goat polyclonal antibody (santa cruz).
The lane strucfure is the same as panel A.
A 4/0 0/0 Skin
l2 34 5 6 7 8 910
410 0/0 Skin















was no positive band shown on western blot following exposure of blot to anti-MMP-7
polyclonal antibody (Figure 3.10 panel A). Furthermore, MMP-13 (52/42 kDa) was
considered as another candidate based on experiments conducted in the wound-healing
laboratory at The Queen Elizabeth Hospital (MMP-I3 band was shown near the bottom of the
casein gel for wounded skin samples). The samples from skin wound were employed in this
experiment as a positive control. Once again, there was no positive signal shown on the
western blotting film. This result suggests that the positive control was not working (Figure
3'10 panel B). Therefore, the possibility could not be excluded if this active casenolytic
species is MMP-7 or MMP-13, due to the lack of positive control signal on'Western blotting
film.
3.3.11 Effects of doxycycline on activify of this newly-recognised caseinolytic MMP in
the lung tissues.
There was an increased production of this active caseinolytic MMP in the lung tissues with
administration of doxycycline (Figure 3.11 lane 6-9 inpanel A&B) prior to bilateral hind limb
4 h ischemia and 24 h of reperfusion compared with untreated corresponding group (Figure
3.11 lane 2-5 in panel B), but it had not reached to the level in sham-operated group (Figure
3.11 lane 2-5 inpanel A).
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Figure3.ll: Effects of doxycycline on the activity of this caseinolytic MMP in the
lung
Rats were classified as 4 groups: (1) 4 h bilateral hindlimb ischemia followed by 24 h
reperfusion before tissues were harvested (4124), (2) 4 h anesthesia followed by 24 h
recovery Ql24), (3) 4 h bilateral hindlimb ischemia followed by 24 h repertusion with
low dose doxycycline treatment (4124 Doxy L.D), (4) 4 h bilateral hindlimb ischemia
followed by 24 h reperfusion with high dose doxycycline treatment (4124 Doxy H.D).
Lane l: molecular weitht marker. Lane l0: supernatant of HT29 colon cancer cell
line, which was expected to produce MMP-7, but in fact no active MMP present. All
experimental lanes (2-9) contain 80 pg of total protein.
Panel A: Effects of low dose doxycycline on the activity of this caseinolytic MMP in
the lung.
Lane 2-5 are 4 individual lung tissues, 0/24.
Lane 6-9 are 4 individual lung tissues, 4124Doxy L. D.
Panel B: Effects of high dose doxycycline on the activity of this caseinolytic MMP in
the lung.
Lane 2-5 are 4 individual lung tissues, 4/24.































According to the specificity of substrate proteolysis, the MMP family is currently divided into
4 subclasses, which include collagenases such as MMP-1 and MMP-8, gelatinases (MMP-2
and MMP-9), stromelysin (MMP-3 and MMP-I1) and matrilysin (MMP-7 and MMP-26). To
facilitate investigation of the activity of MMPs, gelatin, collagen III, and casein have all been
used as zymographic substrates in previous studies (480), (481). In the current study, gelatin
or casein were embedded in SDS-PAGE gel to study the proteolytic activity of MMPs in
tissues of rats that have undergone bilateral hindlimb ischemia and reperfusion.
Using caseinolyic zymography, a newly-identified caseinolytic species was detected in the
lung tissues. It was demonstrated to be an MMP with low molecular weight, but the identity
has not been confirmed by western blotting due to the lack of suitable positive control. This
newly-identified MMP was expressed in normal lung tissues. It was less strongly expressed
under anaesthesia, but it was up-regulated in the lung tissues while skeletal muscle was
subjected to 4 h ischemia. The activity of this MMP was becoming weak again with
reperfusion, it then recovered to the baseline level after 72 h of reperfusion. There was no
caseinol¡ic activity detected both in skeletal muscle and the liver. In addition, two
caseinol¡ic activity bands were detected in the kidney with molecular weight 80-90 kDa.
However, no changes of the activity were observed following skeletal muscle ischemia and
reperfusion. Therefore, no further investigations were conducted in the kidney.
On gelatinolytic zymography, there was detectable pro-MMP-2 at baseline level in normal
skeletal muscle, whereas there was no detectable MMP-9 present in normal skeletal muscle.
However, MMP-9 was induced dramatically by ischemia and reperfusion in skeletal muscle.
PToMMP-2 was also increased in skeletal muscle after ischemia followed by reperfusion.
These alterations in MMP-2 and MMP-9 in skeletal muscle are consistent with those observed
by Roach et al and have been discussed in their report (302).In kidney, a baseline level of
85
proMMP-2 detected and maintained at the same level under all conditions. Moreover, there
was no detectable MMP-9 in kidney under all conditions. In liver, there was a detectable low
baseline level of both MMP-9 and PToMMP-2, which was remained under all conditions.
Therefore, the expression of MMP-2 and MMP-9 was considered less important in the kidney
and liver following skeletal muscle ischemia and reperfusion because of their low baseline
level and lack of change with I/R. In normal lung tissue, and as well as experimental lung
tissue, gelatinolytic activity corresponding to proMMP-9, active MMP-9, proMMP-2, and
active MMP-2 was all detected on zymography. PToMMP-9 and active MMP-9 were up-
regulated in the lung tissues of rats following 4 h bilateral hindlimb ischemia either before
reperfusion or after 4 h, 24 h, or 72 h of reperfusion respectively, while there was no
significant change in MMP-2 observed.
The current investigation suggested that MMP-9 and MMP-2 are involved in remote lung
injury after skeletal muscle ischemia and reperfusion. Recently, it has been reported that
expression of MMP-2 and MMP-9 correlated with altered alveolar-capillary permeability and
increased with severity of ischemia/reperfusion-induced lung injury in a porcine model (289).
'Ihe increased alveolar permeability was considered to be the result of capillary basal
membrane disruption, occurring as a result of degradation of collagen IV, an important
constituent of the lung basement membrane by MMP-2 and MMP-9. The role of MMP-9
activity in pulmonary ischemia/reperfusion injury has also been emphasised by Yano et al
(293).In addition, a higher concentration of MMP-9 has been found in lung edema fluid of
patients with adult respiratory distress syndrome (ARDS) (297). Although the primary causes
of pulmonary injury vary, the basic undergoing pathological condition is in common, that is
pulmonary edema due to disruption of alveolar-capillary basal membrane disruption. MMPs
have been suggested to play a crucial role during this pathological progression. Furthermore,
the important role of MMP-2 and MMP-9 in I/R injury in other organs such as brain and heart
has been investigated in other studies (34I), (348).
86
In the lung, MMP-2 is expressed by fibroblasts, endothelial cells and vascular smooth muscle
cells, while MMP-9 was widely found in inflammatory cells, especially in neutrophils.
Bronchial and type II alveolar epithelial cells produce both MMP-2 and MMP-9 (360), (361),
(362). The production of MMP-2 and MMP-9 may also be regulated by pro-inflammatory
cytokines. Gottschall et al (363) have demonstrated that TNF-cr and IL-1B induced MMP-9
production in rat astrocytes. High levels of MMP-9, TNF-o, and IL-18 were found in the
bronchoalveolar lavage fluid from the patients with acute respiratory distress syndrome
(ARDS) (301). IL-IP was found to elevate MMP-2 production in human dental pulp cell
cultures (482).Inhibition of these cytokines could be another option to ameliorate pulmonary
injury following ischemia/reperfusion.
In order to investigate further the role of MMPs in I/R injury both in ischemic organ and
remote organs, caseinol¡i c zymography was conducted to detect caseinolytic MMP activity
in the tissues. Matrilysin and stromelysin are caseinolytic MMPs that arc detectable on casein
gel zymography. Caseinolytic MMPs were not detected either in normal skeletal muscle or in
skeletal muscle after 4 h ischemia followed by reperfusion. However, a significant active
species was identified in the lung tissues on caseinolyic zymography. The molecular weight
of this active species was approximately 20 kDa according to the standard protein molecular
weight marker. This active enzyme was recognised as one of the matrix metalloproteinases
since its activity was completely inhibited by EDTA and l,l0-phenanthroline respectively,
but was not inhibited by PMSF, an inhibitor of serine proteases. Among the MMPs, MMP-7
and MMP- 12 are of lower molecular weight, suggesting this new casenolytic MMP may be
MMP-7 or MMP-12. The molecular weight of the pro-form of MMP-7 is 28 kDa and its
active form is 19 kDa, while the pro-enzyme of MMP-12 is 54 kDa and the active form is 20
kDa (418); (449). To confirm if this active species is MMP-7, a polyclonal MMP-7 antibody
was used in western blotting. However, there was no positive signal detected. Even so' the
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active enzyme could not be excluded as MMP-7, because there was no suitable MMP-7
positive control available in this experiment. A previous study in wound healing laboratory in
our hospital has found that there was an over-expression of MMP-13 in wounded skin (T.
Rayner, personal communication). These active bands were also detected at a similar size on
casein gels to those observed in the current study. To conf,trm if the active enzyme was MMP-
13, positive control samples from wounded skin and MMP-13 antibody were used in the
western blot. Again, no positive signal was detected at the predicted 20 kDa position. So
could it be concluded that this active enzyme is not active MMP-13. The question was raised
if this active caseinolytic species were MMP -12 úæ to its lower molecular weight, active
form 20 kDa. Because a suitable MMP-12 positive control was not available for this study'
further study is therefore still needed to determine the identity of this caseinolytic species'
A number of studies have shown that lower torso I/R can lead to multiple-organ injury with
local events including permeability edema, compartment syndrome, and muscle necrosis'
(302), (285). Remote organ pulmonary insufficiency is the most frequent adverse event
following lower torso I/R, characterised by neutrophil sequestration and increased pulmonary
vascular permeability (285) (4S3). Kyriakides and coworkers have shown that neutrophil
sequestration in lung tissue is the major pathological event in the development of distant lung
injury (2S0). It was determined that neutrophil sequestration was dependent upon L-selectin
and E-selectin with lung injury reduced by infusion of anti-selectin antibodies in a rat model
(257).Moreover, remote lung injury was also related to complement activation, with a94%o of
reduction in lung permeability when animals were treated with sCRl (soluble complement
receptor-l), even though pulmonary neutrophil sequestration was not abolished (285) (280)
(256). The adhesion of neutrophils to activated microvascular endothelium is a key step in the
remote organ injury, leading to the release of oxygen free radicals and cytotoxic proteinases,
and facilitating neutrophil diapedesis, resulting in increased vascular permeability (278);
(484).
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In recent studies, disruption of the alveolar extracellular matrix and protein exudate into the
alveolar space with hyalinisation of the alveolar membranes have been elucidated as key
pathologic changes of adult respiratory distress syndrome (485). MMPs were implicated to
play an important role in the degradation and remodelling of extracellular matrix. Increased
expression of MMP-9 was detected in the bronchoalveolar lavage fluid (BALF) of patients
with adult respiratory distress syndrome and asthma, suggesting over-expression of MMP-9
may play a key role in the lung injury (295), (294). The administration of MMP inhibitors
have been shown to abolish both elastase and MMP activity, reducing neutrophil infiltration,
decreasing capillary extravasation and therefore preventing lung dysfunction secondary to
cardiopulmonary bypass (298). Up-regulation of MMP-9 and MMP-2 was also observed in
the lungs following hind limb or lung IiR injury, associated with leukocyte infiltration into the
tissues (302), (289), (293). Moreover, MMPs have been demonstrated to be involved in the
recruitment of inflammatory cells into the lung tissues. Metalloelastase-deficient animals had
less neutrophil infiltration into the lung tissues as compared with the wild-type control
animals (298). Stromelysin-l was identified to be associated with modulation of leukocyte
infiltration into inflamed tissues (436). So was MMP-9 found to be necessary for neutrophil
migration into the lung tissues in necrotizingpanueatitis-induced lung injury (299).
The expression of caseinolytic MMPs in the lung tissues following remote organ I/R has not
been reported in the literature. In this study, we therefore for the first time have detected the
over-expression of caseinolyic MMP in the lung tissues following bilateral hind limb I/R
injury. Although the identity of this casenol¡ic MMP has not been confirmed, it was shown
to be a lower molecular weight MMP. Matrilysin (MMP-7), one of low molecular MMPs has
found to be expressed in the epithelium of peribronchial glands and conducting airways in
normal lungs. The expression of MMP-7 was increased in migrating airway epithelial cells in
wounded human and mouse trachea. Its up-regulation following injury, its induction by
89
alveolar epithelium, and its secretion either apically or basally suggested that MMP-7 serves
multiple functions such as reepithelialization in intact and injured lungs (443), (296).
MMP-12 is another candidate for the identity of lower molecular weight caseinolytic MMP,
especially in its active 20I<Da form. It has been demonstrated that alveolar macrophages from
rats produce a spectrum of MMPs, including MMP-12 that is similar to the spectrum of
enzymes produced by human alveolar macrophages (450). MMP-12 shares many substrates
such as collagen V, FN and vitronectin with MMP-7 due to their close structural similarities
(452), (451). Ectopic or excessive expression of MMP-I2has been associated with several
pathological conditions including aortic aneurysm, cancer growth and metastasis, host defense
of infection, chronic obstructive pulmonary disease, and gastrointestinal ulcerations.
Moreover, it has been determined that the activity of MMP-12 contributes to the pathogenesis
of pulmonary emphysema (463) (464). Mice without macrophage elastase (MME) failed to
recruit macrophages and did not develop lung destruction in response to cigarette smoke,
whereas the lungs of wild-type mice exposed to cigarette smoke demonstrated inflammatory
cell recruitment and dilatation and destruction of alveolar walls and alveolar ducts. These
observations mirror the pathology of smoker's lungs, although human lungs also have
destruction and dilatation of respiratory bronchioles. These findings suggest a primary role for
macrophages and macrophage elastase in the development of emphysema induced by
cigarette smoking (464).In addition, MMP-12 has been found to be an important mediator in
immune complex-induced acute lung injury. It was observed that MMP-12 is necessary for
the full development of acute alveolitis in this model of lung injury, while reduced injury was
found in MMP-l2-deficient mice model (465). Furthermore, the synthesis and secretion of
MMP-12 by alveolar macrophages was stimulated by surfactant protein D (SP-D) (466).
The repair of acute lung injury depends on the balance between deposition and breakdown of
matrix molecules. MMP-12 has been implicated to be involved in this process. It has been
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shown that MMP-12 increased significantly during the acute phase of bleomycin-induced
pulmonary fibrosis in animal experiment, which is produced by activated macrophages and is
capable of degrading elastin and collagen type IV, the components of the basement
membrane. This activation appears to be associated with areas of hemorrhage (467) (a68). In
contrast, it was observed that macrophages from MMP-12 knockout mice have a reduced
capacity to degrade extracellular matrix protein, rendering them unable to penetrate basement
membrane (468). Clinically, it was found that the secretion of MMP-12 by macrophages was
associated with damaged areas in the lungs (463).
In this study, the identity of the cells producing the caseinolytic MMP is not clear. Most
likely, the elevated activity of this MMP is expressed by lung epithelial cells or macrophages
following hind limb I/R and the over-expression may be mediated by cytokines. Interestingly,
halothane anesthesia suppressed the expression of this MMP in the lung; however, the
mechanism of the suppression is unknown. It has been found that increased expression of
MMP-2 and MMP-9 was observed in the lung tissues during acute exposure to I00 % oxygen
and in rat lungs by subacute hyperoxia (487) (488). The levels of MMP-9 were also elevated
in the lung after halothane anesthesia of rats in this study.
Doxycycline is a broad-spectrum MMP inhibitor, which has been demonstrated in a number
of studies (302), (396), (489), (490). However, there was an up-regulation of this active
caseinolytic MMP in lung tissues after skeletal muscle VR with administration of
doxycycline. It is unclear whether doxycycline directly stimulates expression of this MMP or
that doxycycline increases the net expression of this MMP by inhibiting the activity of other
MMPs.
Taken together, no single mechanism is responsible for the remote lung injury after bilateral
hind limb I/R. Previous and present studies have demonstrated that over-production of MMPs
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play an important role in the acute lung injury following hind timb I/R (302). MMPs (both
gelatinolytic and caseinolytic MMPs) participate in the degradation of extracellular matrix,
facilitate the migration of neutrophils, enhance the vascular permeability and increase
albumin extravasation. Moreover, there might be some complicated interactions between
MMps and lor MMPs and cytokines, such as activation of MMP-2by MMP-7 or MMP-12













Fibronectin (FN) and laminin (LN), major components of the basement membrane (BM) have
not yet been investigated in the tissues following skeletal muscle I/R. The studies in this
chapter aimed to investigate the alterations in FN and LN in basement membrane and the
levels of FN in plasma after rat bilateral hindlimb I/R. To achieve the investigation, both
immunohistochemical techniques and ELISA were employed to quantify the levels of FN and
LN.
4.1,.1 Basement Membrane (BM)
Basement membranes (BM) are thin, sheet like structures found in many locations in the
body, usually in close vicinity to the cells, which produce these extracellular matrices.
Basement membranes may be deposited in a polarised fashion beneath such cells (epithelium
and endothelium) or completely surround cells (muscle, fat and nerve cells) (49I). Generally,
basement membranes possess three main functions, which include participation in the
maintenance and compartmentalisation of tissue architecture, control of fluid and substrate
exchange, regulation of cell growth and differentiation and regulation of cell adhesion and
migration (492). Basement membrane contains various glycoproteins' Although the number
of components in any particular basement membrane is unknown, collagen IV, FN and LN
are considered to be the major components. Collagen IV is a ubiquitous constituent in the
BM, providing mechanical strength. Its loss will lead to cystic tissue transformation as was
evidenced by analysis of polycystic nephropathies (492). FN and LN are another two of the
most abundant extracellular matrix proteins and share many biological properties with each
other. FN oonsists of two very similar polypeptide chains connected to each other by disulfide
bonds at their C-terminal ends, whereas LN consists of a rodlike long arm (length 77nm) and
three morphologically indistinguishable short arms (length 37nm) The components of
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basement membranes for cell proliferation, migration and differentiation implies that their
composition is more complex than their structure suggests. The molecular orientation of the
individual components varies in the basement membrane according to biological needs (493).
The differences in ultra-structure of basement membrane suggested to be related to the
physiologic functions (494). The importance of basement membranes in adult tissue function
has also been directly determined by the identif,rcation of genetic diseases caused by
mutations in the genes of components in structural basement membrane, such as Alport
syndrome and junctional epidermolysis bullosa (495). In addition, pathological damage is
often observed in basement membranes in various diseases such as diabetic nephropathy
(496), and Crohn's disease (497). Moreover, MMPs together with TIMPs have been found to
play a crucial role in the balance between degradation and synthesis of extracellular matrices
(49g). The ability of MMps to degrade basement membrane is also essential for the diverse
invasive processes of angiogenesis and tumor metastasis (393), (419).
4.L.2 Plasma Fibronectin (PFN)
In recent studies, pFN has been implicated in playing an important role in ischemia-induced
tissue injury. It has been demonstrated that levels of pFN were significantly higher in patients
with acute myocardial infarction (AMI) than control subjects (499), (500). Accumulation of
circulating pFN in sclerotic lesions has been implicated to be the major process of
glomerulosclerosis in immunologically mediated kidney diseases and in chronic graft-versus-
host disease (501). In rat models of kidney ischemia and reperfusion injury, a major change in
glycoprotein levels in plasma and the extracellular matrix was observed. FN, which originated
in the plasma, accumulated in tubular lumens, contributing to obstruction and subsequent
renal failure. It was suggested that pFN might play a pivotal role in the pathogenesis of acute
renal failure and repair of the ischemia-induced kidney injury (502). Moreover, pFN has been
determined to be able to reduce brain injury following transient focal cerebral ischemia. This
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is because pFN provides a matrix for adherence, migration and proliferation of white blood
cells to repair the tissue damage. On the other hand, pFN also protects neuronal and non-
neuronal cells from cell death by interacting with integrins to increase Bcl-2 expression,
inhibiting apoptosis (2 1 8).
4. 1.3 Immunohistochemistry
The components of basement membrane can be detected by immunohistochemical methods
using labelled antibodies, to localise specific tissue antigen constituents. Antibodies are not
visible with standard microscopy and must be labelled in a manner that does not interfere with
their binding specificity. The marker must be of sufficient intensity to be detected and include
fluorescent compounds, such as fluorescein and rhodamine and compounds used for light
microscopy including horseradish peroxidase, glucose oxidase and intestinal alkaline
phosphatase (503). A specific antibody reacts with the desired antigen (fibronectin or laminin)
and the remaining constituents of the reagent are Íemoved by washing. Biotinylated anti-
rabbit IgG then binds to the primary antibody. Biotin has a very strong affinity for
streptavidin and then binds strongly to atertiary streptavidin-FlTc conjugate. Streptavidin has
an isoelectric point close to neutrality and contains no carbohydrate, making it less prone to
non-specific binding (Amersham Pharmacia Biotech UK). A Digital camera connected to a
fluorescence microscope was employed to capture the images, which were stoted on the
computer hardware for further quantitative analysis.
Immunohistochemistry has been extensively used in the study of the components in the
basement membranes. Saylam et al (504) has demonstrated the dynamic relationship of FN,
LN and collagen IV following conception in mice by employing immunohistochemical
methods. Roach et aI (302) successfully investigated the alterations in collagen IV by
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immunohistochemistry in the basement membrane after skeletal muscle ischemia and
reperfusion in rats. Moreover, immunohistochemistry has been employed to investigate the
components in the basement membrane of the lungs, liver and kidney (505), (506), (507).
4.1.4 Enzyme-Linked Immunos orbent Ass ay (ELISA)
Enzyme immunoassays combine the specificity of antibodies with the sensitivity of simple
spectrophotometric enzyme assays by using antibodies or antigen coupled to an easily assayed
enzyme.In competitive ELISAS, a mixture of known amount of enzyme-labelled antigen and
an unknown amount of unlabelled antigen is allowed to react with a specific antibody
attached to a microtitre plate. After the complex has been washed with buffer, the eîzyme
substrate is added and the plate incubated for a certain period before the enzyme activity is
measured. The difference between this value and that of a sample lacking unlabelled antigen
is a measure of the concentration of unlabelled antigen. Under standard conditions, the
enzyme activity measured is proportional to the proportion of labelled antigen in the mixture
of labelled and unlabelled antigen. This method requires the preparation of a calibration curve
during the assay (479). In the literature, ELISA has been widely employed to detect the
concentration ofpFN (508), (509), (510).
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4.2 Materials and Methods
4.2.L Quantitative Immunohistochemistry
4.2.1.L Investigation of Alterations of Fibronectin and Laminin in the Basement
membrane by Immunohistochemical Techniques
Frozen tissue samples obtained during I/R experiment were fixed to a cryostat chuck using
Tissue-tek@ OCT fixative. Sections were cut as follows: skeletal muscle 10 pm, lung, kidney
and liver 5 pm and then applied to poly-L-lysine-coated slides. The slides were allowed to air
dry, then immersed in20 o/o acetone solution at-20 oC for 20 minutes and dried again' Tissue
sections were circled with a PAP pen to create a well and then washed in 0.1 % BSA (bovine
serum albumin)/PBs (2.3.1) solution for 3x5 minutes. Each slide was incubated with 100 ¡rl
of 1:200 anti fibronectin or anti laminin primary antibody (Rockland; Gilbertsville, PA,
U.S.A) in a humidified chamber for 15 h at 4 oC. Following a further wash in 0.1 %
BSA/PBS, the sections were incubated with 100 ¡rt of 1:400 secondary antibody (anti-rabbit
serum antibody) (Vector Laboratories; Burlingame, CA, U.S.A) in a humidified chamber at
room temperature for t h. A third wash was performed prior to addition of 100 pl of 1: 200
streptavidin fluorescein label (Amersham Biosciences) and incubation fot Itlz hr at room
temperature in the humidifred chamber. A final wash preceded the addition of fluorescent
mounting medium (DAKO, Australia) and the application of a cover slip.
Images of tissue sections were captured on an Olympus BH2 microscope with Reflected Light
Fluoresecent Attachment (Olympus BHRFL-V/) on maximum excitation wavelength of 494
nm and maximum emission wavelength of 518 nm. Colour images were then captured under a
magnification of 200X. The pictures were then transmitted on a Panasonic Camera (WVCL
700) and saved as TIFF files. The images were analysed using a Video Pto 32 automated
image analysis system (Leading Edge Pty Ltd, Marion, South Australia). In the previous
studies conducted by Roach (511)), it was determined that the cumulative mean brightness
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reached a steady state after 25 images had captured. This implied that after 25 images had
been captured, any fuither images included would not change the arithmetic mean to be used
in the statistical analysis. Therefore, for the immunohistochemical quantitation analyses, 25
images were collected for each rat in a standardised pattern through the whole experiment.
This ensured that the number of images reached a normal statistical distribution. The level of
brightness was chosen for quantitative comparisons analysis. The whole field brightness of
each image was detected and the figure was recorded in tables of Appendix 6'5.
4.2.1.2 D escriptive Statistics
Each group contained 5 rats, 25 images were collected from each rat (I25 images involved in
each group). Brightness measurements representing quantity of fibronectin (or laminin), were
analysed using Analysis of Variance (ANOVA) to study the difference between different
treatment groups. Student-Newman-Keuls of Multiple Comparisons Test was used for
comparison between the individual groups. P < 0.05 was considered as significant.
4.2.2Plasma Fibronectin Analysis By ELISA Kit
The ELISA was carried out according to manufacturer's instruction. Briefly, the contents of a
vial of Diluent Buffer Concentrate (BT-702) was transferred to a graduated cylinder and
distilled water added to a volume of 150 ml before a set of working standards in the range of
25 nglmlto 2000 nglml was prepared with working diluent buffer as shown inTable 4'2.1
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Table 4.2.1
25 nglmlF. 0.1 ml Solution C+ 0.9 ml diluent
50 nglmlE. 0.1 ml Solution B + 0.9 ml diluent
100 nglmlD. 0.5 ml Solution B + 2.0 ml diluent
250 nglmlC. 1.0 ml Solution B + 1.0 ml diluent
500 nglmlB. 1.0 ml Solution A+ 3.0 ml diluent
2000 nglmlA. 100 ul stock + 4.9 ml diluent
Fibronectin
ConcentrationDilution
Diluent buffer 150 ¡rl was then pipetted into blank wells and 100p1 of buffer into the Bmax
wells. Subsequently, 100 pl of standards, conttols or samples were added to appropriate wells.
To start detection, 50 pl of Fibronectin Antiserum (BT-703) was pipetted into all wells except
blanks, followed by gentle mixing for 30 seconds. The wells were then covered tightly with
parafilm and incubated at37oC for t h, followed by the addition of 50 ¡"rl FN Tracer (BT-704)
to all wells, further incubated at 37"C f'or 60 minutes. Wells were then aspirated, filled with
diluent buffer and aspirated again. This process \ryas repeated 3 times. The excess liquid was
removed by gently tapping the empty plate on a paper towel. Prepared substrate solution (200
¡rl) was added to all wells, and incubated at 31"C. Measurement of absorbance was conducted
at 400-410 nm in 5 minutes intervals until desired range was reached after 60 minutes
incubation. Finally, 20 p) of Stop Solution (BT-707) was pipetted into all wells and the
absorbance was measured within t h.
100
To obtain net mean absorbance, all duplicates and the blank was averaged. A standard curve
was then constructed by plotting mean absorbance of each standard concentration or log
concentration. The concentration of pFN was determined from this standard curve.
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4.3. Results
As reported by D.Roach (D.Roach Thesis 2001, Adelaide University), the levels of collagen
IV in basement membranes were not influenced by anesthesia. There were no significant
differences in levels of collagen IV between different sham-operated groups (0/0/, 014,0124 or
0172). Therefore, in this study the levels of fibronectin or laminin in the basement membranes
following skeletal muscle ischemia with varying times of reperfusion were assessed using the
same sham-group (0124). Student-Newman-Keuls of Comparison Test was conducted for
comparison between the I/R group and sham-operated group (0124). P < 0.05 is considered as
significant.
4.3.1 Elevation of FN in the basement membrane of skeletal muscle following I/R.
There was a significant accumulation of FN in the basement membrane of ischemic skeletal
muscle following 4 h ischemia only (P < 0.05), when compared to sham-operated group. The
level of FN was elevated throughout the time course of reperfusion, at least until 72 h (P <
0.05). The representative immunohistochemical pictures of fibronectin staining in skeletal
muscle are shown in Figure 4.1, illustrating the trend of elevation in FN within different
experimental groups.
The raw data of quantitative immunohistochemical analysis is shown in Appendix (6.4.1).
The grouped descriptive statistical data for the analysis of brightness of FN staining is
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Figure 4.1 Representative immunohistochemistry images of skeletal
muscle showing levels of fibronectin
Images were magified 200 X. The primary antibody was directed against
fibronectin and secondary detection was carried out using biotin-labelled
antibody and SÍeptavidin-Fluorescein Isothiocyanate. Images were captured
on olympus BH2microscope with Reflected Light Fluorescent Attachment.
llP.0124 Skeletal muscle from rats that have undergone 4 h anaesthesia
followed by 24 h recovery, with no ischemia.
I/R:4/0 Skeletal muscle from rats following 4 h bilateral hindlimb ischemia,
sacrificed before reperfu sion.
I/R:414 Skeletal muscle from rats following 4 h bilateral hindlimb ischemia
and 4 hreperfusion.
IJR:4124 Skelet¿l muscle from rats following 4 hbilateral hindlimb ischemia
and24 h reperfusion.







SM FN: Fibronectin in the basement membrane of skeletal muscle
IlR0124: rats underwent 4 h anaesthesia with24 h recovery, no ischemia.
llP.4l0: rats underwent 4 h bilateral hindlimb ischemia only, with no reperfusion.
llR4l4: rats underwent 4 h bilateral hindlimb ischemia followed by 4h reperfusion.
IlR4124 rats underwent 4 h bilateral hindlimb ischemia followed by 24 h reperfusion.
llR 4172: rats underwent 4 h bilateral hindlimb ischemia followed by 72 h reperfusion.
SEM: Standard effor mean.
St Dev: Standard deviation.
4.3.2 Degradation of FN in the basement membrane of lung tissues following skeletal
muscle I/R.
A significant degradation of FN was observed (P < 0.05) in the basement membrane of lung
in rats following 4 hbllateral hindlimb ischemia only. Persistent degradation was found with
increasing duration of reperfusion. Fibronectin was at its lowest level af\er 12 h of
reperfusion. Representative pictures of FN staining in lung are shown in Figute 4.2,
illustrating the trend of alterations in fibronectin of the lung within different experimental
gfoups
Raw data of quantitative immunohistochemical analysis is shown in Appendix (6.4.2). The
grouped descriptive statistical data for the analysis of brightness of FN staining is summarised
inTable 4.3.2
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Figure 4.2. Representative immunohistochemistry images of lung tissues showing
levels of fibronectin
Images were magified 200 X. The primary antibody was directed against fibronectin and
.rrJndury deteciion was canied out using biotinJabelled antibody and Streptavidin-
Fluorescein Isothiocyanate. Images wefe captured on Olympus BH, microscope with
Reflected Light Fluorescent Attachment.
IIB.0124 Lung tissues from rats that have undergone 4 h anaesthesia followedby 24 h
recovery, with no ischemia.
VR:4/0 Lung tissues from rats following 4 h bilateral hindlimb ischemia, sacrificed
before reperfusion.
IIR:414 Lung tissues from rats following 4 h bilateral hindlimb ischemia and 4 h
reperftrsion.
llq:4124 Lung tissues from rats following 4 h bilateral hindlimb ischemia and 24 h
reperfusion.













UR 4172UR 4/24vP.4/4UR 4t0r/R 0/24Lung FN
Lung FN: Fibronectin in the basement membrane of lung
IlR0124: rats underwent 4h anaesthesia with24 h recovery, with no ischemia.
IlP.4l0: rats underwent 4 h bilateral hindlimb ischemia only, with no reperfusion.
IlR4l4: rats underwent 4 h bilateral hindlimb ischemia followed by 4h reperfusion.
UR4l24: rats underwent 4 h bilateral hindlimb ischemia followed by 24 h reperfusion.
UR4172: rats underwent 4 h bilateral hindlimb ischemia followed by 72 h reperfusion.
SEM: Standard error mean.
St Dev: Standard deviation.
4.3.3 FN in the basement membrane of renal tissues.
There was no clear evidence of degradation of FN in the basement membrane of kidneys
following 4h bilateral hindlimb ischemia only (P > 0.05). Significant degradation occurued
during reperfusion. Intensity of FN staining was lowest after 72 h of reperfusion.
Representative immunohistochemical pictures of FN staining in kidney are shown in Figure
4.3, illustrating the degradation of FN in the kidney within different experimental groups.
Raw data of quantitative immunohistochemical analysis is shown in Appendix (6.4.3). The
grouped descriptive statistical data for analysis of levels of fibronectin in kidney is
summarised in the Table 4.3.3.
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Figure 4. 3. Representative immunohistochemistry images of renal tissues showing
levels of fibrone*tin in the kidney
Images were magified200 X. The primary antibody was directed against fibronectin and
secondary detection was canied out using biotin-labelled antibody and Streptavidin-
Fluorescein Isothiocyanate. Images were captured on Olympus BH, microscope with
Refl ected Light Fluorescent Attachment.
IIR0124 Renal tissues from rats that have undergone 4 h anaesthesia followedby 24 h
recovery, with no ischemia.
IIR:410 Renal tissues from rats following 4 h bilateral hindlimb ischemia, sacrificed
before reperfusion.
IIP.:414 Renal tissues from rats following 4 h bilateral hindlimb ischemia and 4 h
reperfusion.
IIR:4124 Renal tissues from rats following 4 h bilateral hindlimb ischemia and 24 h
reperfusion.













IIR 4172UR 4t24UR 4/4IIP. 4t0vR 0t24Kidney FN
Kidney FN: Fibronectin in the basement membrane of kidney
IlR0124 rats underwent 4 h anaesthesia with24 h recovery, with no ischemia.
IlP.4l0: rats underwent 4 h bilateral hindlimb ischemia only, with no reperfusion.
UR 414: rats underwent 4 h bilateral hindlimb ischemia followed by 4 hreperfusion.
IlR4124: rats underwent 4 h bilateral hindlimb ischemia followed by 24 h reperfusion.
llR4172: rats underwent 4 h bilateral hindlimb ischemia followed by 72 h reperfusion.
SEM: Standard effor mean.
St Dev: Standard deviation.
NS: No significance
4.3-4 Alterations of FN in the basement membrane of hepatic tissues. Quantitative
immunohistochemistry for FN in the liver.
FN immunostaining was decreased markedly (P<0.05) in the liver immediately following
skeletal muscle ischemia (410,414).It then increased with reperfusion, exceeding the baseline
level after 24 h of reperfusion, reaching the highest level after 72 hours of reperfusion.
Representative immunohistochemical pictures of FN staining in liver are shown in Figure 4.4,
illustrating the elevation of FN in the liver following increasing duration of reperfusion.
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Figure 4. 4. Representative Ímmunohistochemistry inages of hepatic tissues
showing levels of fibronectin in the liver
Images were magified 200 X. The primary antibody was directed against fibronectin and
secondary detection was carried out using biotin-labelled antibody and Streptavidin-
Fluorescein Isothiocyanate, Images were captured on Olympus BH, microscope with
Reflected Light Fluorescent Attachment.
IIR.:0124 Hepatic tissues from rats that have undergone 4 h anaesthesia followedby 24
h recovery, with no ischemia.
IIF.:410 Hepatic tissues from rats following 4 h bilateral hindlimb ischemia, sacrificed
before reperfusion.
IIR.414 Hepatic tissues from rats following 4 h bilateral hindlimb ischemia and 4 h
reperfusion,
IIR:4124 Hepatic tissues from rats following 4 h bilateral hindlimb ischemia and 24 h
reperfusion.







Raw data of quantitative immunohistochemistry is shown in Appendix (6.a.\. The grouped








UR 4172ItP.4124UP.4l4r/R 4/0UR0124Liver FN
Liver FN: Fibronectin in the basement membrane of liver
IlR0l24: rats underwent 4 h anaesthesia with24 h recovery, with no ischemia.
IlF.4l0: rats underwent 4 h bilateral hindlimb ischemia only, with no reperfusion.
IlR4l4: rats underwent 4 h bilateral hindlimb ischemia followed by 4hreperfusion.
IlR4124: rats underwent 4 h bilateral hindlimb ischemia followed by 24 h reperfusion.
IIR 4172: rats underwent 4 h bilateral hindlimb ischemia followed by 72 h reperfusion.
SEM: Standard error mean.
St Dev: Standard deviation.
4.3.5 Summary of alterations of FN in the basement membranes of skeletal muscle, lung,
kidney and liver of rats following 4 h bilateral hindlimb ischemia and increasing
duration of reperfusion.
Figure 4.5 illustrates graphically the changes in FN level in basement membranes after
skeletal muscle ischemia and reperfusion. As discussed above, there was a trend of
accumulation of FN in skeletal muscle following I/R. In contrast, degradation of FN in lung
and kidney was detected following skeletal muscle I/R. However, fibronectin initially
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Figure 4.5. The graph showing alterations of fïbronectin in the basement
membrane of skeletal muscle, lungo kidney, and liver of rats following 4 h
bilateral hindlimb ischemia with increasing duration of reperfusion
Tissue sections were labelled with fibronectin antibody, prepared and analysed
as describe d in 4.2.1. Brightness refers to level of flrbronectin detected with
immunofluorescence.
Each column on the graph represents the mean brightness level of fibronectin
in the basement membranes. Given five rats in each group, 25 images for each
rat, 125 images were included in total. The standard deviation bars are shown
on the graph.
IR 0124 refers to rats that underwent a 4 h anaesthesia only, with no ischemia
and were sacrificed after 24 h recovery.
IR 4/0 refers to rats that underwent a 4 h bilateral hindlimb ischemia and were
sacrificed immediately after ischemia.
IR 414 refers to rats that underwent a 4 h bilateral hindlimb ischemia followed
by4hofreperfusion.
IR4124 refers to rats that underwenta4 h bilateral hindlimb ischemia followed
by 24 h of reperfusion.
IR 4172 refers to rats that underwenL a 4 h bilateral hindlimb ischemia followed




























decreased in the liver following skeletal muscle ischemia, then increasing with further
reperfusion, exceeding the baseline level after 24 h of reperfusion. This change from baseline
is significant (P < 0.05).
4.3.6 Alterations of LN in the basement membrane of skeletal muscle following I/R.
There was no clear change of Laminin in basement membrane of skeletal muscle immediately
following 4 h of ischemic insult (410,414). LN levels were then slightly elevated in basement
membrane with the further reperfusion, exceeding the baseline level after 24 h reperfusion (P
< 0.05). Representative immunohistochemical pictures of LN staining in skeletal muscle are
shown in Figure 4.6, illustrating the trend of changes for LN in the skeletal muscle within
different experimental groups.
Raw data of quantitative immunohistochemistry is shown in Appendix (6.4.5). The grouped








r/P.4/72UR 4124UR 4l4vP.410uF.0124SM LN
SM LN: Laminin in the basement membrane of skeletal muscle
IlR0l24 rats underwent 4 h anaesthesia with24 h recovery, with no ischemia.
I/R 4/0: rats underwent 4 h bilateral hindlimb ischemia only, with no reperfusion.
IlF.4l4 rats underwent 4 h bilateral hindlimb ischemia followed by 4 h reperfusion.
IlR4124 rats underwent 4 h bilateral hindlimb ischemia followed by 24 h reperfusion.
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Figure 4.6. Representative immunohistochemistry images of skeletal muscle
showing levels of laminin in skeletal muscle
Images were magified 200 X. The primary antibody was directed against laminin and
secondary detection was carried out using biotin-labelled antibody and Streptavidin-
Fluorescein Isothiocyanate. Images were captured on Olympus BH, microscope with
Reflected Light Fluorescent Attachment.
IIR:0124 Skeletal muscle from rats that have undergone 4 h anaesthesia followedby 24
h recovery, with no ischemia.
I/R:4/0 Skeletal muscle from rats following 4 h bilateral hindlimb ischemia, sacrificed
before reperfusion.
IIF..414 Skeletal muscle from rats following 4 h bilateral hindlimb ischemia and 4 h of
reperfusion.
UR:4124 Skeletal muscle from rats following 4 h bilateral hindlimb ischemia and 24 h
of reperfusion.







IlR4/72: rats underwent 4 h bilateral hindlimb ischemia followed by 72 h reperfusion.
SEM: Standard effor mean.
St Dev: Standard deviation.
NS:No significance.
4.3.7 Alterations of LN in the basement membrane of renal tissues following skeletal
muscle I/R.
LN was degraded significantly (P < 0.05) in basement membrane of the kidney after 4 h of
skeletal muscle ischemia. The degradation was persistent in the early phase of reperfusion,
reaching the lowest level after 4 h of reperfusion. LN levels then increased in basement
membrane with the progression of reperfusion, returning to baseline level (sham 0124) after
24 h rcperfusion. There was no difference in LN level between group 4124 and 0124, bú lhe
change in LN level from time course 414 to 4124 reached significance (P<0.05).
Representative immunohistochemical pictures of LN staining in the kidney are shown in
Figure 4.7, illustrating the trend of changes for LN in the renal tissues within different
experimental groups.
Raw data of quantitative immunohistochemistry is shown in Appendix (6.a.Q. The grouped
descriptive statistical data for the analysis of LN levels in the kidney is summarised in the
Table 4.3.6.
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Figure 4. 7. Representative immunohistochemistry images of renal tissues showing
levels of laminin in the kidney
Images were magified 200 X. The primary antibody was directed against laminin and
secondary detection was canied out using biotin-labelled antibody and Streptavidin-
Fluorescein Isothiocyanate, Images were captured on Olympus BH, microscope with
Refl ected Light Fluorescent Attachment.
IIR:0124 Renal tissues from rats that have undergone 4 h anaesthesia followedby 24 h
recovery, with no ischemia.
I/R:4/0 Renal tissues from rats following 4 h bilateral hindlimb ischemia, sacrificed
before reperfusion.
IIR:414 Renal tissues from rats followrng 4 h bilateral hindlimb ischemia and 4 h of
reperfusion.
IIR:4124 Renal tissues from rats following 4 h bilateral hindlimb ischemia and24 h of
reperfusion.
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UR 4172UR 4124vR 414I/R 4/0vR 0124Kidney LN
Kidney LN: Laminin in the basement membrane of kidney
IlR0l24: rats underwent 4 h anaesthesia with24 h recovery, with no ischemia.
I/R 4/0: rats underwent 4 h bilateral hindlimb ischemia only, with no reperfusion.
IlR4l4: rats underwent 4 h bilateral hindlimb ischemia followed by 4hreperfusion.
llp4124: rats underwent 4 h bilateral hindlimb ischemia followed by 24 h reperfusion.
IlR4172: rats underwent 4 h bilateral hindlimb ischemia followed by 72 h reperfusion.
SEM: Standard effor mean.
St Dev: Standard deviation.
NS:No significance.
4.3.8 Summary of alterations of LN in basement membranes of skeletal muscle and
kidney of rats following 4 h bilateral hindlimb ischemia and increasing duration of
reperfusion.
Figure 4.8 illustrates graphically the changes in LN level in basement membranes of skeletal
muscle and kidney following bilateral hindlimb ischemia and reperfusion. There were no
clear changes of LN level in skeletal muscle immediately following ischemia/reperfusion, but
slightly elevation in LN level was detected with further reperfusion (4124, 4172), exceeding
the baseline level after 24 h of reperfusion. A significant degradation of LN was observed in
kidney following skeletal muscle ischemia. The LN level then returned to baseline after 24 h
of reperfusion.
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Figure 4.8 Changes in laminin patterns in the basement membranes of skeletal
muscle and kidney of rats that had undergone 4 h of bilateral hindlimb
ischemia with increasing duration of reperfusion
Tissue sections were labelled with laminin antibody, prepared and analysed
as described in 4.2.1. Brightness refers to level of laminin detected with
immunofluorescence.
Each column on the graph represents the mean brightness level of laminin in the
basement membranes, Given five rats in each group, 25 images for each rat, 125
images were included in total. The standard deviation bars are shown on the graph.
IR 0124 refers to rats that underwent a 4 h anaesthesia only, with no ischemia and
were sacrificed after 24hrecovery.
IR 4/0 refers to rats that underwenf a 4 h bilateral hindlimb ischemia and were
sacrifi ced immediately after ischemia.
IR 414 refers to rats that underwent a 4 h bilateral hindlimb ischemia followed by 4
h of reperfusion.
lR 4124 refers to rats that underwent a 4 h bilateral hindlimb ischemia followed by
24 h of reperfusion.
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4.3.9 Alterations of LN in the basement membrane of lung tissues following skeletal
muscle I/R.
A fluctuation in laminin level was observed in basement membrane of the lung following 4 h
of skeletal muscle ischemia/reperfusion. The laminin level decreased initially after ischemia
only, it then returning to baseline level after reperfusion (414,4124), decreasing subsequently
with the further reperfusion. Finally, the laminin level reached the lowest level after 72 h of
reperfusion (P < 0.05). The representative immunohistochemical pictures of laminin staining
in the lung are shown in Figure 4.9, illustrating the wave of alterations of LN in the lung
tissues within different experimental groups.
Raw data of quantitative immunohistochemistry is shown in Appendix (6.4.1). The grouped








vR 4t72UR 4124vR 414r/R 4/0UR 0124Lung LN
Lung LN: Laminin in the basement membrane of lung
IlR0l24 rats underwent 4 h anaesthesia with24 h recovery, with no ischemia.
I/R 4/0: rats underwent 4 h bilateral hindlimb ischemia only, with no reperfusion.
llR4l4: rats underwent 4 h bilateral hindlimb ischemia followed by 4 h reperfusion
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Figure 4. 9. Representative immunohistochemistry images of lung tissues showing
levels of laminin in the lung
Images were magified 200 X. The primary antibody was directed against laminin and
,..olndury detection was carried out using biotin-labelled antibody and Streptavidin-
Fluorescein Isothiocyanate. Images \ryefe captured on Olympus BH, microscope with
Reflected Light Fluorescent Attachment.
IIp:0124 Lung tissues from rats that have undergone 4 h anaesthesia followedby 24 h
recovery, with no ischemia.
IiR:4/0 Lung tissues from rats following 4 h bilateral hindlimb ischemia, sacrificed
before reperfusion.
llp¡:414 Lung tissues from rats following 4 h bilateral hindlimb ischemia and 4 h of
reperfusion,
IIR:4124 Lung tissues from rats following 4 h bilateral hindlimb ischemia and 24 h of
reperfusion.







IlR4124: rats underwent 4 h bilateral hindlimb ischemia followed by 24 h reperfusion.
IIR 4172: rats underwent 4 h bilateral hindlimb ischemia followed by 72 h reperfusion.
SEM: Standard effor mean.
St Dev: Standard deviation.
NS: No significance.
4.3.10 Summary in graph showing change pattern of LN in basement membranes of the
lung of rats following 4 h of bilateral hindlimb ischemia and increasing duration of
reperfusion.
Figure 4.10 illustrates graphically the changes in LN levels in basement membrane of the lung
following bilateral hindlimb yR. A fluctuation in laminin level was observed in lung after
skeletal muscle I/R. LN was initially degraded, then increasing with progression of
reperfusion, returning to the baseline level after reperfusion (414,4124), decreasing again with
further reperfusion, reaching the lowest level after 72 h of reperfusion.
4.3.11The effects of doxycycline on the alterations of FN in the basement membrane of
skeletal muscle following I/R. Quantitative immunohistochemistry for FN in skeletal
muscle after doxycycline treatment
In following groups of experiment (4.3.1 l-4.3.19), doxycycline was administered in low dose
and high dose respectively prior to 4 h of bilateral hindlimb ischemia followed by 24 h of
reperfusion. Student-Newman-Keuls of Comparison Test was conducted for comparison
between doxycycline treatment groups (llB::4124 Doxy L.D and IIF.:4124 Doxy H'D) and no
treatment group (llR:4124). P < 0.05 is considered as significant.
FN level in skeletal muscle increased following I/R (4124). After administration of
doxycycline, FN level was reduced slightly in the basement membranes of skeletal muscle,
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Figure 4.10. Change patterns of laminin in the basement membrane of lung
of rats that had undergone 4 hours of bilateral hindlimb ischemia with
increasing duration of reperfusion
Tissue sections were labelled with laminin antibody, prepared and analysed
as described in 4.2.1. Brightness refers to level of laminin detected with
immunofluorescence.
Each column on the graph represents the mean brightness level of laminin in the
basement membranes, Given five rats in each group, 25 images for each rat,l25
images were included in total. The standard deviation bars are shown on the
graph.
IR 0124 refers to rats that underwent a 4 h anaesthesia only, with no ischemia and
were sacrificed after 24 h of rçcovery.
IR 4/0 refers to rats that underwent a 4 h bilateral hindlimb ischemia and were
sacrificed immediatelv after ischemia.
IR 414 refers to rats that underwenf a 4 h bilateral hindlimb ischemia followed by
4 h of reperfusion.
IR 4124 refers to rats that underwent a 4 h bilateral hindlimb ischemia followed
by 24 h of reperfusion.
IR 4172 refers to rats that underwent a 4 h bilateral hindlimb ischemia followed
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Figure 4.11. Representative immunohistochemistry images of skeletal muscle
snõwing levels ãf fTbronectin after treatment of rats with various dose of
doxycycline
IIR:0124 Skeletal muscle from rats that have undergone 4 h anaesthesia followedby 24
h of recovery, with no ischemia, no doxycycline administration.
IIF.:4124 Skeletal muscle from rats that have undergone 4 h bilateral hindlimb ischemia,
sacrificed after 24 h of reperfusion, no doxycycline treatment.
ll}}p4 Doxy L.D Skeletal muscle from rats that were administered low dose of
doxycycline irior to 4 h of bilateral hindlimb isohemia, sacrificed after 24 h of
reperfusion.
IIpi124 Doxy H.D Skeletal muscle from rats that were administered high dose of
doxycyclin. i.io, to 4 h of bilateral hindlimb isohemia, sacriflrced after 24 h of
reperfusion.
I/R:0124 I/R :4124
I/R :4l24DoxY L.D I/R :4124 DoxY H'D
compared to no treatment group. Representative images of the immunohistochemical staining
of skeletal muscle are shown in Figure 4.11, illustrating the alterations of FN after
doxycycline treatment in immunostaining that occurred within the different experimental
groups.
Raw data of quantitative immunohistochemistry is shown in Appendix (6.a'S). The grouped
descriptive statistical data for analysis of FN levels in skeletal muscle is summarised in the













SM FN Doxy: Fibronectin in skeletal muscle after doxycycline treatment
ll1 0124: Rats in Sham-group underwent 4 h anaesthesia followed by 24 h of recovery, with
no ischemia.
IIR 4124 no Doxy: Rats underwent 4 h bilateral hindlimb ischemia followed by 24 h of
reperfusion, no doxycycline treatment.
llF- 4124 Doxy L.D: Rats were administered low dose of doxycycline (50 mg/Kg, twice daily
for 7 days) prior to 4 h of bilateral hindlimb ischemia followed by 24 h of reperfusion.
IIR 4124 Doxy H.D: Rats were administered high dose of doxycycline (200 mglKg, twice
daily for 7 days) prior to 4 h of bilateral hindlimb ischemia followed by 24 h of reperfusion.
SEM: Standard error mean.
7t2
St Dev: Standard deviation.
4.3.L2 The effects of doxycycline on the alterations of FN in the basement membrane of
lung tissues following skeletal muscle I/R.
The degradation of FN in the basement membrane of lung was inhibited significantly (P <
0.05) by administration of doxycycline, compared to no treatment group (llR: 4124 no Doxy)
following skeletal muscle I/R. There was no significant difference between low dose and high
dose of doxycycline. Representative images of the immunohistochemistry of the lung are
shown in Figure 4.12, illustrating the alterations of FN in immunostaining that occurred
within the different experimental groups after doxycycline treatment.
Raw data of quantitative immunohistochemistry is shown in Appendix (6.a.9). The grouped








Lung FN Doxy: Fibronectin in the lung of rats with doxycycline treatment
IIR 0124: Rats in Sham-group underwent 4 hours anaesthesia followed by 24 h of recovery,
with no ischemic insult.















Figure 4.12. Representative immunohistochemistry images of lung tissue showing
levels of fibronectin following skeletal muscle ischemia/reperfusion with
doxycycline treatment
UR:0124 Lung tissues from rats that have undergone 4 h anaesthesia followedby 24 h
of recovery, with no ischemia, no doxycycline administration.
IIF.4124 Lung tissues from rats that have undergone 4 h bilateral hindlimb ischemia"
sacrificed after 24 h of reperfusion, no doxycycline treatment.
IIP*:4124 Doxy L.D Lung tissues from rats that were administered low dose of
doxycycline prior to 4 h of bilateral hindlimb ischemia, sacrificed after 24 h of
reperfusion.
llR:4124 Doxy H.D Lung tissues from rats that were administered high dose of
doxycycline prior to 4 h of bilateral hindlimb ischemia, sacrificed after 24 h of
reperfusion.
Sham I/R :0124 IIR :4124
I/R :4124 DoxY L.D IIR :4124 DoxY H'D
UR 4124 Doxy L.D: Rats were administered low dose of doxycycline (50mg/Kg, twice daily
for 7 days) prior to 4 h of bilateral hindlimb ischemia followed by 24 h of reperfusion.
IIR 4124 Doxy H.D: Rats were administered high dose of doxycycline (200 mglKg, twice
daily for 7 days) prior to 4 h of bilateral hindlimb ischemia followed by 24 h of reperfusion.
SEM: Standard error mean.
St Dev: Standard deviation.
4.3.13 The effects of doxycycline on the alterations of FN in the basement membrane of
renal tissues following skeletal muscle I/R.
There was no change of FN in the kidney after skeletal muscle 4 h of ischemia followed by 24
h of reperfusion. The FN level in kidney was not elevated significantly (P > 0.05) by
administration of doxycycline either with low dose or high dose. Representative images of the
immunohistochemistry of the kidney are shown in Figure 4.13, illustrating the FN levels in
kidney with doxycycline treatment in immunostaining that occurred within the different
experimental groups.
Raw data of quantitative immunohistochemistry is shown in Appendix (6.4.10). The grouped
descriptive statistical data for the analysis of FN level in kidney is summarised in the Table
4.3.10
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Figure 4.13. Representative immunohistochemistry images of renal tissues showing
levels of fibronectin following skeletal muscle ischemia/reperfusion after treatment
of rats with doxycycline
IIR:0124 Renal tissues from rats that have undergone 4 h anaesthesia followedby 24 h
of recovery, with no ischemia, no doxycycline administration.
IIFi:4124 Renal tissues from rats that have undergone 4 h bilateral hindlimb ischemia,
sacrificed after 24 h of reperfusion, no doxycycline treatment.
IIFI:4124 Doxy L.D Renal tissues from rats that were administered low
dorycycline prior to 4 h of bilateral hindlimb ischemia, sacriflrced after
reperfusion.
IIPi:4124 Doxy H.D Renal tissues from rats that were administered high
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Kidney FN Doxy: Fibronectin in the kidney of rats with doxycycline treatment.
IIR 0124: Rats in Sham-group underwent 4 h anaesthesia followed by 24 h of recovery, with
no ischemic insult.
IIR 4124 No Doxy: Rats underwent 4 h bilateral hindlimb ischemia followed by 24 h of
reperfusion
IIR 4124 Doxy L.D: Rats were administered low dose of doxycycline (50 mglKg, twice daily
for 7 days) prior to 4 h of bilateral hindlimb ischemia followed by 24 h of reperfusion.
IIR 4124 Doxy H.D: Rats were administered high dose of doxycycline (200 mglKg, twice
daily for 7 days) prior to 4 h of bilateral hindlimb ischemia followed by 24 h of reperfusion.
SEM: Standard error mean.
St Dev: Standard deviation
NS:No significance.
4.3.14 The effects of doxycycline on the alterations of FN in the basement membrane of
hepatic tissue following skeletal muscle I/R.
There was an increase in FN in basement membrane of the liver after 4 h skeletal muscle
ischemia followed by 24 h reperfusion. A further increase in FN was detected in the liver after
treatment with doxycycline (P < 0.05). The further increase was also correlated to the dose of
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doxycycline (P < 0.05). Representative images of the immunohistochemistry of the hepatic
tissues are shown in Figure 4.14, illustrating FN level in the liver after doxycycline treatment.
Raw data of quantitative immunohistochemistry is shown in Appendix (6.4.11). The grouped
















Liver FN Doxy: Fibronectin in the liver after doxycycline treatment
IIR 0124: Rats in Sham-group underwent 4 h anaesthesia followed by 24 h of recovery, with
no ischemic insult.
IlR4124: Rats underwent 4 h bilateral hindlimb ischemia followed by 24 h of reperfusion.
IIR 4124 Doxy L.D: Rats were administered low dose of doxycycline (50 mglKg, twice daily
for 7 days) prior to 4 h of bilateral hindlimb ischemia followed by 24 h of reperfusion.
IIP. 4124 Doxy H.D: Rats were administered high dose of doxycycline (200 mg/Kg, twice
daily for 7 days) prior to 4 h of bilateral hindlimb ischemia followed by 24 h of reperfusion.
SEM: Standard error mean.
St Dev: Standard deviation.
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Figure 4.14. Representative immunohistochemistry images of hepatic tissues
showing levels of fibronectin following skeletal muscle ischemia/reperfusion after
treatment of rats with doxycycline
llR:0124 Renal tissues from rats that have undergone 4 h anaesthesia followedby 24 h
of recovery, with no ischemia, no doxycycline administration.
IIP*4124 Renal tissues from rats that have undergone 4 h bilateral hindlimb ischemia,
sacrificed after 24 h of reperfusion, no doxycycline treatment,
llP.:4124 Doxy L.D Renal tissues from rats that were administered low dose of
doxycycline prior to 4 h of bilateral hindlimb ischemia, sacrificed after 24 h of
reperfusion.
llF.:4124 Doxy H.D Renal tissues from rats that were administered high dose of
doxycycline prior to 4 h of bilateral hindlimb ischemia, sacrificed after 24 h of
reperfusion.
I/R :0124 I/R :4124
IIR :4l24DoxY L.D IIR :4124 DoxY H'D
4.3.15 Summary of effects of doxycycline on alterations of FN in basement membranes
of skeletal muscle, lung, kidney and liver following 4 h of bilateral hindlimb ischemia
and 24 h of reperfusion.
Figure 4.15 illustrates graphically the changes in FN levels in basement membranes following
skeletal muscle ischemia and reperfusion after treatment of rats with doxycycline. FN level
increased in basement membranes of skeletal muscle after 4 h of bilateral hindlimb ischemia
and 24 h of reperfusion (llR, 4124). The increased FN level was reduced in basement
membrane of skeletal muscle when rats were treated with doxycycline prior to IIP* (4124). The
degradation of FN in lung was inhibited signihcantly after treatment of rats with doxycycline
(P < 0.05). However, FN expression in kidney was not affected by doxycycline. In addition, a
further increase in FN was detected in the liver after treatment of rats with doxycycline
(P<0.05). The increase was also related to the dose of doxycycline.
4.3.L6 The effects of doxycycline on degradation of LN in basement membrane of
skeletal muscle following I/R.
There was a degradation of LN in basement membrane of skeletal muscle following 4 h of
ischemia and24 h of reperfusion. The degradation was inhibited significantly (P<0.05) when
rats were treated with doxycycline prior to ischemic insult. There was no significance
between low dose and high dose of doxycycline treatment. Representative images of the
immunohistochemistry of skeletal muscle are shown in Figure 4.16, illustrating the LN level
after doxycycline treatment.
Raw data of quantitative immunohistochemistry is shown in Appendix $.a.D). The grouped
descriptive statistical data for the analysis of LN level is summarised in the Table 4.3.12.
1t7
Figure 4.15. Analysis graph showing the effects of doxycycline on
fibronectin in the basement membranes of skeletal muscle, lung, kidney
and liver following bilateral hindlimb ischemia and reperfusion
Tissue sections were labelled with fibronectin antibody, prepared and analysed
as describedin4.2.1. Brightness refers to level of f,rbronectin detected with
immunofluorescence.
Each column on the graph represents the mean brightness level of flrbronectin
in the basement membranes. Given five rats in each group, 25 images for each
rat, 125 images were included in total. The standard deviation bars are shown
on the graph.
lR: 0124 are rats that underwent 4 hanaesthesia only, and then sacrif,rced
after 24 h of recovery.
lR: 4124 are rats that underwent 4 h of bilateral hindlimb ischemia under
anaesthesia followed by 24 h of reperfusion.
Doxy L.D are rats that had been administered low dose of doxycycline (50
mgikg, twice daily for 7 days) orally before subjected to 4 h of bilateral
hindlimb ischemia and 24 h of reperfusion.
Doxy H.D are rats that had been administered high dose of doxycycline (200
mg/kg, twice daily for 7 days) orally before subjected to 4 h of bilateral
























Figure 4.16. Representative immunohistochemistry images of skeletal muscle
showing levels of laminin after treatment of rats with doxycycline
IIR:0124 Skeletal muscle from rats that have undergone 4 h anaesthesia followedby 24
h of recovery, with no ischemia, no doxycycline administration.
IIF.:4124 Skeletal muscle from rats that have undergone 4 h bilateral hindlimb ischemia,
sacrificed after 24 h of reperfusion, no doxycycline treatment.
IIF.:4124 Doxy L.D Skeletal muscle from rats that were administered low dose of
doxycycline prior to 4 h of bilateral hindlimb ischemia, sacrificed after 24 h of
reperfusion.
IIF.4124 Doxy H.D Skeletal muscle from rats that were administered high dose of
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SM LN Doxy: Laminin in skeletal muscle after doxycycline treatment.
IIR 0124: Rats in Sham-group underwent 4 h anaesthesia followed by 24 h of recovery, with
no ischemic insult.
IIR 4124 No Doxy: Rats underwent 4 h of bilateral hindlimb ischemia followed by 24 h of
reperfusion, no treatment with doxycycline.
llR4124 Doxy L.D: Rats were administered low dose of doxycycline (50 mglKg, twice daily
for 7 days) prior to 4 h of bilateral hindlimb ischemia followed by 24 h of reperfusion.
llR 4124 Doxy H.D: Rats were administered high dose of doxycycline (200 mglKg, twice
daily for 7 days) prior to 4 h of bilateral hindlimb ischemia followed by 24 h of reperfusion.
SEM: Standard effor mean.
St Dev: Standard deviation.
4.3.17 The effects of doxycycline on LN in basement membrane of lung tissues following
skeletal muscle IlR.
LN level decreased in basement membrane of lung tissues following skeletal muscle 4 h of
ischemia and 24 h of reperfusion (4124). The decreased level of LN was elevated by
administration of doxycycline either in low dose or high dose (P < 0.05). Representative
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FÍgure 4.17. Representative immunohistochemistry images of lung tíssue showing
levels of laminin after treatment of rats with doxycycline
IIR:0124 Lung tissues from rats that have undergone 4 h anaesthesia followedby 24 h
of recovery, with no ischemia, no doxycycline administration'
IIFI:4124 Lung tíssues from rats that have undergone 4 h bilateral hindlimb ischemia,
sacriflrced after 24 h of reperfusion, no doxycycline treatment.
IIR:4124 Doxy L.D Lung tissues from rats that were administered low dose of
doxycycline prior to 4 h of bilateral hindlimb ischemia, sacrificed aftet 24 h of
reperfusion.
llpi:4124 Doxy H.D Lung tissues from rats that were administered high dose of
doxycycline prior to 4 h of bilateral hindlimb ischemia, saorificed after 24 h of
reperfusion.
I/R :0124 I/R :4124
I/R :4124 Doxy L.D I/R :4124 DoxY H'D
images of the immunohistochemistry of the lung are shown in Figure 4.17, illustrating the LN
staining in different experimental groups after doxycycline treatment'
Raw data of quantitative immunohistochemistry is shown in Appendix (6.4.13). The grouped
descriptive statistical data for the analysis of LN level is summarised in the Table 4'3 '73 '
Table 4.3.13
P<0.05P value













Lung LN Doxy: Laminin in the lung of rats after doxycycline treatment'
IIR 0124: Rats in Sham-group underwent 4 h anaesthesia followed by 24 h of recovery, with
no ischemic insult.
IIR 4124 No Doxy: Rats underwent 4 h of bilateral hindlimb ischemia followed by 24 h of
reperfusion, no treatment with doxycycline.
IIF_ 4124 Doxy L.D: Rats were administered low dose of doxycycline (50 mg/Kg, twice daily
for 7 days) prior to 4 h of bilateral hindlimb ischemia followed by 24 h of reperfusion'
IIF_ 4124 Doxy H.D: Rats were administered high dose of doxycycline (200 mg/Kg, twice
daily for 7 days) prior to 4 h of bilateral hindlimb ischemia followed by 24 h of reperfusion'
SEM: Standard effor mean.
St Dev: Standard deviation.
4.3.18 The effects of doxycycline on LN in the basement membrane of renal tissues
following skeletal muscle I/R.
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LN level decreased in basement membrane of kidney following skeletal muscle 4h of
ischemia and24h of reperfusion (I/R, 4124). After doxycycline treatment, LN level was then
elevated either with low dose or high dose (P < 0.05). Representative images of the
immunohistochemistry of renal tissue are shown in Figure 4.18, illustrating the LN staining in
different experimental groups.
Raw data of quantitative immunohistochemistry is shown in Appendix (6.4.14). The grouped
descriptive statistical data for the analysis of LN level is summarised in the Table 4.3.14.
Table 4.3.14
P <0.0 5P<0.05P value
6517 .95 602.13612.457 83 .7St Dev
5 83501.1323.1517.3SEM










Kidney LN Doxy: Laminin in the kidney after doxycycline treatment.
IIR 0124: Rats in Sham-group underwent 4 h anaesthesia followed by 24 h of recovery, with
no ischemic insult.
IlR. 4124 No Doxy: Rats underwent 4 h of bilateral hindlimb ischemia followed by 24 h of
reperfusion
IIF* 4124 Doxy L.D: Rats were administered low dose of doxycycline (50 mg/Kg, twice daily
for 7 days) prior to 4 h of bilateral hindlimb ischemia followed by 24 h of reperfusion.
IIP. 4124 Doxy H.D: Rats were administered high dose of doxycycline (200 mg/Kg, twice
daily for 7 days) prior to 4 h of bilateral hindlimb ischemia followed by 24 h of reperfusion.
SEM: Standard error mean.
St Dev: Standard deviation.
t20
Figure 4.18. Representative immunohistochemistry images of renal tissue showing
levels of laminin after treatment of rats with doxycycline
IIR:0124 Renal tissues from rats that have undergone 4 h anaesthesia followedby 24 h
of recovery, wittì no ischemia, no doxycycline administration.
IIR:4124 Renal tissues from rats that have undergone 4 hbilateral hindlimb ischemia,
sacrificed after 24 h of reperfusion, no doxycycline treatment.
IIR:4124 Doxy L.D Renal tissues from rats that were administered low dose of
doxycycline prior to 4 h of bilateral hindlimb ischemia, sacrificed after 24 h of
reperfusion.
IIF..4124 Doxy H.D Renal tissues from rats that were administered high dose of
doxycycline prior to 4 h of bilateral hindlimb ischemia, sacrificed after 24 h of
reperfusion.
I/R :0124 I/R :4124
I/R :4l24Doxy L.D I/R :4124 DoxY H.D
4.3.19 Summary of effects of doxycycline on LN in basement membranes of skeletal
muscle, lung and kidney following 4 h of bilateral hindtimb ischemia and 24 h of
reperfusion.
Figure 4.19 illustrates graphically the change patterns of LN in basement membranes of
skeletal muscle, lung and kidney following 4 h of bilateral hindlimb ischemia and 24 h of
reperfusion (IIP., 4124). LN level decreased in basement membranes of skeletal muscle, lung
and kidney after I/R (4124). After doxycycline treatment prior to I/R, LN level was elevated
either in low dose or high dose. These results suggest that doxycycline is capable of inhibiting
the degradation of LN in basement membranes of skeletal muscle, lung and kidney.
4.3.20. Alterations of FN in the plasma following skeletal muscle I/R.
In the immunohistochemical experiments, a rapid accumulation of FN was detected in
basement membrane of the skeletal muscle subjected to I/R. The pattern of FN expression is
different from those of collagen IV. Previous work from this laboratory demonstrated
degradation of collagen IV in basement membrane following VR (511). However, in the
current experiments, FN was found to accumulate in basement membranes of skeletal muscle
after I/R. Therefore, it was postulated that plasma FN may incorporate into the tissue FN
following ischemic injury, leading to the accumulation in basement membrane observed on
immunohistochemistry. Alterations of pFN have also been reported after tissue injury, such as
burn. So changes in pFN may occur following bilateral hindlimb ischemia and reperfusion.
pFN was analysed using ELISA. It was rapidly depleted after 4 h of skeletal muscle ischemia
(4/0) and during early reperfusion (414 h). FN then increased with the increasing periods of
reperfusion, exceeding the normal baseline level compared to sham-group after 24 h of
reperfusion. There was a trend for FN to recover to baseline level thereafter (Figure 4.20).
The plasma protein concentration was also analysed using Bio-Rad Protein Assay and the
relative pFN was calculated. The fraction of FN constituting plasma protein was increased
immediately after skeletal muscle ischemia, and then decreased significantly with the
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progressing of reperfusion. It was recovered to baseline level with the reperfusion up to 72 h
(Figure 4.21and4.22).
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Figure 4.192 Analysis graph showing effects of doxycycline on the
degradation of laminin in the basement membranes of skeletal musclet
lung and kidney foltowing bilateral hÍndtimb ischemia and reperfusion
Tissue sections were labelled with laminin antibody, prepafed and analysed
as describe d in 4 .2.1 . Brightness refers to level of laminin detected with
immunofluorescence.
Each column on the graph represents the mean brightness level of laminin in
the basement membranes. Given flrve rats in each grollp, 25 images for each
rut,125 images were included in total, The standard deviation bars are shown
on the graph.
IFr:0124 are rats that underwent 4 h anaesthesia only, and then sacrificed
after 24 h of recovery.
IFt: 4124 No Doxy are rats that underwent 4 h of bilateral hindlimb ischemia
under anaesthesia followed by 24 h of reperfusion, no doxycycline treatment.
Doxy L.D are rats that had been administered low dose of doxycycline (50
mg/kg, twice daily for 7 days) orally before subjected to 4 h of bilateral
hindlimb ischemia and 24 h of reperfusion.
Doxy H.D are rats that had been administered high dose of doxycycline (200
mglkg, twice daily for 7 days) orally before subjected to 4 h of bilateral


















FÍgure 4.20. Concentration of circulating plasma fibronectin of rats subjected
to ischemia and reperfusionr compâred with sham rats
Concentrations of circulating fibronectin were determined by competitive ELISA
of sodium citrate-anticoagulated rat plasma collected by cardiac puncture on
sacrifice. Values shown for each timepoint are the duplicate means + SEM for each
of five rats. Timepoints at which sham and ischemic values were significantþ
different are asterisked(p -<0.05, Tukey's HSD Post-hoc analysis).























Elschemic 35.1 4 36.53
41.82 38.40
lSham 40.00 39.78 39.11
37.84
0h 4h 24h 72h
Figure 4.21: Plasma protein concentration
Total plasma protein was determined by the Bradford, Protein Assay, using BSA
as a standard (1976). Values shown for each timepoint are the means of two
determinations for each of five rats, + SEM. Timepoints at which sham and
ischemic values were significantly different are asteriskedþ s0.05, Tukey's HSD
Post-hoc analysis).
36.854E lschemic 50.004 45.99 37.286















Figure 4,22zThe relative concentration of plasma fibronectin
The fraction of total plasma protein comprising fibronectin was determined by
dividing each of the ELISA duplicates by the corresponding plasma
concentration, means and SEM's were then recalculated. This is an indication of
changes in fibronectin release into plasma and sequestration from it. Means +
SEM are shown for each timepoint. Timepoints at which sham and ischemic
values were significantly different are asterisked Q, -<0.05, Tukey's HSD Post-hoc
analysis).
0.1 03I lschemic o.o74 0.093 0.109





























Relatiræ plasma fi bronect¡n
t-l
4.4 Discussion
Fibronectins (FNs) are dimeric glycoproteins that exist both in blood, namely plasma
hbronectin (pFN) and in tissue extracellular matrices-cellular fibronectin (cFN). Although
both pFN and cFN are generated from a single gene, their isoforms differ due to alternative
splicing (1S1). pFN is produced only by hepatocytes and is secreted in a soluble form into
plasma where it has a half-life of two days, whereas cFN is expressed by a variety of cells
such as endothelial cells and macrophages (171). Extensive studies indicate that fibronectins
modulate cell proliferation, migration, survival and immunoreactivity (171) (184) (235) (221).
Integrins serve as fibronectin receptors at the cell surface and this interaction is crucial for the
ability of f,rbronectins to affect cellular activity (184), (512).
In the current study, we observed that the pFN was depleted immediately after 4 h bilateral
hindlimb ischemia as compffed with sham-operated group. Circulating pFN subsequently
increased following reperfusion of ischemic skeletal muscle, exceeding levels of pFN in the
sham group, reaching a maximum after 24 h of reperfusion and subsequently decreasing
again. However, the fraction of FN in total plasma protein was elevated after 4 h ischemia of
skeletal muscle, then dropped to a minimum level at 4 h of reperfusion, and consequently was
enhanced with reperfusion.
Furthermore, a rapid accumulation of FN in the basement membrane of ischemic skeletal
muscle was detected after 4 h of bilateral hind limb ischemia. This is the result of
incorporation of FN from the plasma in retained blood into the basement membrane due to the
increased vascular permeability during the period of ischemia. The binding of FN to the
basement membrane continued with reperfusion at least unúil 72 h. Local endothelial cells
newly synthesize another possible resource of accumulated FN. In contrast, FN was degraded
in the basement membrane in remote organs (lung and kidney). The degradation persisted
during the period of reperfusion. Moreover, FN was depleted markedly in the liver after
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bilateral hind limb ischemia and during early reperfusion, then increased significantly with
later periods of skeletal muscle reperfusion, exceeding the baseline level after 24 h of
reperfusion.
Similar alterations have been observed by Thompson et al (188) in their study of tissue injury
in a rat model. The ischemia of skeletal muscle was created by applying the tourniquet at
upper thigh of hindlimb beneath the skin. They found that the rise of pFN was signif,rcantly
greater at 22 h both in rats that underwent skeletal muscle ischemia/reperfusion and in sham-
operated group compared to those in normal control group. The initial increase in pFN
occurred after 2 hours of reperfusion, continued with the progressing of reperfusion. It has
been concluded that prior pFN deptetion is not required for this hyperfibronectinemic
response and that it reflects a rather rapid increase in fibronectin synthesis. In addition,
increased deposition of exogenorrs lt5l labelled fibronectin was detected at the site of injured
muscle after release of the tourniquet. Its binding may form the provisional matrix for wound
healing that is anticipated to occur following ischemic injury. Moreover, the liver and spleen
were demonstrated greater FN deposition due to large populations of reticuloendothelial cells.
Alterations in pFN were also observed in sublethal burn injury in a pattern of the depletion
over 15-minute to 2-h period after burns, then normalisation by 4-8 h followed by a rebound
hyper-fibronectinemia at 24 h ( 1 93 ), ( 1 90), ( 1 9 1 ).
pFN is an opsonic molecule that markedly enhances macrophage phagocytic clearance of
blood-borne nonbacterial particulates (136). Clearance of such debris from blood by
macrophages in the liver and spleen minimises deposition of the debris in extrahepatic beds
such as the lung and kidney and is thought to ensure integrity of organ function by preventing
micro-embolization of these particulates in vascular beds (1S7). It was suggested that the
acute depletion of pFN might be attributed to its deposition at the site of injured tissue and its
removal from the circulation by the liver (191)
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The sequestration of pFN in areas of tissue injury reflects not only the affinity that FN may
have for sites of tissue injury but also the increased vascular permeability at the site of injury.
Incorporation of pFN into the tissue matrices was observed in a distribution pattern
comparable to endogenous tissue f,rbronectin (513). Hayman and Ruoslahti demonstrated the
patterns of incorporation of exogenously added pFN into the extracellular matrix of kidney
cells in culture (514). It was considered that the deposition of pFN in the tissue matrix may
play a crucial role in early tissue repair by improving fibroblast, epithelial and endothelial cell
adhesion and migration, as well as regulating collagen matrix assembly (239). Moreover, the
deposition of pFN was suggested to inhibit ischemia-induced tissue injury. Sakai et al (218)
have found that there is a significant greater infarction volume in FN gene knockout mice
than those in normal mice, accompanied by a lack of deposition of pFN in infarct area.
Incidentally, an increased number of apoptotic cells were observed in infarct area in pFN-null
mice with decreased number of Bcl-2 protein positive cells. These results indicate that the
pFN interacts with the cells to inhibit apoptosis by inducing the expression of Bcl-2 protein.
In addition, it has been demonstrated that interaction of pFN with cr5ß1 integrin leads to an
over expression of the anti-apoptotic protein Bcl-2 and this over expression of Bcl-2 may
protect cells against ischemic damage (515) (516). Therefore, it was postulated that the rapid
accumulation of FN in the basement membrane of ischemic skeletal muscle not only
improves tissue repair but also protects the tissue against apoptosis.
Nevertheless, the mechanisms of degradation of FN in remote organ lung and kidney are not
well characterised. A likely mechanism may involve the activation of neutrophils and their
infiltration into the remote organ, releasing the enzymes such as MMPs and resulting in the
degradation of extracellular matrix. Previous studies in our laboratory (302) have shown that
there was an up-regulation of MMP-2 and MMP-9 accompanied by degradation of collagen
IV in the basement membrane in both lung and kidney. Although the degradation of
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extracellular matrix FN by MMPs may occur in ischemic skeletal muscle, the burst of
deposition of FN in the injured tissue outweighed the degradation. As a result, a net
accumulation of FN in the basement membrane of skeletal muscle was observed. The FN may
possibly also be expressed by macrophages, which infiltrate into the tissue during I/R. The
alterations of FN in liver observed in this study are consistent with the changes in FN levels in
plasma, indicating that liver may be the source of pFN. This observation is in agreement with
Thompson et al who demonstrated that the major source of rebound elevation of pFN after
bilateral hind limb I/R was due to elevated synthesis of FN by the liver mediated by certain
cytokines, such as TNF-cr andlL-6 (188).
Furthermore, in a recent study, it was shown that intravenous administration of FN peptide V
(FN-C/H-V) significantly diminished in a dose-dependent fashion, polymorphonuclear
monocytes (PlvIN) accumulation in ischemic tissue, reducing the size of infarction, and
improving neurological outcomes after transient focal cerebral ischemia in rafs (220).
Although the role of FN-C/H-V in mediating the adhesion of leukocytes is complex and
poorly understood, FN-C/H-V may inhibit PMN accumulation directly via interaction with
proteoglycans on the cell surface. It has also been hypothesised that cytokines or other cells
that are related to fibronectin and PMN may play a role in the inhibition of PMN
accumulation. Galkina and co-workers (517) observed that inhibition of neutrophil spreading
during their adhesion to FN induced formation of long tubulovesicular cell extension
(cytonemes). In addition, it is possible that FN-C/H-V could interact with a cell surface
proteoglycan on effector cells and inhibits PMN accumulation, because proteoglycan
interactions with selectins have been shown to facilitate leukoclte rolling (518). On the other
hand, the adhesion of macrophages to FN may improve macrophage phagocytosis of
apoptotic neutrophils at inflammatory sites, facilitating resolution of the inflammatory
response (243).
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Similarly, alterations of FN have been identified in the basement membrane of organ
allografts that underwent I/R during transplant. In a small bowel transplant model, increased
fibronectin levels were observed in the basement membrane within the villi cores and crypt
areas after VR (194). In heart allografts, it was found that the accumulation of FN in the
cytoplasm was positively correlated with the degree of cardiomyocyte coagulation necrosis.
Ischemia-induced damage of myocytes presents an intense FN cytoplasmic immunoreactivity
that occurs before the morphological architectural changes observed on hematoxylin and
eosin sections (519), Labanere et al (195) have found that there was a correlation between the
deposits of FN by immunohistochemistry on biopsy and the development of chronic rejection
or graft failure during the follow-up of cardiac transplants. Similarly, the increased FN
deposition found during biopsies of heart allograft predicted the high risk of graft failure
(1e6).
In the kidney, it was shown that FN was markedly increased in the corlex, corticomedullary
junction and glomeruli after ischemia and subsequent reperfusion. This deposition of FN was
considered to originate from pFN (20a). Kidney is unique in that after ischemic injury to the
renal tubules, essentially complete regenerative repair can occur. In this respect, FN is
suggested to be of potential importance in tubular regeneration after injury, as it contains
multiple functional domains including cellular binding, spreading, proliferation and
differentiation domains (215). It was postulated that FN might serve to organise the
subsequent regeneration tubular epithelium. FN of the provisional matrix has been shown to
promote the movement of fibroblast, macrophages and blood vessels into the wound space
(520). Livant et al (521) observed that administration of the PHSRN polypeptide sequence of
pFN appears to enhance the migration-dependent processes of re-epithelialization and
neovascularization in the dermal wounds of healing-impaired mice. Therefore, pFN may be
sollrces of a locally acting peptide chemotactic factor that function to attract the cells which
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are crucial for tissue repair by inducing chemotaxis through the stroma and directional
migration on the provisional matrix.
Furthermore, the accumulation of FN in the basement membrane after I/R may predispose the
allograft to undergo fibrosis and lead to chronic allograft dysfunction. This was speculated to
be the result of imbalance between the synthesis and degradation of extracellular matrix in
favour of its accumulation. Both cytokines and MMPs are thought to be involved in this
process. It has been demonstrated that chronic fibrosis in renal allograft is related to the up-
regulation of expression of TGF-ß (522). Likewise, it has been shown that an increased
infiltration of macrophages occurs with concomitant up-regulation of cytokines such as TGF-
ß1 and TGF-ß3 and increased deposition of ECM during chronic lung rejection. These
cytokines have an important role in stimulating fibroblasts to produce fibronectins, which are
a major source of ECM (523).
FN is an active participant in the immune cascade in organ transplantation. (194), (221).ln
more recent studies, FN has been found to play a crucial role in allograft rejection. It was
observed that intra-allografts EIII A * FN expression by macrophages is a critical feature of
graft rejection versus tolerance. The lack of EIII A. FN expression by infiltrating
macrophages in the tolerant state was associated with marked depression of IL-2 and IFN-r at
both mRNA and protein levels. The expression of EIIIA+ FN may amplify the rejection
cascade via up-regulation of type 1 cytokines, IL-2 and IFN-r in allografts (221). The
interaction between alpha-4-intergrin and FN may be important for leukocyte homing to the
graft site (223). Pathologically, the most prominent feature of chronic rejection is expansion
of extracellular matrix and widening of the basement membrane. FN is one of major
constituent in basement membrane. Clinically, in patients with acute or chronic kidney
allograft rejection, urinary FN levels are found to be significantly higher than those of patients
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with stable graft function. This enhanced urinary FN is likely to arise from glomerular protein
leakage and tubular cell secretion(224)
LN level remained unchanged in basement membrane of the skeletal muscle following
bilateral hindlimb I/R, but it decreased in the remote organs (kidney and lung). The LN level
increased subsequently in basement membrane with further reperfusion. This result is similar
to the alterations of collagen IV in basement membrane following bilateral hindlimb IiR
(302). It has been demonstrated that degradation of collagen IV was associated with the up-
regulation of MMP-2 and MMP-9 (302). Therefore, it is postulated that degradation of LN
observed in this study may be also related to the over-production of MMP-2 and MMP-9. LN
could also be degraded by MMP-3 andlor MMP-7. So studies were carried out to investigate
if MMP-3 and MMP-7 were produced in skeletal muscle by using casein geI zymography.
However, there was no expression of MMP-3, nor MMP-7 in either healthy skeletal muscle,
or after I/R (Chapter 3). V/hether other MMPs are expressed following ischemia and
reperfusion in the skeletal muscle remain unclear. Frisdal et al have also demonstrated that
LN and collagen IV in the basement membrane of skeletal muscle were degraded after
ischemia but without reperfusion. This degradation was closely correlated with the up-
regulation of matrix metalloproteinases, MMP-2 and MMP-9 (271).
LN is a multifunctional glycoprotein and a major component of extracellular matrix that
contributes to the architecture of the basement membrane. It plays significant roles in cellular
adhesion, growth, migration and differentiation of several cell types (251). However, it has
not been determined whether breakdown of LN may stimulate remodeling of the basement
membrane and repair of skeletal muscle after I/R or if the alterations in LN are solely
indicative of the degree of integrity of the basement membrane. Moreover, degradation of LN
was observed in the basement membrane in cerebral and renal ischemia followed by
reperfusion (269), (204). The loss of LN and other basement membrane components was
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considered to be responsible for the disruption of microvascular integrity and increased
vascular permeability.
LN may also contribute to muscle proliferation and fusion of satellite cells after injury (524).
In addition, ECM proteins may serve as reservoir for various growth factors, which have
benef,rcial effects on the control of muscle regeneration and angiogenesis (525). Furthermore,
the changes of LN in the basement membrane during cold ischemia were more prominent
than those after warm ischemia, suggesting these alterations were also potentiated by cold
temperature (270).
Like FN, LN has also been found to participate in the immunoreactive cascade. It was
observed that different isoforms of LN are able to improve PMN migration into the sites of
inflammation and act as a signal to direct lymphocyte migration to the specific organs (26I)
(263). Administration of LN peptide could inhibit leukocyte accumulation and ameliorate
brain injury in a rat model of transient focal cerebral ischemia (526). This result may offer a
novel therapeutic approach to protect tissue against I/R-induced injury. In organ transplant,
the elevation of LN in basement membrane may increase the risk of subsequent early allograft
rejection (268). Therefore, the alterations of LN in the basement membrane after I/R may
improve tissue repair by directing interactions between ECM-cells and cell-cytokines and the
inhltration of inflammatory cells may exacerbate the existing injury. On the other hand, these
alterations may change the expressions of major histocompatibility (MHC) and predispose the
allograft to undergo immunoreactivity. Intervention in the changes of ECM will provide a
new approach to attenuate the I/R injury and reduce allograft rejection.
Doxycycline belongs to the family of tetracyclines and is one of several chemically modified
tetracyclines, which have been proven to have long-term safety and efhcacy as antibiotics in
the treatment of acne vulgaris (527). Recently, it has been shown that doxycycline is of
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therapeutic beneht in several animal models of disease and in human abdominal aortic
aneurysm, in which the activity of MMPs has been suggested to play a crucial role in the
formation of lesions (525) (529) (377) (1) (475). In addition, a number of studies have
demonstrated that doxycycline not only inhibits the expression and activity of MMPs (528)
(475), but also modulates the expressions of cytokines, such as inducing up-regulation of
protective cytokines TGF-ß3 and down-regulating pro-inflammatory cytokines including IL-
1cr and IL-lß (530). In this study, it was observed that the degradation of LN in the basement
membrane was diminished by oral administration of doxycycline both in the
ischemic/reperfused skeletal muscle and in the remote organs lung and kidney. Nevertheless,
reduced degradation of FN following doxycycline treatment was only observed in the remote
organs, lung, kidney and liver, but not in skeletal muscle itself. This observation implies that
doxycycline may diminish the extent of degradation of LN and FN in basement membranes
by inhibiting the activity of MMP-2 and/or MMP-9. Similarly, a previous study in our
laboratory has determined that doxycycline could inhibit the activity of MMP-2 and MMP-9
after bilateral hind limb I/R, accompanied by reduced degradation of collagen IV in skeletal
muscle (302). However, in the current study, doxycycline did not significantly reduce
fibronectin loss from skeletal muscle when compared to placebo-treated reperfused controls.
This may occur because the deposition of FN from the plasma into the basement membrane
plays a major role in the accumulation of FN other than the possibility of reduced degradation
of FN after doxycycline administration. It remains unclear why there was a further increase in
FN in the liver after 4 h ischemia and 24 h reperfusion following administration of
doxycycline. This increase may be associated with modulation of some cytokines after
administration of doxycycline, except for the inhibition of FN degradation. As has been
demonstrated the production of FN in the liver is increased by cytokines IL-6 and TNF-c¿
after hind limb I/R (188). Therefore, doxycycline appears to inhibit basement membrane
degradation after I/R, but it is not clear whether this effect is beneficial or harmful for tissue
repair. Further studies are needed to investigate the effects of doxycycline in ischemia and
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reperfusion injury. Hopefully, the administration of doxycycline will be a novel approach for
reducing the severity of this injury.
In conclusion, the results of this study suggest that FN has an specific affinity to the injured
tissue and may promote cell migration and tissue repair, as mirrored by rapid depletion of
plasma FN. Interestingly, the changed patterns of FN in liver imply that pFN was secreted by
the liver. Furthermore, we hypothesise that alterations of FN in lung and kidney and LN in all
tissues are at least partially due to over-production of MMPs. Moreover, doxycycline ìwas
suggested to have an effect in reducing the extent of degradation of FN and LN by inhibiting
the activity of MMPs. However, this effect was not shown in skeletal muscle and liver,









5.1 Summary of chapter 1
Ischemia and reperfusion is a coÍìmon clinical event, that is encountered in ischemic heart
disease, stroke, shock, following cardiopulmonary resuscitation, vascular surgery and in organ
transplants. The morbidity and mortality of I/R-induced injury is very high, leading to
ischemic tissue edema, or even necrosis, as well as remote organ injury such as pulmonary
edema secondary to lower torso ischemia. A large number of studies have been conducted to
explore the mechanisms of I/R.
During ischemia, the blood supply to the tissue is interrupted and oxygen is lacking. ATP is
degraded, resulting in conversion of xanthine dehydrogenase to xanthine oxidase and
hypoxanthine to xanthine within endothelial cells. Therefore, a burst of oxygen free radicals is
produced following reperfusion. On the other hand, the depletion of ATP also causes
elevation of intracellular calcium, leading to activation of proteases. The oxygen free radicals
are highly reactive, initiating peroxidation of cellular lipid membranes and resulting in
structural and functional cell damage. Lipid peroxidation induces the production of
metabolites of arachidonic acid, thromboxane A2,leukotriene B4 (LTB4), platelet activating
factor (PAF) and prostaglandins. All these metabolites are considered to contribute to the
activation of neutrophils, release of cytokines and activation of complement. Activated
neutrophils, with the help of adhesive molecules such as ICAM-I and selectins, migrate
across the capillary endothelium, leading to an increase in microvascular permeability and
albumin extravasation. Plugging of neutrophils in capillaries, endothelial swelling, platelet
aggregates, and compression by extravasated albumin combine to result in the "no flow"
phenomena and tissue injury. In addition, activation of neutrophils also releases oxygen free
radicals, cytokines and proteases. Moreover, nitric oxide (NO), a vasodilator and endothelin
(ET), a vasoconstrictor are produced by endothelium, and are involved in I/R injury. The
balance between NO and ET is tipped in favour of production of ET, improving neutrophil
adhesion to the endothelium and increasing vascular constriction, thereby prolonging hypoxia'
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Apoptosis also plays an important role in a variefy of tissues following ischemia and
reperfusion. The production of ROS, damage to mitochondria and activation of caspase
family members all contribute to the process of apoptosis. The advantage of apoptosis is that
it permits cell death without destruction of adjacent cells.
Alterations of fibronectin (FN) and laminin (LN) following ischemia/reperfusion imply that
FN and LN play a role in l/R-induced injury. The rapid deposition of FN in the basement
membrane during I/R is considered to attenuate tissue injury, as well to facilitate tissue repair.
There are also complex interactions between FN and integrin family members on cell surface
or cytokines by which cellular functions could be changed. Administration of FN and LN
peptide has been suggested to ameliorate tissue injury.
MMPs are a family of zinc dependent enzymes that have been demonstrated to be able to
degrade the extracellular matrix and to be involved in the multiple patho-physiological
conditions. In recent studies, MMPs have been determined to play a crucial role in I/R injury.
An eievation of MMP -9 andlor MMP-2 has been found in the brain, heart, kidney and lung
tissues during ischemia and progressive reperfusion. The over-production of MMPs has been
suggested to contribute to the disruption of basement membranes and increases in vascular
permeability. Up-regulation of MMPs, combined with adhesive molecules, facilitates cell
adhesion and migration through endothelial cells into the target site, improving tissue
remodelling.
Based on understanding of the mechanisms of I/R injury, a number of therapeutic strategies
have been employed to ameliorate the injury, which include antioxidation and scavenging of
ROS, inhibition of proinflammatory cytokines, adhesive molecules, complements, and
MMPs. A number of studies have been published to show that down-regulation of MMPs
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either by MMP-antibodies or inhibitor, including doxycycline significantly decreases I/R
organ mJury
The aims of this study were to investigate the alterations of fibronectin and laminin, major
components of basement membrane and expression of potential caseinolytic MMPs involved
in I/R. The effects of doxycycline on these substrates during ischemia/reperfusion injury were
also explored.
5.2 Summary of chapter 2
The animal model for skeletal muscle ischemia and reperfusion was described in chapter 2.
This animal model has been established in surgical laboratory at The Queen Elizabeth
Hospital for study of I/R injury. The model mirrors the clinical procedure in repair of
abdominal aorlic aneurysm, in which the abdominal aortic is clamped and lower torso
ischemia is created.
A tourniquet model of I/R injury has been used in many studies (531), (532), (533). These
methods commonly apply a tape tourniquet or a rubber band above the level of greater
trochanter of the rat. The advantages of this model are that it was easily established and
reproduced. It also includes muscles of each fibre type in the ischaemic area and thus the
overall effect of a mixture of fibre types was included in the element of reperfusion. This
model corresponds to the human situation of ischaemic limbs arising due to trauma,
embolism, thrombosis or in vascular surgery.
Vascular pedicle techniques have also been extensively employed in the studies of ischemic
injury, such as canine gracilis muscle (534) Unlike the tourniquet model, this method involves
isolating the selected muscle and compartment syndrome due to edema formation may have
less pathogenic influences in this model since fascial planes are opened.
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Samples were processed as follows. Two ml of blood were anticoagulated and centrifuged to
obtain plasma. Both quadriceps muscles were harvested and divided into 3 parts, the upper
part for histopathology, middle part for zymography and lower part for
immunohistochemistry. The lung, kidney and liver were also retrieved and divided into 3
parts for histopathology, zymography and immunohistochemistry respectively.
In situ occlusion of artery with maintenance of venous outflow has also been utilized in the
investigation of skeletal muscle I/R injury (535) This model needs surgical isolation of
arterial vessels to the limbs and is more technically demanding than a tourniquet model.
Nevertheless, it closely resembles clinical ischaemic events including thrombotic or embolic
occlusions to the arterial vessels or aortic surgery.
A four-hour time course of ischemia was chosen in the current study. The length of ischaemia
has been determined to be sufficientlly long to produce a histological damage to the skeletal
muscle followed by reperfusion changes (511).
5.3 Summary of chapter 3
The proteolytic activity of MMPs has been investigated in various tissues following skeletal
muscle ischemia and reperfusion in this chapter. The tissue samples were homogenised and
dialysed for zymographic analysis. SDS-PAGE gels were embedded with gelatin or casein
substrates for the detection of zymographic activity of MMPs. 'Western blots was also
employed in these experiments for conf,rrmation the identity of MMPs detected on
zymograms.
A significant elevation of proMMP-2 and MMP-9 was observed in skeletal muscle following
4 h ischemia and reperfusion. MMP-9 was elevated only after 4 h of reperfusion. Elevation of
MMP-9 and active MMP-2 were also detected in the lung tissue following skeletal muscle
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ischemia and reperfusion. PToMMP-2 was detected at baseline level in renal tissue, while
MMP-9 was not detected. proMMP-2 was present in the liver at low baseline levels, but no
alterations of any MMP wwere detected in the liver following skeletal muscle ischemia and
reperfusion. There was no caseinol¡ic MMP present in the skeletal muscle and liver on
zymogram. Howerer, there were two proteolytically active bands observed in renal tissue but
no changes in activity occurred following skeletal muscle ischemia and reperfusion. More
significantly, a new active caseinolyic species was detected in lung tissues by zymography. It
was a low molecular weight MMP (20 kDa), which was up-regulated in the lung immediately
after hindlimb ischemia and early reperfusion. It then decreased following reperfusion, with
the lowest level at 24hreperfusion and recovery to baseline levels thereafter.
In the literature, it has been reported that there was an elevation of MMP-9 and / or MMP-2 in
the brain, heart, kidney, and lung following ischemia and reperfusion. The elevation of MMP-
9 and MMP-2 was suggested to be responsible for the disruption of basement membrane and
tissue edema observed in reperfusion injury. In the current study, not only were MMP-9 and
MMP-2 up-regulated both in ischemic skeletal muscle and in lung, but also a newly
recognised caseinolytic MMP was elevated in lung tissue immediately after skeletal muscle
ischemia. The over-production of multiple MMPs in the lung could explain why the lung is
the most l-ulnerable target organ for injury following remote organ ischemia and reperfusion.
Moreover, elevation of MMP-9 has been found in the lung tissues of patient with ARDS
(301). It has also been determined that the production of MMPs was stimulated by some
cytokines such as IL-I (482).
5.4 Summary of chapter 4
Alterations of FN and LN were investigated in the basement membrane following skeletal
muscle I/R injury. Immunohistochemical techniques were used to identify and quantify the
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levels of FN and LN in the basement membrane. In addition, the pFN was analysed by
ELISA.
Tlrere was a rapid depletion of pFN immediately after 4 h bilateral hindlimb ischemia and
during early reperfusion. It was then elevated upon 24 h reprfusion, even exceeding the
control levels, recovering to baseline levels after 72 h of reperfusion. Moreover, deposition of
FN in the basement membrane of skeletal muscle was detected following ischaemia and the
deposition of FN continued during reperfusion. In contrast, FN was degraded in the basement
membrane of remote organs, lung and kidney. This degradation persisted in the period of
reperfusion. Moreover, FN was decreased significantly in the liver after skeletal muscle
ischemia and during early reperfusion, then increased markedly with the progression of
reperfusion. LN was degraded in the basement membrane of skeletal muscle, as well as in
remote organs, kidney and lung. It was then increased in the basement membrane with
reperfusion. After administration of doxycycline, degradation of LN was inhibited in the
basement membrane of skeletal muscle, lung and kidney. However, the degradation of FN
was only inhibited by doxycycline in the basement membrane of lung and kidney.
The observations from this study support the hypothesis that FN has a specific affinity to
injured tissues and promotes cell migration and tissue repair, as was mirrored by the depletion
of pFN and accumulation of FN in the basement membrane of skeletal muscle. The liver was
considered to produce the fibronectin under these conditions. The degradation of FN in the
lung and kidney, and degradation of LN in all basement membranes is suggested to be the
result of over-production of MMPs. Therefore, inhibition of MMP may be a new therapeutic
approach to reduce I/R injury. Doxycycline, a broad-spectrum MMP inhibitor has been found




As in chapter 1, the mechanism of I/R injury is very complicated and remains to be elucidated
fuither. Our studies have found that alterations of MMP-2 and MMP-9 occurred both in the
ischemic skeletal muscle and remote organ lung. In addition, another caseinolytic MMP was
recognised in the lung tissue. This caseinolytic MMP was defined as low molecular MMP
according to the standard molecular weight marker. However, It has not been identified to be
which one of MMPs on western blots, because the suitable control MMP candidates such as
MMP-7 and MMP-12 were not available in this experiment. Therefore, this newly detected
caseinolytic MMP need to be identified on Vy'estern blotting in the near future.
MMPs have been emphasised to be involved in the I/R injury, degrading the extracellular
matrix, participating the neutrophil extravasation and migration across basement membrane,
enhancing tissue edema, shedding the molecules such as ICAM-I and L-selectin from cell
surface. The source of elevated MMPs has been studied in other studies. MMP-9 was
suggested to be released by bronchial and type II alveolar epithelial cells and neutrophils that
have infiltrated into the tissues, while MMP-2 was constitutively expressed by fibroblasts,
endothelial cells, vascular smooth muscle cells and type II alveolar epithelial cells. MMP-7
was produced by type II epithelial cells in the lung. So the cellular source of this new
caseinol¡,tic MMP should be investigated in the future study.
In this study, it was found that MMPs play a role in remote organ lung injury after skeletal
muscle ischemia and reperfusion. The mechanisms leading to elevation or suppression of
MMP levels remains unclear. Elevation of MMP-9 was detected in parallel with the increase
in proinflammatory cytokines such as IL-l and TNF-a, in the lung of patients with ARDS
(482). ROS was implicated to stimulate the production of MMPs. Therefore, exploration of
the interactions between MMPs and cytokines and modulation of MMP expression by some
agents could be the future direction in the area of ischemia and reperfusion injury.
r40
5.6 Conclusions
A rat model for study of I/R injury has been established in Surgical Laboratory at The eueen
Elizabeth Hospital, Adelaide University. In the current study, it was found that there was a
rapid depletion of pFN immediately following skeletal muscle ischemia and during early
period of reperfusion and then increased with reperfusion. This corresponded to the
accumulation of FN in the basement membrane of ischemic muscle. Liver was induced to
produce FN after depletion of fibronectin in plasma. Observation in this study supports the
theory that FN has a specific afhnity to ischemic tissue and facilitates tissue repair. The
degradation of FN in the basement membrane of lung and kidney was detected after skeletal
muscle I/R. Furthermore, the degradation of LN in the basement membrane of ischemic
skeletal rnuscle, remote organ lung and kidney. This degradation of FN and LN was
implicated to be the result of elevation of MMPs such as MMP-9 and MMP-2. Doxycycline, a
broad-spectrum inhibitor of MMPs was found to be able to diminish the degradation of FN
and LN occurred in the basement membrane.
Lung is vulnerable to organ damage following bilateral hindlimb I/R injury. Multiple MMPs
have been detected in the lung tissues after skeletal muscle ischemia and reperfusion. MMP-2
and MMP-9 were increased in the lung of rats that have undergone 4 h bilateral hindlimb
ischemia before, as well as after reperfusion. Moreover, a ne\¡r' caseinolytic MMP was
detected in the normal lung tissue on zymogram. It was decreased in the lung following 4 h
anesthesia by inhalation of oxygen, nitrous oxide and halothane and then increased with
recovery. However, this caseinol¡ic MMP was increased significantly in the lung after
skeletal muscle ischemia, and then decreased with the progression of reperfusion. This newly
recognised caseinolyic MMP was def,rned as low molecular weight MMP, 20 kDa. Further
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Tx Az thromboxane A2
VCAM vascular cell adhesion
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6.2 Chemicals and Reagents
6.2.1 Sigma Chemical Co Ltd., St Louis MO USA, Supplied the chemicals and reagents.
Ammonium persulfate (APS)
Bovine serum albumin-Fraction V (BSA)
BriJ 35 solution 30%WN. Brij is a registered trademark of ICI Americas, Incorporated
Casein
Coomassie Brilliant Blue-R
Etþlenediamine tetracetic acid (EDTA)
Gelatin (Type A from porcine skin)
Glycine
MMP control-l (M2928)
Phenylmethanesulfonyl fluoride a - toluenesufonyl fluoride (PMSF)
N, N, N', N' -tetrametþletþlenediamine (TEMED)
pm
Tris [hydroxymethyl] aminomethane (Tris base)
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Tris [hydroxymethyl] aminomethane hydroxychloride (Tris HCI)
Sodium dodecyl sulfate (SDS)
Urea
6.2.2 AjaxChemicals, NSW, Australia supplied the chemicals and reagents'
Calcium chloride dihydrate (Caclz)
Glacial Acetic acid
Methanol
S odium chloride Q'{aCl)
Triton-X 100
6.2.3 Other chemicals and reagents.
Acetone Anala R MERCK 1td, Kils¡h, Vic, Australia
300/o Acrylamide/Bis (37.5:1,2.6%) Bio-Rad Laboratories, Hercules, cA, USA
Biotinylated anti-rabbit IgG (H+L) vector Laboratories,Inc, Burlingame cA, usA
Bromophenol Blue May + Baker Ltd, Pakenham, England
Affinity purified anti-fibronectin (Rabbit) Rockland, Gilbersville, PA, USA
Affrnity purified anti-laminin (Rabbit) Rockland, Gilbersville' PA, USA
Dako fluorescent mounting medium Dako corporation, cA, usA
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ECL Amersham Pharmacia, Biotech UK Limited,
Buckinghamshire, England
Foetal calf serum Gibco BRL LIFE technologies
Glycerol Merck Pty Ltd, Vic Australia
Milli Q Plus HzO (MQ H2O) Millipore, Australia
Nitrocellulose membrane Hybond ECl-Enhanced Chemiluminescence
Amersham Pharmacia, Biotech UK Limited.
PAP Pen Zymed Laboratories, Inc, San Francisco
California, USA
Skim milk powder Bonlac Food Pty, Melbourne
Tissue Tek OCT Sakura Finetek, Toffance, CA, USA
Streptavidin-fluorescein (RPN 1232) Amersham Pharmacia, Biotech UK Limited,
Buckinghamshire, England
Tween 20 Bio-Rad Laboratories, Hercules, CA, USA
X-ray film Hyperhlm Amersham Pharmacia, Biotech UK Limited,
Buckinghamshire, England
6.3 Equipment
Coverslips Menzel GLASER, Gerhard Menzel, Glasbearbeitungswek, GmbH
& Co.KG
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Parks Medical Electronics Inc. Oregon, USA
B.Braun. Melsungen AG
Kane-May Ltd, Welwyn Garden City, Herts
Varian DMS 200, UV Visible Spectrometer
6.4 Raw Data of Quantitative Immunohistochemistry
For all tables in section 6.5, the figures of brightness represent the level of fibronectin (or
laminin) detected in the basement membrane by fluorescent immunohistochemistry. IR 0/24
refers to rats in sham-operated group that have undergone 4 hours anaesthesia with 24 hours
recovery, no ischemia created. IR 4/0 refers to the group in which rats have undergone 4
hours bilateral hindlimb ischemia, without progressing of reperfusion. . IR 414 refers to the
group in which rats have undergone 4 hours bilateral hindlimb ischemia followed by 4 hours
of reperfusion. IR 4124 refers to the group in which rats have undergone 4 hours bilateral
hindlimb ischemia followed by 24 hours of reperfusion. IR 4172 rcfers to the group in which
rats have undergone 4 hours bilateral hindlimb ischemia followed by 72 hours of reperfusion.
There were five rats in each different group. Twenty-five individual figures were recorded for
each tissue , 125 frgures in total for each group, except in Table 6.5.5, Table 6.5.7, and Table
6.5.8 in which 30 figures were recorded for each tissue, 150 hgures in total.
The mean refers to the arithmetic mean of al 125 figures (or 150 figures in Table 6.5.5, Table
6.5.7, and Table 6.5.8) representing the brightness for fibronectin (or laminin).
SEM refers to standard effor mean.
St Dev refers to standard deviation
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Ta ble 6.4.8. Data for fibronecti n q uantitative immu noh istochemistry
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Table 6.4.9. Data for fibronectin quantitative immunohistochemistry
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Table 6.4.1 0. Data for fibronectin quantitative immunohistochemistry
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Table 6.4.1 1. Data for f i bronectin q uantitative imm u noh istochemistry



































































































































7724 21838.39 12416.1 28235.71
181
Table 6.4.12. Data for laminin quantitative immunohistochemistry
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Table 6.4.13.Data for laminin quantitative immunohistochemistry
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Table 6.4.l4.Data for laminin quantitative immunohistochemistry
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